cik,name,report_year,docID,sentenceID,section_name,section_item,section_ID,form,sentence_index,sentence,SIC,filingDate,reportDate,temporal_bin,sample_created_at,last_modified_date,sample_version,source_file_path,load_method
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_0,Business,ITEM_1,0,10-K,0,"Item 1Business Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_1,Business,ITEM_1,0,10-K,1,"We discover, develop, manufacture, and market products in a single business segment-human pharmaceutical products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_2,Business,ITEM_1,0,10-K,2,"Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_3,Business,ITEM_1,0,10-K,3,"We manufacture and distribute our products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. Our products are sold in approximately 95 countries.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_4,Business,ITEM_1,0,10-K,4,"Products Our products include: Therapeutic area Products Certain Indications Cardiometabolic Health products Basaglar In collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_5,Business,ITEM_1,0,10-K,5,"Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_6,Business,ITEM_1,0,10-K,6,Human insulin analogs for the treatment of diabetes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_7,Business,ITEM_1,0,10-K,7,"Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_8,Business,ITEM_1,0,10-K,8,Human insulins of recombinant DNA origin for the treatment of diabetes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_9,Business,ITEM_1,0,10-K,9,"Jardiance In collaboration with Boehringer Ingelheim, for the treatment of type 2 diabetes; to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and established cardiovascular disease; to reduce the risk of cardiovascular death and hospitalizations for heart failure in adults; and to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_10,Business,ITEM_1,0,10-K,10,"Mounjaro A glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for the treatment of adults with type 2 diabetes in combination with diet and exercise to improve glycemic control.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_11,Business,ITEM_1,0,10-K,11,Trulicity For the treatment of type 2 diabetes in adults and pediatric patients 10 years of age and older; and to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_12,Business,ITEM_1,0,10-K,12,Zepbound For the treatment of adults with obesity or overweight with at least one weight-related comorbid condition in combination with a reduced-calorie diet and increased physical activity; and for the treatment of moderate to severe obstructive sleep apnea in adults with obesity in combination with a reduced-calorie diet and increased physical activity (relevant indications marketed under Mounjaro in various markets outside the U.S.).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_13,Business,ITEM_1,0,10-K,13,Therapeutic area Products Certain Indications Oncology products Cyramza For use as monotherapy or in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma; in combination with another agent as a second-line treatment of metastatic non-small cell lung cancer (NSCLC); in combination with another agent as a second-line treatment of metastatic colorectal cancer; as a monotherapy as a second-line treatment of hepatocellular carcinoma; and in combination with another agent as a first-line treatment of adult patients with metastatic NSCLC with activating epidermal growth factor receptor (EGFR) mutations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_14,Business,ITEM_1,0,10-K,14,"Erbitux Indicated both as monotherapy and in combination with another agent for the treatment of certain types of colorectal cancers; and as monotherapy, in combination with chemotherapy, or in combination with radiation therapy for the treatment of certain types of head and neck cancers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_15,Business,ITEM_1,0,10-K,15,"Jaypirca For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor; and for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_16,Business,ITEM_1,0,10-K,16,Retevmo For the treatment of metastatic NSCLC with a rearranged during transfection (RET) gene fusion in adult patients; for the treatment of advanced metastatic medullary thyroid cancer with a RET mutation who require systemic therapy in adult and pediatric patients; for the treatment of advanced or metastatic thyroid cancer with a RET gene fusion in adult and pediatric patients who require systemic therapy and are radioactive iodine-refractory; and for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_17,Business,ITEM_1,0,10-K,17,"Tyvyt In collaboration with Innovent Biologics, Inc., for the treatment of relapsed or refractory classic Hodgkin's lymphoma; for the first-line treatment of non-squamous NSCLC in combination with Alimta and another agent; for the first-line treatment of squamous NSCLC in combination with two other agents; for the first-line treatment of hepatocellular carcinoma in combination with another agent; for the first-line treatment of esophageal squamous cell carcinoma in combination with certain other agents; for the first-line treatment of gastric cancer in combination with two other agents; and, in combination with two other agents, for patients with EGFR-mutated non-squamous NSCLC that progressed after EGFR-tyrosine kinase inhibitor therapy, each in China.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_18,Business,ITEM_1,0,10-K,18,"Verzenio For use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer, and in combination with endocrine therapy for treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_19,Business,ITEM_1,0,10-K,19,"Therapeutic area Products Certain Indications Immunology products Ebglyss For the treatment of adult and adolescent patients 12 years or older with moderate to severe atopic dermatitis (in Europe, in collaboration with Almirall S.A.).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_20,Business,ITEM_1,0,10-K,20,"Olumiant In collaboration with Incyte Corporation, for the treatment of adults with moderately to severely active rheumatoid arthritis after treatment with one or more tumor necrosis factor (TNF) blockers that did not work well enough or could not be tolerated; moderate to severe atopic dermatitis; severe alopecia areata; and for the treatment of hospitalized adults with COVID-19 who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_21,Business,ITEM_1,0,10-K,21,Omvoh For the treatment of moderately to severely active ulcerative colitis in adults and for the treatment of moderately to severely active Crohn's disease in adults.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_22,Business,ITEM_1,0,10-K,22,Taltz For the treatment of adults and pediatric patients aged 6 years or older with moderate to severe plaque psoriasis; adults with active psoriatic arthritis; adults with ankylosing spondylitis; and adults with active non-radiographic axial spondyloarthritis.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_23,Business,ITEM_1,0,10-K,23,Neuroscience products Emgality For migraine prevention and the treatment of episodic cluster headache in adults.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_24,Business,ITEM_1,0,10-K,24,Kisunla For adults with early symptomatic Alzheimer's disease with confirmed amyloid pathology and with mild cognitive impairment or mild dementia stage of disease.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_25,Business,ITEM_1,0,10-K,25,Marketing and Distribution We sell most of our products worldwide. We adapt our marketing methods and product emphasis in various countries to meet local customer needs and comply with local regulations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_26,Business,ITEM_1,0,10-K,26,U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_27,Business,ITEM_1,0,10-K,27,"We educate healthcare providers about our products in various ways, including promoting in online channels, distributing literature and samples of certain products to physicians, and exhibiting at medical meetings.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_28,Business,ITEM_1,0,10-K,28,"In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our major products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_29,Business,ITEM_1,0,10-K,29,Promotion of our major products in the U.S. includes engagement by employee or contracted sales representatives with physicians and other healthcare professionals.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_30,Business,ITEM_1,0,10-K,30,"Our account managers service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. We enter into arrangements with these organizations to provide discounts or rebates on our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_31,Business,ITEM_1,0,10-K,31,"In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_32,Business,ITEM_1,0,10-K,32,"In 2024, 2023, and 2022, three wholesale distributors in the U.S.-McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.-each accounted for a significant percentage of our consolidated revenue.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_33,Business,ITEM_1,0,10-K,33,No other customer accounted for more than 10 percent of our consolidated revenue in any of these years.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_34,Business,ITEM_1,0,10-K,34,"For additional information, see Item 8, ""Financial Statements and Supplementary Data-Note 2: Revenue.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_35,Business,ITEM_1,0,10-K,35,"We recently launched LillyDirect, a direct-to-consumer digital health care platform designed to, among other things, provide patients in the U.S. living with obesity, migraine and diabetes with tools to help them access care from independent healthcare providers, as well as the option for home delivery of select prescribed Lilly medicines through third-party pharmacies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_36,Business,ITEM_1,0,10-K,36,Programs to assist patients in adhering to treatment plans are also available for use.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_37,Business,ITEM_1,0,10-K,37,"We have launched, and continue to explore, new partnerships and tools, including through LillyDirect, to expand access to our medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_38,Business,ITEM_1,0,10-K,38,New initiatives may expose us to new risks or exacerbate existing risks.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_39,Business,ITEM_1,0,10-K,39,"See, for examples, Item 1A, ""Risk Factors-Risks Related to Our Operations-Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could each result in material harm to our",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_40,Business,ITEM_1,0,10-K,40,"business and reputation"" and ""Risk Factors-Risks Related to Litigation and Government Regulation-Regulatory compliance problems could be damaging to the company.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_41,Business,ITEM_1,0,10-K,41,Outside the U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_42,Business,ITEM_1,0,10-K,42,The products we market and their distribution vary from country to country.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_43,Business,ITEM_1,0,10-K,43,"Outside the U.S., we promote our products to healthcare providers through sales representatives and other channels.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_44,Business,ITEM_1,0,10-K,44,We maintain our own sales organizations in many countries.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_45,Business,ITEM_1,0,10-K,45,"We also often utilize third parties for commercial sales operations, some of which are engaged through distribution and promotion arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_46,Business,ITEM_1,0,10-K,46,Marketing Collaborations Certain of our products are marketed in arrangements with other pharmaceutical companies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_47,Business,ITEM_1,0,10-K,47,"For example, we and Boehringer Ingelheim have a global agreement to develop and commercialize a portfolio of diabetes products, including Jardiance, Glyxambi, Synjardy, and Trijardy XR.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_48,Business,ITEM_1,0,10-K,48,"For additional information, see Item 8, ""Financial Statements and Supplementary Data-Note 4: Collaborations and Other Arrangements.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_49,Business,ITEM_1,0,10-K,49,Competition Our products compete globally with many other pharmaceutical products in highly competitive markets.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_50,Business,ITEM_1,0,10-K,50,"Important competitive factors include effectiveness, safety, availability, ease of use, and overall patient experience; formulary placement, price, payer coverage and reimbursement rates, and demonstrated cost-effectiveness; regulatory approvals; marketing effectiveness; and research and development of new products, processes, modalities, indications, and uses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_51,Business,ITEM_1,0,10-K,51,Early market entry and rapid patient access can also be important to achieve product acceptance and success.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_52,Business,ITEM_1,0,10-K,52,Barriers to reimbursable patient access in some cases include default payer coverage restrictions for our medicines.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_53,Business,ITEM_1,0,10-K,53,"For example, in the U.S., anti-obesity medicines are often excluded from commercial benefit plans.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_54,Business,ITEM_1,0,10-K,54,Self-insured employers must opt in for coverage of these medicines.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_55,Business,ITEM_1,0,10-K,55,Medicare and payers in various international markets also have not covered anti-obesity medicines for weight loss.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_56,Business,ITEM_1,0,10-K,56,"Our anti-obesity medicines comprise a significant portion of our revenues, and barriers to reimbursable patient access may impact our sales volumes, business, and results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_57,Business,ITEM_1,0,10-K,57,"Most new products or uses that we introduce must compete with other branded, biosimilar, or generic products already on the market or that are later developed.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_58,Business,ITEM_1,0,10-K,58,"When new products, uses, or delivery systems with therapeutic, convenience, or cost advantages are introduced, including by developing new modalities, our existing products become subject to decreased sales volumes, progressive price reductions, or both.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_59,Business,ITEM_1,0,10-K,59,"We believe our long-term competitive success depends on discovering and developing or acquiring innovative, cost-effective products that provide improved outcomes for patients and deliver value to payers, and continuously improving the productivity of our operations in a highly competitive environment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_60,Business,ITEM_1,0,10-K,60,"There can be no assurance that our efforts will result in commercially successful products, and it is possible that our products or indications will be, or will become, uncompetitive from time to time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_61,Business,ITEM_1,0,10-K,61,"See also ""-Competition-U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_62,Business,ITEM_1,0,10-K,62,"Private Sector Dynamics.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_63,Business,ITEM_1,0,10-K,63,"Generic Pharmaceuticals, Biosimilars, and Compounding Generic Pharmaceuticals and Biosimilars Generic pharmaceuticals and biosimilars can pose major competitive challenges to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_64,Business,ITEM_1,0,10-K,64,"In most major jurisdictions, the regulatory approval process for pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_65,Business,ITEM_1,0,10-K,65,"As a result, generic manufacturers generally invest far fewer resources than we do for our branded products in research and development and can price their products significantly lower than our branded products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_66,Business,ITEM_1,0,10-K,66,"Accordingly, when a branded non-biologic pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product, which can result in the loss of a significant portion of the branded product's revenue in a very short period of time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_67,Business,ITEM_1,0,10-K,67,"Moreover, governments in some countries leverage generic entrants to drive price concessions through the utilization of volume-based procurement bidding and other measures.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_68,Business,ITEM_1,0,10-K,68,"Further, public and private payers typically encourage the use of generics as alternatives to branded products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_69,Business,ITEM_1,0,10-K,69,"Laws in the U.S. generally allow, and in many cases require, pharmacists to substitute generics that have been rated under government procedures to be essentially equivalent to a branded product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_70,Business,ITEM_1,0,10-K,70,"Where substitution is mandatory, it must be made unless the prescribing physician expressly forbids it.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_71,Business,ITEM_1,0,10-K,71,"In certain countries, intellectual property protection is weak, and we must compete with generic versions of our products at or relatively shortly after launch.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_72,Business,ITEM_1,0,10-K,72,"In addition, competition for our biologics, which constitute a substantial portion of our products and pipeline, may be affected by the approval of follow-on biologics, also known as biosimilars.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_73,Business,ITEM_1,0,10-K,73,"A biosimilar is a subsequent version of an approved innovator biologic that, due to its analytical and clinical similarity to the innovator biologic, may be approved based on an abbreviated data package that relies in part on the full testing required of the innovator biologic.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_74,Business,ITEM_1,0,10-K,74,"Globally, most governments have developed abbreviated regulatory pathways to approve biosimilars as follow-ons to innovator biologics, including the Biologics Price Competition and Innovation Act of 2009 (the BPCIA) in the U.S. A number of biosimilars have been licensed under the BPCIA, as well as in Europe and Japan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_75,Business,ITEM_1,0,10-K,75,"Regulatory interpretation of important aspects of the laws regulating biosimilars continues to evolve, and therefore the impact of these laws on our business remains subject to substantial uncertainty.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_76,Business,ITEM_1,0,10-K,76,"For example, the extent to which a biosimilar, once approved, will be substituted for the innovator biologic in a way that is similar to traditional generic substitution for non-biologic products will depend on a number of regulatory and marketplace factors that are still developing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_77,Business,ITEM_1,0,10-K,77,"Biosimilars may present both competitive challenges and opportunities. While competitors have developed biosimilars that compete with our products, we have developed our own biosimilar and may develop others in the future.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_78,Business,ITEM_1,0,10-K,78,"Compounding In recent periods, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_79,Business,ITEM_1,0,10-K,79,"These practices may impact patient safety, undermine regulatory drug approval processes, and present market risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_80,Business,ITEM_1,0,10-K,80,"If inadequately regulated, these practices could materially impact our business and reputation, including by creating consumer confusion or misperceptions about the safety and efficacy of our genuine products, diversion of potential sales, and potential net price erosion for our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_81,Business,ITEM_1,0,10-K,81,"See Item 1, ""Business-Government Regulation of Our Operations and Products,"" for additional information on market risks related to counterfeit, misbranded, adulterated, and compounded medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_82,Business,ITEM_1,0,10-K,82,U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_83,Business,ITEM_1,0,10-K,83,"Private Sector Dynamics In the U.S. private sector, consolidation and integration among healthcare organizations significantly affects the competitive marketplace for pharmaceuticals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_84,Business,ITEM_1,0,10-K,84,"Health plans, managed care organizations, pharmacy benefit managers, wholesalers, pharmacies, and other supply chain entities have consolidated into fewer, larger entities, thus enhancing their market power and importance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_85,Business,ITEM_1,0,10-K,85,"Private third-party insurers, as well as governments, typically maintain formularies that specify coverage (the conditions under which drugs are included on a plan's formulary) and reimbursement (the associated out-of-pocket cost to the consumer) to control costs by negotiating discounts or rebates in exchange for formulary inclusion and placement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_86,Business,ITEM_1,0,10-K,86,"Formulary placement can lead to reduced usage of a product for the relevant patient population due to coverage restrictions, such as prior authorizations and formulary exclusions, or due to reimbursement limitations that result in higher consumer out-of-pocket cost, such as non-preferred co-pay tiers, increased co-insurance levels, and higher deductibles.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_87,Business,ITEM_1,0,10-K,87,"Consequently, pharmaceutical companies face increased pressure in negotiations, and compete fiercely for formulary placement, not only on the basis of product attributes such as efficacy, safety profile, or patient ease of use, but also by providing rebates or other concessions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_88,Business,ITEM_1,0,10-K,88,"As payers and pharmaceutical companies continue to negotiate formulary placement and rebates, value-based agreements, where rebates may be based on achievement (or not) of specified outcomes, are another increasingly prevalent tool.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_89,Business,ITEM_1,0,10-K,89,"Rebates and net cost are increasingly important factors in formulary decisions, particularly in treatment areas in which the payer has taken the position that multiple branded products are therapeutically comparable.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_90,Business,ITEM_1,0,10-K,90,"These pressures have negatively affected, and could continue to negatively affect, our consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_91,Business,ITEM_1,0,10-K,91,"In addition to formulary placement, changes in insurance designs continue to drive greater consumer cost-sharing through high deductible plans, higher co-insurance, or co-pays, including increased utilization of co-pay accumulator adjustment or maximization programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_92,Business,ITEM_1,0,10-K,92,Supply chain entities have also increasingly imposed utilization management tools to favor the use of generic products or otherwise limit access to our products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_93,Business,ITEM_1,0,10-K,93,"For additional information on pricing and reimbursement for our pharmaceutical products, see ""-Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_94,Business,ITEM_1,0,10-K,94,"Patents, Trademarks, and Other Intellectual Property Rights Overview Intellectual property protection is critical to our ability to successfully commercialize our life sciences innovations and invest in the search for new medicines and uses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_95,Business,ITEM_1,0,10-K,95,"Loss of effective patent protection for pharmaceuticals, especially for non-biologic products, typically results in the loss of effective market exclusivity for the product, often leading to a severe and rapid decline in revenues for the product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_96,Business,ITEM_1,0,10-K,96,"We own, have applied for, or are licensed under, a large number of patents in the U.S. and many other countries relating to products, product uses, formulations, and manufacturing processes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_97,Business,ITEM_1,0,10-K,97,"In addition, for some products we have effective intellectual property protection in the form of data protection under pharmaceutical regulatory laws.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_98,Business,ITEM_1,0,10-K,98,"The patent protection generally anticipated to be of most relevance to pharmaceuticals is provided by patents claiming the active ingredient (the compound patent) for our products, particularly those in major markets such as the U.S., major European countries, and Japan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_99,Business,ITEM_1,0,10-K,99,"In general, patents in each relevant country last for a period of 20 years from their filing date, which is often years prior to the launch of a commercial product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_100,Business,ITEM_1,0,10-K,100,Further patent term adjustments and restorations may extend the original patent term:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_101,Business,ITEM_1,0,10-K,101,•Patent term adjustment is available to all U.S. patent applicants to provide relief in the event that a patent grant is delayed during examination by the U.S. Patent and Trademark Office (USPTO).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_102,Business,ITEM_1,0,10-K,102,•Patent term restoration for a single patent for a pharmaceutical product is provided to U.S. patent holders to compensate for a portion of the time invested in clinical trials and the U.S. Food and Drug Administration (FDA) review process.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_103,Business,ITEM_1,0,10-K,103,"There is a five-year cap on any restoration, and no patent's expiration date may be extended beyond 14 years from initial FDA approval.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_104,Business,ITEM_1,0,10-K,104,Some countries outside the U.S. similarly offer forms of patent term restoration.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_105,Business,ITEM_1,0,10-K,105,"For example, Supplementary Protection Certificates are available to extend the life of a European patent up to an additional five years (subject to a 15-year cap from European Medicines Agency (EMA) approval) and in Japan patent terms can be extended up to five years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_106,Business,ITEM_1,0,10-K,106,"In some cases, the innovator company may retain exclusivity despite approval of the generic, biosimilar, or other follow-on versions of a new medicine beyond the expiration of the compound patent through market dynamics and challenges, later-expiring patents on manufacturing processes, methods of use or formulations, or data protection that may be available under pharmaceutical regulatory laws.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_107,Business,ITEM_1,0,10-K,107,The primary forms of data protection are as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_108,Business,ITEM_1,0,10-K,108,•Data package protection generally prohibits regulatory approval of other manufacturers' applications for marketing approval if they rely on the innovator company's regulatory submission data for the drug.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_109,Business,ITEM_1,0,10-K,109,"The base period is generally five years in the U.S. (12 years for new biologics under the BPCIA, subject to certain conditions), effectively 10 years in Europe, and eight years in Japan, which can be extended to 10 years with qualifying pediatric studies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_110,Business,ITEM_1,0,10-K,110,The period begins on the date of product approval and runs concurrently with the patent term for any relevant patents.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_111,Business,ITEM_1,0,10-K,111,"Legislative bodies in the European Union (EU) are discussing proposed reductions in data protection periods but it remains uncertain if, or when, these proposals might be adopted.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_112,Business,ITEM_1,0,10-K,112,"•In the U.S., the FDA has the authority to grant additional data protection for approved drugs where the sponsor conducts specified testing in pediatric populations within a specified time period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_113,Business,ITEM_1,0,10-K,113,"If granted, this ""pediatric exclusivity"" provides an additional six months of exclusivity, which is added to the term of data protection, orphan drug exclusivity and, for products other than biologics, pediatric exclusivity is also added to the term of any relevant and non-expired patents.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_114,Business,ITEM_1,0,10-K,114,"•A specific use of a drug or biologic can receive ""orphan"" designation in the U.S. if it is intended to treat a disease or condition affecting fewer than 200,000 people in the U.S., or where it is not reasonably expected to recover development and marketing costs through U.S. sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_115,Business,ITEM_1,0,10-K,115,"Orphan designation entitles a particular use of the drug to seven years of market exclusivity, which runs in parallel with any applicable patents.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_116,Business,ITEM_1,0,10-K,116,"Outside the major markets, the adequacy and effectiveness of intellectual property protection for pharmaceuticals vary widely.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_117,Business,ITEM_1,0,10-K,117,International and U.S. free trade agreements like the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs Agreement) administered by the World Trade Organization provide global protection of certain intellectual property rights.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_118,Business,ITEM_1,0,10-K,118,But in a number of markets we are unable to patent our products or to enforce the patents that we receive for our products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_119,Business,ITEM_1,0,10-K,119,"Further, many developing countries, and some developed countries, do not provide effective data package protection even though it is specified in the TRIPs Agreement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_120,Business,ITEM_1,0,10-K,120,"Our Intellectual Property Portfolio We consider intellectual property protection for certain products, processes, uses, and formulations to be important to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_121,Business,ITEM_1,0,10-K,121,"In addition to the patents and data protection identified below, we may hold patents on manufacturing processes, formulations, devices, or uses that provide protection beyond the estimated dates shown below.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_122,Business,ITEM_1,0,10-K,122,"For approved products, estimated dates include, where applicable, pending or granted patent term extensions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_123,Business,ITEM_1,0,10-K,123,"Where granted, estimated dates for approved products also reflect pediatric or orphan drug exclusivity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_124,Business,ITEM_1,0,10-K,124,The length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_125,Business,ITEM_1,0,10-K,125,There can be no assurance that a particular product will maintain market exclusivity for the duration of the estimated expiry or that exclusivity will be limited to that time frame.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_126,Business,ITEM_1,0,10-K,126,The most relevant patent protection or data protection and associated expiry dates for our major or recently launched patent-protected marketed products are as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_127,Business,ITEM_1,0,10-K,127,Therapeutic Area Product Protection Territory Estimated Expiry Date Cardiometabolic Health products Jardiance compound patent U.S.* 2029 major European countries 2029 Japan 2030 Mounjaro/Zepbound compound patent U.S. 2036 major European countries 2037 Japan 2040 data protection U.S. 2027 major European countries 2033 Japan 2030 Trulicity compound patent U.S. 2027 major European countries 2029 Japan 2029 biologics data protection U.S. 2027 data protection major European countries 2024 Therapeutic Area Product Protection Territory Estimated Expiry Date Oncology products Cyramza compound patent U.S. 2026 major European countries 2028 Japan 2026 biologics data protection U.S. 2026 data protection major European countries 2024 Jaypirca compound patent U.S. 2037 major European countries 2038 Japan 2040 data protection U.S. 2028 major European countries 2033 Japan 2032 Retevmo compound patent U.S. 2037 major European countries 2037 Japan 2038 data protection U.S. 2025 major European countries 2031 Japan 2031 Verzenio compound patent U.S. 2031 major European countries 2033 Japan 2034 data protection major European countries 2028 Japan 2026 Immunology products Ebglyss compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_128,Business,ITEM_1,0,10-K,128,major European countries Japan biologics data protection U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_129,Business,ITEM_1,0,10-K,129,data protection major European countries Japan Olumiant compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_130,Business,ITEM_1,0,10-K,130,major European countries Japan data protection major European countries Japan Omvoh compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_131,Business,ITEM_1,0,10-K,131,major European countries Japan biologics data protection U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_132,Business,ITEM_1,0,10-K,132,data protection major European countries Japan Taltz compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_133,Business,ITEM_1,0,10-K,133,major European countries Japan biologics data protection U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_134,Business,ITEM_1,0,10-K,134,data protection major European countries Japan Therapeutic Area Product Protection Territory Estimated Expiry Date Neuroscience products Emgality compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_135,Business,ITEM_1,0,10-K,135,major European countries Japan biologics data protection U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_136,Business,ITEM_1,0,10-K,136,data protection major European countries Japan Kisunla compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_137,Business,ITEM_1,0,10-K,137,Japan biologics data protection U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_138,Business,ITEM_1,0,10-K,138,data protection Japan Reyvow compound patent U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_139,Business,ITEM_1,0,10-K,139,"Japan data protection major European countries Japan * Jardiance and the related combination product, Glyxambi.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_140,Business,ITEM_1,0,10-K,140,"The following product candidates are the most relevant that are currently under regulatory review. Upon approval, we expect relevant compound patent and data protections to apply:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_141,Business,ITEM_1,0,10-K,141,•Donanemab has been submitted for regulatory review in the EU for the treatment of early Alzheimer's disease.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_142,Business,ITEM_1,0,10-K,142,"•Imlunestrant has been submitted for regulatory review in the U.S., the EU, and Japan for the treatment of ER-positive HER2-negative metastatic breast cancer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_143,Business,ITEM_1,0,10-K,143,"Worldwide, we sell all of our major products under trademarks consisting of our product names, logos, and unique product appearances that we consider in the aggregate to be important to our operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_144,Business,ITEM_1,0,10-K,144,Trademark protection varies throughout the world.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_145,Business,ITEM_1,0,10-K,145,Trademark protection typically extends beyond the patent and data protection for a product.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_146,Business,ITEM_1,0,10-K,146,We also rely in some circumstances on trade secrets and other unpatented know-how.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_147,Business,ITEM_1,0,10-K,147,"We seek to protect our confidential information in part through confidentiality agreements with our employees, corporate partners, collaborators, and vendors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_148,Business,ITEM_1,0,10-K,148,"These agreements may be breached, and we cannot be certain that we have adequate remedies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_149,Business,ITEM_1,0,10-K,149,"If our trade secrets or confidential information become known or are independently discovered by competitors, or if we enter into disputes over ownership of inventions, our business and results of operations could be adversely affected.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_150,Business,ITEM_1,0,10-K,150,"Patent Licenses and Collaborations Some of our products are subject to significant license and collaboration agreements. For information on our license and collaboration agreements, see Item 8, ""Financial Statements and Supplementary Data-Note 4: Collaborations and Other Arrangements.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_151,Business,ITEM_1,0,10-K,151,"Patent Challenges In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, authorizes the FDA to approve generic versions of innovative pharmaceuticals (other than biologics) when the generic manufacturer files an Abbreviated New Drug Application (ANDA).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_152,Business,ITEM_1,0,10-K,152,"Absent a patent challenge, the FDA cannot approve an ANDA until after certain of the innovator's patents expire.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_153,Business,ITEM_1,0,10-K,153,"However, after the innovator has marketed its product for four years, a generic manufacturer may file an ANDA alleging that the patent(s) listed in the innovator's New Drug Application (NDA) are invalid, unenforceable or not infringed.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_154,Business,ITEM_1,0,10-K,154,"Generic manufacturers use this process extensively to challenge patents on innovative pharmaceuticals. In addition, generic companies have shown willingness to launch ""at risk,"" i.e., after receiving ANDA approval but before final resolution of their patent challenge.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_155,Business,ITEM_1,0,10-K,155,"Under the BPCIA, the FDA cannot approve an application for a biosimilar product until data protection expires, 12 years after initial marketing approval of the innovator biologic, and an application may not be submitted until four years following the date the innovator biologic was first approved.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_156,Business,ITEM_1,0,10-K,156,"However, the BPCIA does provide a mechanism for a prospective biosimilar competitor to challenge the validity of an innovator's patents as early as four years after initial marketing approval of the innovator biologic.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_157,Business,ITEM_1,0,10-K,157,"The patent litigation scheme under the BPCIA, and the BPCIA itself, is complex and continues to be interpreted and implemented by the FDA, as well as by courts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_158,Business,ITEM_1,0,10-K,158,Courts have held that biosimilar applicants are not required to engage in the BPCIA patent litigation scheme and patent holders retain the right to bring suit under normal patent law procedures if a biosimilar applicant attempts to commercialize a product prior to patent expiration.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_159,Business,ITEM_1,0,10-K,159,"In addition, there is a procedure in U.S. patent law, known as inter partes review (IPR), which allows any member of the public to file a petition with the USPTO seeking the review of any issued U.S. patent for validity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_160,Business,ITEM_1,0,10-K,160,IPRs are conducted before Administrative Patent Judges in the USPTO using a lower standard of proof than used in federal district court and challenged patents are not accorded the presumption of validity.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_161,Business,ITEM_1,0,10-K,161,Generic drug companies and even some investment firms have engaged in the IPR process in attempts to invalidate our patents.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_162,Business,ITEM_1,0,10-K,162,"In recent years, U.S. government officials have proposed the exercise of ""march-in-rights"" and various other measures that, if enacted, could have a negative impact on our patent rights.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_163,Business,ITEM_1,0,10-K,163,"We cannot predict the likelihood that these or similar proposals will be adopted, but, if adopted, our business and results of operations could be adversely affected.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_164,Business,ITEM_1,0,10-K,164,"Outside the U.S., the legal doctrines and processes by which pharmaceutical patents can be challenged vary widely. In recent years, we have experienced an increase in patent challenges from generic manufacturers in many countries outside the U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_165,Business,ITEM_1,0,10-K,165,"For more information on patent challenges and litigation involving our intellectual property rights, see Item 1A, ""Risk Factors-Risks Related to Our Business-Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected"" and Item 8, ""Financial Statements and Supplementary Data-Note 16: Contingencies.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_166,Business,ITEM_1,0,10-K,166,Government Regulation of Our Operations and Products Our operations are regulated extensively by numerous government agencies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_167,Business,ITEM_1,0,10-K,167,"The lengthy process of laboratory and clinical testing, data analysis, manufacturing development, and regulatory review necessary for governmental approvals of our products is extremely costly and can significantly delay product introductions and revenue generation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_168,Business,ITEM_1,0,10-K,168,"In addition, our operations are subject to complex federal, state, local, and foreign laws and regulations concerning relationships with healthcare providers and suppliers, pricing and reimbursement for our products, the environment, occupational health and safety, data privacy and security, and other matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_169,Business,ITEM_1,0,10-K,169,"Evolving regulatory priorities have intensified governmental scrutiny of our operations and those of other healthcare intermediaries, including with respect to current Good Manufacturing Practices (cGMP), quality assurance, and similar regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_170,Business,ITEM_1,0,10-K,170,"Regulatory oversight of the pharmaceutical industry entails judgment and interpretation, which can result in varying interpretations of laws and regulations by health and other authorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_171,Business,ITEM_1,0,10-K,171,"In addition, changing political leadership, including the new presidential administration and regulatory authorities in the U.S., may propose, enact, or pursue policy, regulatory, and enforcement changes that create additional uncertainty for our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_172,Business,ITEM_1,0,10-K,172,"Compliance with the laws and regulations affecting the manufacture and sale of our current products and the discovery, development, and introduction of new products and uses has and will continue to require substantial effort, expense, and capital investment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_173,Business,ITEM_1,0,10-K,173,"Of particular importance to our business is regulation by the FDA in the U.S. Pursuant to laws and regulations that include the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHS), the FDA exercises jurisdiction over all of our products and devices in the U.S. and administers requirements covering the testing, safety, effectiveness, manufacturing, quality control, distribution, labeling, marketing, promotion, advertising, dissemination of information, and post-marketing surveillance of those products and devices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_174,Business,ITEM_1,0,10-K,174,The FDA holds broad discretion under the FDCA to interpret the conditions and evidence necessary for timely approval of and ability to market our drugs and devices as well as those of our competitors.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_175,Business,ITEM_1,0,10-K,175,"The centrality to our business of the FDA and corresponding international regulators exposes us to risks of oversight, administrative, and enforcement changes, delays, inconsistencies, lapses, or failures, including as may derive from insufficient staffing levels, expertise, or resources.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_176,Business,ITEM_1,0,10-K,176,"Following approval, our products must meet, and must continue to comply with, regulation by various government and regulatory agencies in connection with labeling, import, export, sale, storage, recordkeeping, advertising, promotion, and safety reporting.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_177,Business,ITEM_1,0,10-K,177,"We conduct extensive post-marketing surveillance of the safety of the products we sell and comply with notification requirements related to safety and efficacy, product supply, and other aspects of our products and operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_178,Business,ITEM_1,0,10-K,178,"The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after a product reaches the market, including as may be identified through market surveillance or third-party studies involving our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_179,Business,ITEM_1,0,10-K,179,"The FDA may also mandate labeling changes, post-marketing studies, or risk management programs to products at any point in a product's life cycle based on new safety information or as part of a labeling change to a particular class of products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_180,Business,ITEM_1,0,10-K,180,"In addition, the FDA strictly regulates marketing, labeling, advertising, and promotion of products to prescribers and patients.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_181,Business,ITEM_1,0,10-K,181,Pharmaceutical products may be promoted only for approved indications and in accordance with the provisions of the approved label.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_182,Business,ITEM_1,0,10-K,182,The FDA and other agencies enforce the laws and regulations prohibiting the promotion of off-label uses.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_183,Business,ITEM_1,0,10-K,183,"Outside the U.S., our products and operations are subject to similar regulatory requirements, notably by the EMA in Europe, the Ministry of Health, Labor and Welfare in Japan, and the National Medical Products Administration in China.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_184,Business,ITEM_1,0,10-K,184,Specific regulatory requirements vary from country to country.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_185,Business,ITEM_1,0,10-K,185,"Regulatory and compliance requirements, as well as approval processes outside the U.S., differ from those in the U.S. and may involve additional costs, uncertainties, and risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_186,Business,ITEM_1,0,10-K,186,The FDA and other regulatory agencies outside the U.S. extensively regulate all aspects of manufacturing quality for pharmaceuticals under their cGMP regulations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_187,Business,ITEM_1,0,10-K,187,"Regulators assess compliance with these regulations by inspecting the equipment, facilities, laboratories, and processes used in the manufacturing and testing of our products prior to marketing approval with periodic reinspection thereafter; this may include inspection of our third-party business partners.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_188,Business,ITEM_1,0,10-K,188,"We make substantial investments of capital and operating expenses to implement comprehensive, company-wide quality systems and controls in our manufacturing, product development, and process development operations in an effort to maintain sustained compliance with cGMP and other regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_189,Business,ITEM_1,0,10-K,189,"Nonetheless, manufacturing quality and other aspects of pharmaceutical regulatory compliance is heavily scrutinized and results in government investigations, regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals, line extensions or supplemental approvals of current products pending resolution of any issues, any of which have and could in the future adversely affect our business and reputation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_190,Business,ITEM_1,0,10-K,190,"Certain of our products, devices and components are manufactured by third parties, and their failure to comply with these regulations has and could in the future adversely affect us, including through failure to supply product to us or delays in approvals of new products or indications.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_191,Business,ITEM_1,0,10-K,191,Any determination by the FDA or other regulatory authorities of manufacturing or other deficiencies could adversely affect our business and reputation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_192,Business,ITEM_1,0,10-K,192,"For more information on product regulation challenges, see Item 1A, ""Risk Factors-Risks Related to Our Operations-Reliance on third-party relationships and outsourcing arrangements could adversely affect our business.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_193,Business,ITEM_1,0,10-K,193,"We rely on the FDA and other regulatory bodies for appropriate oversight, administration, and enforcement of our industry, anyone marketing or purporting to market medicines, and public health.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_194,Business,ITEM_1,0,10-K,194,"We have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_195,Business,ITEM_1,0,10-K,195,"In the U.S., these activities include mass compounding based on asserted reliance on regulatory exceptions that permit limited compounding in certain circumstances by certain entities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_196,Business,ITEM_1,0,10-K,196,"In contrast to the strict regulation of our facilities and manufacturing practices, these actors have experienced low barriers to entry and a lack of regulatory oversight and enforcement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_197,Business,ITEM_1,0,10-K,197,These practices may impact patient safety and undermine regulatory drug approval processes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_198,Business,ITEM_1,0,10-K,198,"If inadequately regulated, these practices could materially impact our business and reputation, including by creating consumer confusion or misperceptions about the safety and efficacy of our genuine products, diversion of potential sales and potential net price erosion for our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_199,Business,ITEM_1,0,10-K,199,"Other Laws and Regulations The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to various other U.S. federal and state laws, as well as analogous foreign laws and regulations, including the federal anti-kickback statute, the False Claims Act, antitrust laws, and state laws governing kickbacks, false claims, unfair trade practices, and consumer protection.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_200,Business,ITEM_1,0,10-K,200,"These laws are administered by, among others, the Department of Justice, the Office of Inspector General of the U.S. Department of Health and Human Services (HHS), the Federal Trade Commission, the Office of Personnel Management, and state attorneys general.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_201,Business,ITEM_1,0,10-K,201,"State, federal, and foreign governments, agencies, and other regulatory bodies are active in their oversight, enforcement activities, and coordination with",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_202,Business,ITEM_1,0,10-K,202,"respect to pharmaceutical companies, which has resulted in intensified scrutiny, litigation costs, corporate criminal sanctions, and substantial civil settlements in the pharmaceutical industry.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_203,Business,ITEM_1,0,10-K,203,"The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits certain individuals and entities, including U.S. publicly traded companies, from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the company obtain or retain business or gain any improper advantage.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_204,Business,ITEM_1,0,10-K,204,The FCPA also imposes specific recordkeeping and internal controls requirements on U.S. publicly traded companies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_205,Business,ITEM_1,0,10-K,205,"As noted above, our business is heavily regulated and therefore involves significant interaction with officials outside the U.S. Additionally, in many countries outside the U.S., healthcare providers who prescribe pharmaceuticals may be employed by the government and purchasers of pharmaceuticals are government entities; therefore, our interactions with these prescribers and purchasers are subject to regulation under the FCPA.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_206,Business,ITEM_1,0,10-K,206,Various other jurisdictions in which we operate and supply our products have laws and regulations aimed at preventing and penalizing corrupt and anticompetitive behavior.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_207,Business,ITEM_1,0,10-K,207,"We are, and could in the future become, subject to administrative and legal proceedings and actions, which could include claims for civil penalties (including treble damages), criminal sanctions, and administrative remedies, including exclusion from participation in government healthcare programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_208,Business,ITEM_1,0,10-K,208,"It is possible that an adverse outcome in future actions could have a material adverse impact on our consolidated results of operations, liquidity, and financial position in any given period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_209,Business,ITEM_1,0,10-K,209,"We are also subject to a variety of federal, state, local, and foreign environmental, health and safety, and other laws and regulations that may affect our research, development, or production efforts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_210,Business,ITEM_1,0,10-K,210,"Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_211,Business,ITEM_1,0,10-K,211,U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_212,Business,ITEM_1,0,10-K,212,There continues to be considerable public and government scrutiny of pharmaceutical pricing.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_213,Business,ITEM_1,0,10-K,213,"In addition, U.S. government actions to reduce federal spending on entitlement programs, including Medicare and Medicaid, affects payment for our products or services associated with the provision of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_214,Business,ITEM_1,0,10-K,214,"In 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_215,Business,ITEM_1,0,10-K,215,"Among other measures, the IRA requires the HHS to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply beginning at nine years (for medicines approved under a New Drug Application) or thirteen years (for medicines approved under a Biologics License Application) following FDA approval or licensure for the molecule and are set at a price that generally represents a significant discount from existing prices to wholesalers and direct purchasers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_216,Business,ITEM_1,0,10-K,216,"While the law specifies a maximum price that HHS can set, it does not set a minimum price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_217,Business,ITEM_1,0,10-K,217,"The Medicare price HHS determines may impact the product's best price determination under the Medicaid Drug Rebate Program and the 340B Drug Pricing Program, potentially leading to a negative impact on both Medicaid and 340B prices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_218,Business,ITEM_1,0,10-K,218,"In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices effective in 2026.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_219,Business,ITEM_1,0,10-K,219,"In August 2024, HHS announced the government-set prices for these medicines with Jardiance subject to a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply and discounts for the other nine medicines ranging from approximately 38% to 79% below list price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_220,Business,ITEM_1,0,10-K,220,"Given our product portfolio, we expect additional significant products will be selected in future years, which would have the effect of accelerating revenue erosion prior to expiry of exclusivities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_221,Business,ITEM_1,0,10-K,221,The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_222,Business,ITEM_1,0,10-K,222,Other IRA provisions require drug manufacturers to provide rebates for Medicare Part B and Part D medicines under certain circumstances.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_223,Business,ITEM_1,0,10-K,223,"Also, on January 1, 2025 the Part D benefit redesign replaced the Part D Coverage Gap Discount Program (CGDP) with the new Manufacturer Discount Program (MDP).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_224,Business,ITEM_1,0,10-K,224,"The 70 percent CGDP discount was replaced by a 10 percent MDP discount for all Medicare Part D beneficiaries that have met their deductible and incurred out of pocket drug costs below a $2,000 threshold and a 20 percent MDP discount for beneficiaries that have incurred out of pocket drug costs above the $2,000 threshold under the new Part D benefit redesign.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_225,Business,ITEM_1,0,10-K,225,"Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties, which could be significant.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_226,Business,ITEM_1,0,10-K,226,"The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_227,Business,ITEM_1,0,10-K,227,"In particular, the nine-year timeline to set prices for medicines approved under a New Drug Application reduces the attractiveness of investment in small molecule innovation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_228,Business,ITEM_1,0,10-K,228,The IRA can cause changes to development approach and timing and investments at-risk.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_229,Business,ITEM_1,0,10-K,229,"The full impact of the IRA on our business and the pharmaceutical industry, including the implications to us of a competitor's product being selected for price setting, remains uncertain.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_230,Business,ITEM_1,0,10-K,230,"Heightened governmental scrutiny over the manner in which drug manufacturers price their marketed products and the practices of pharmacy benefit managers and other supply chain entities has also resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, require advance notice of list price increases, establish upper payment limits or other restrictions by drug affordability review boards, allow the importation of drugs from other countries, address pharmacy benefit manager practices, and reform government program reimbursement methodologies for drug products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_231,Business,ITEM_1,0,10-K,231,Pharmacy benefit manager reform could be pursued or enacted in 2025.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_232,Business,ITEM_1,0,10-K,232,"Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers could also adversely impact our business and financial results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_233,Business,ITEM_1,0,10-K,233,"Additional policies, regulations, legislation, or enforcement, including those proposed or pursued by the U.S. Congress, the U.S. executive branch and regulatory authorities worldwide, could intensify these efforts and adversely impact our business and consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_234,Business,ITEM_1,0,10-K,234,"In the U.S., we are required to provide rebates to the federal government and state governments on their purchases of our pharmaceuticals under various federal and state healthcare programs, including state Medicaid and Medicaid Managed Care programs (a minimum of 23.1 percent plus adjustments for price increases above the consumer price index over time) and discounts to private entities who treat patients in certain types of healthcare facilities intended to serve low-income and uninsured patients (known as 340B covered entities).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_235,Business,ITEM_1,0,10-K,235,"Additionally, an annual fee is imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs, such as Medicare Part B and Part D, and Medicaid.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_236,Business,ITEM_1,0,10-K,236,Changes to the 340B program or the Medicaid programs could have a material adverse impact on our business.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_237,Business,ITEM_1,0,10-K,237,"For example, continued expansion of the 340B program and growth of entities claiming entitlement to 340B pricing, including in ways that may be inconsistent with the statutory scheme, impacts our revenue on an increasing percentage of sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_238,Business,ITEM_1,0,10-K,238,Changes to the calculation of rebates under the Medicaid program could also increase our Medicaid rebate obligations and decrease the prices charged to 340B covered entities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_239,Business,ITEM_1,0,10-K,239,"We have implemented a Contract Pharmacy Limited Distribution System applicable to sales through the 340B program, which generally limits distribution of 340B-priced product to: (i) covered entities and their child sites; or (ii) if a covered entity lacks an in-house outpatient pharmacy, a single contract pharmacy designated by a covered entity to establish a 340B bill to/ship to arrangement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_240,Business,ITEM_1,0,10-K,240,Claims-level data is ordinarily required for any contract pharmacy.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_241,Business,ITEM_1,0,10-K,241,"Our Contract Pharmacy Limited Distribution System contains certain exceptions that permit broader contract pharmacy usage, including for ""penny priced"" insulin products, provided that the covered entity passes through all discounts to eligible patients at the point of sale and meets other conditions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_242,Business,ITEM_1,0,10-K,242,"We believe our Contract Pharmacy Limited Distribution System complies with the 340B statute, but it remains subject to ongoing inquiries and litigation that could have a material impact on our business, as discussed in Item 8, ""Financial Statements and Supplementary Data-Note 16: Contingencies.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_243,Business,ITEM_1,0,10-K,243,"Other aspects of the 340B program, including the manner in which manufacturers can offer 340B pricing, and proper definitions of ""patient"" and ""child site"" under the 340B statute, are also subject to ongoing litigation by Lilly and/or other parties, the resolution of which could impact the growth and scope of the 340B program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_244,Business,ITEM_1,0,10-K,244,"For example, on November 14, 2024, Lilly sued the Health Resources and Services Administration (HRSA) over its purported rejection of Lilly's plan to implement a cash replenishment model to make 340B pricing available to 340B covered entities, in place of the current product replenishment model.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_245,Business,ITEM_1,0,10-K,245,Rebates are also negotiated in the private sector.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_246,Business,ITEM_1,0,10-K,246,We pay rebates to private payers that provide prescription drug benefits to seniors covered by Medicare and to private payers that provide prescription drug benefits to their customers.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_247,Business,ITEM_1,0,10-K,247,These rebates are affected by the introduction of competitive products and generics in the same class.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_248,Business,ITEM_1,0,10-K,248,"For a discussion of risks related to how we price our products, see Item 1A, ""Risk Factors-Risks Related to Our Business-We are party to litigation and investigations related to our products, how we price or commercialize our products, and other aspects of our business, which could adversely affect our business, and we are self-insured for such matters.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_249,Business,ITEM_1,0,10-K,249,Outside the U.S.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_250,Business,ITEM_1,0,10-K,250,"Globally, public and private payers are increasingly restricting access to pharmaceuticals based on assessments of comparative effectiveness and value, including through the establishment of formal health technology assessment processes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_251,Business,ITEM_1,0,10-K,251,"In addition, third-party organizations, including professional associations, academic institutions, and non-profit entities associated with payers, conduct and publish comparative effectiveness and cost/benefit analyses on medicines, the impact of which can influence pharmaceutical access and pricing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_252,Business,ITEM_1,0,10-K,252,"In most international markets, we operate in an environment of government-mandated cost-containment programs, which may include price controls, international reference pricing, discounts and rebates, therapeutic reference pricing (to other, often generic, pharmaceutical choices), health technology assessments, regulatory hurdles, restrictions on physician prescription levels, and mandatory generic substitution.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_253,Business,ITEM_1,0,10-K,253,"In these markets, healthcare services and the determination of pricing and reimbursement for pharmaceutical products are impacted by government control at the point of care or as the primary payer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_254,Business,ITEM_1,0,10-K,254,The European Commission published its draft General Pharmaceutical Legislation in April 2023.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_255,Business,ITEM_1,0,10-K,255,"While certain elements in the European Commission draft could expedite regulatory timelines, we anticipate that the overall market and patient impact would be negative if the legislation is approved as drafted.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_256,Business,ITEM_1,0,10-K,256,Implementation timing is unknown at this time.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_257,Business,ITEM_1,0,10-K,257,"Health care cost containment remains a focus in the EU, among other jurisdictions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_258,Business,ITEM_1,0,10-K,258,Most countries in the EU attempt to contain drug costs by engaging in some form of reference pricing in which authorities examine pre-determined internal or external markets for published prices of a product or national class of drugs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_259,Business,ITEM_1,0,10-K,259,Member states also have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement and may condition access on agreement of a reimbursement price or completion of cost-effectiveness or other gating studies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_260,Business,ITEM_1,0,10-K,260,"In Japan, our products can be subject to government-mandated annual price reductions. The government may also order re-pricings for specific products or classes of products if certain criteria are met, including exceeding product use thresholds.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_261,Business,ITEM_1,0,10-K,261,China has introduced and implemented reforms to accelerate access to innovative products and reduce costs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_262,Business,ITEM_1,0,10-K,262,"To drive patient access, we seek inclusion of many of our branded products on China's National Reimbursement Drug List, a list of drugs fully or partially reimbursed by China's national basic health insurance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_263,Business,ITEM_1,0,10-K,263,"In exchange for broad access, these products are generally subject to negotiation of significant price concessions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_264,Business,ITEM_1,0,10-K,264,China also utilizes a value-based procurement program process for products that have generic substitutes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_265,Business,ITEM_1,0,10-K,265,"As a general matter, products that we choose to tender through this process are similarly subject to price reductions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_266,Business,ITEM_1,0,10-K,266,"Our business in China may be significantly impacted by the country's evolving pharmaceutical regulatory environment, including access, intellectual property protection, regulatory enforcement and compliance, and trade policies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_267,Business,ITEM_1,0,10-K,267,Governments in many emerging markets are also focused on limiting health care costs and have enacted price controls and measures impacting intellectual property.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_268,Business,ITEM_1,0,10-K,268,"Reforms in our product markets, including those that may stem from periods of uneven economic growth or downturns or uncertainty, or as a result of high inflation, emergence, or escalation of, and responses to, international tension and conflicts, or government budgeting priorities, may continue to result in added pressure on pricing, access, and reimbursement for our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_269,Business,ITEM_1,0,10-K,269,"We cannot predict the extent to which our business may be affected by current or potential future legislative, regulatory, or payer developments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_270,Business,ITEM_1,0,10-K,270,"However, in general we expect to see continued focus on regulating pricing, resulting in additional state, federal, and international legislative and regulatory developments that could have further negative effects on pricing, access, and reimbursement for our products as well as overall operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_271,Business,ITEM_1,0,10-K,271,"See Item 7, ""Management's Discussion and Analysis-Executive Overview-Other Matters-Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access and Certain Other Regulatory Developments,"" for additional information regarding recent legislative, administrative, and other pricing initiatives and their impact on our results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_272,Business,ITEM_1,0,10-K,272,Research and Development Our commitment to research and development dates back nearly 150 years.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_273,Business,ITEM_1,0,10-K,273,We invest heavily in research and development because we believe it is critical to our long-term competitiveness.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_274,Business,ITEM_1,0,10-K,274,"At the end of 2024, we employed approximately 11,000 people in pharmaceutical research and development activities, including a substantial number of physicians, scientists holding graduate or postgraduate degrees, and highly skilled technical personnel.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_275,Business,ITEM_1,0,10-K,275,"Our internal pharmaceutical research focuses primarily on the areas of immunology, metabolism (including diabetes, obesity and cardiovascular), neuroscience, and oncology.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_276,Business,ITEM_1,0,10-K,276,"In addition to discovering and developing new medicines, we seek to expand the value of existing products through new uses, formulations, and therapeutic approaches, including complementary delivery devices or diagnostic tools, that can provide additional value to patients.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_277,Business,ITEM_1,0,10-K,277,"To supplement our internal efforts, we collaborate with others, including academic institutions and research-based pharmaceutical and biotechnology companies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_278,Business,ITEM_1,0,10-K,278,"We use the services of physicians, hospitals, medical schools, and other organizations worldwide to conduct clinical trials to establish the safety and effectiveness of our medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_279,Business,ITEM_1,0,10-K,279,We also invest in external research and technologies that we believe complement and strengthen our own efforts.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_280,Business,ITEM_1,0,10-K,280,"These investments can take many forms, including, among others, licensing arrangements, co-development agreements, co-promotion arrangements, joint ventures, acquisitions, and equity investments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_281,Business,ITEM_1,0,10-K,281,"Pharmaceutical development is time-consuming, expensive, and risky.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_282,Business,ITEM_1,0,10-K,282,Very few of the candidates discovered by researchers ultimately become approved medicines.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_283,Business,ITEM_1,0,10-K,283,The process from discovery to regulatory approval can take over a decade.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_284,Business,ITEM_1,0,10-K,284,"Candidates can fail at any stage of the process, and even late-stage candidates sometimes fail to receive regulatory approval or achieve commercial success.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_285,Business,ITEM_1,0,10-K,285,"In addition, novel modalities can present more challenging or lengthy development timelines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_286,Business,ITEM_1,0,10-K,286,The following describes in more detail the research and development process for pharmaceutical products:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_287,Business,ITEM_1,0,10-K,287,"Phases of New Drug Development •Discovery Phase In the discovery phase, scientists identify, design, and synthesize promising candidates by analyzing their effect on biological targets considered to play a role in disease.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_288,Business,ITEM_1,0,10-K,288,"Targets are often unproven and only candidates that are expected to have the desired effect on the target and meet other design criteria move to the next phase of development, which includes the initiation of studies in animals to support regulatory and safety requirements for clinical research in humans.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_289,Business,ITEM_1,0,10-K,289,The discovery phase can take years and the probability of any one candidate becoming a medicine is extremely low.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_290,Business,ITEM_1,0,10-K,290,•Early Development Phase Early development includes initial testing for safety and efficacy and early analyses of manufacturing requirements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_291,Business,ITEM_1,0,10-K,291,"Safety testing is initially performed in laboratory tests and animals, as necessary.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_292,Business,ITEM_1,0,10-K,292,"In general, the first human tests (often referred to as Phase 1) are conducted in small groups of subjects to assess safety and evaluate the potential dosing range.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_293,Business,ITEM_1,0,10-K,293,"Subsequently, larger populations of patients are studied (Phase 2) to identify signs of efficacy while continuing to assess safety.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_294,Business,ITEM_1,0,10-K,294,"In parallel, scientists work to identify safe, effective, and economical manufacturing processes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_295,Business,ITEM_1,0,10-K,295,Long-term animal studies may continue to test for potential safety issues.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_296,Business,ITEM_1,0,10-K,296,"Of the candidates that enter the early development phase, only a fraction move to the late development phase.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_297,Business,ITEM_1,0,10-K,297,The early development phase varies but can take several years to complete.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_298,Business,ITEM_1,0,10-K,298,•Late Development Phase Late phase development projects (typically Phase 3) have met initial safety requirements and shown initial evidence of efficacy in earlier studies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_299,Business,ITEM_1,0,10-K,299,"As a result, these candidates generally have a higher likelihood of success and trials include larger patient populations to demonstrate safety and efficacy of the candidate in treating the disease.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_300,Business,ITEM_1,0,10-K,300,"These studies are designed to demonstrate the benefit and risk of the potential new medicine and may be compared to competitive therapies, placebo, or both.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_301,Business,ITEM_1,0,10-K,301,"Phase 3 studies are generally conducted globally, are costly, and are designed to support regulatory filings for marketing approval.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_302,Business,ITEM_1,0,10-K,302,The duration of Phase 3 testing varies by disease and may take years.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_303,Business,ITEM_1,0,10-K,303,"•Submission Phase Once a potential new medicine is submitted to regulatory agencies, the time to final marketing approval can vary from several months to several years, depending on the disease state, the strength and complexity of available data, the degree of unmet need, and the time required for the regulatory agency(ies) to evaluate the submission, which can depend on prioritization by regulators and other factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_304,Business,ITEM_1,0,10-K,304,"There is no guarantee that a potential medicine will receive marketing approval, or that decisions on marketing approvals or indications will be consistent across geographic areas.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_305,Business,ITEM_1,0,10-K,305,"See Item 7, ""Management's Discussion and Analysis-Executive Overview-Clinical Development Pipeline,"" for more details about our current product pipeline.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_306,Business,ITEM_1,0,10-K,306,Raw Materials and Product Supply Most of the principal materials we use in our manufacturing operations are available from more than one source.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_307,Business,ITEM_1,0,10-K,307,"However, certain materials are procured from a single source.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_308,Business,ITEM_1,0,10-K,308,We seek to maintain sufficient inventory to provide reliability of production and manage unforeseen supply variability.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_309,Business,ITEM_1,0,10-K,309,"However, various developments have led, and may in the future lead, to interruption or shortages in supply until we establish new sources, implement alternative processes, bring new manufacturing facilities online, or pause or discontinue product sales in one or more markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_310,Business,ITEM_1,0,10-K,310,"Our active ingredient manufacturing and finishing operations, including formulation, filling, assembling, delivery device manufacturing, and packaging, take place at sites in the U.S., including Puerto Rico, Ireland and a number of other sites throughout the world.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_311,Business,ITEM_1,0,10-K,311,"To support anticipated demand for our current and prospective products, we have undertaken significant manufacturing expansion initiatives.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_312,Business,ITEM_1,0,10-K,312,"Investments to increase our manufacturing capacity include sites in North Carolina, Wisconsin, Ireland, Germany, and two in Indiana.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_313,Business,ITEM_1,0,10-K,313,"We also utilize and are expanding arrangements with third parties for certain active ingredient manufacturing, filling, finishing operations, and for device or component production and assembly.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_314,Business,ITEM_1,0,10-K,314,"Among these third parties, we, and the pharmaceutical industry generally, depend on China-based suppliers for portions of our supply chain.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_315,Business,ITEM_1,0,10-K,315,"U.S. federal lawmakers are considering legislation that is intended to limit supply chain reliance on China, including the proposed BIOSECURE Act.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_316,Business,ITEM_1,0,10-K,316,"In addition, historically, geopolitical tensions between the U.S. and China have led to the imposition of tariffs, sanctions, and certain other business restrictions between the U.S. and China.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_317,Business,ITEM_1,0,10-K,317,"In February 2025, the U.S. presidential administration imposed new tariffs on China and China responded with tariffs on select U.S. goods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_318,Business,ITEM_1,0,10-K,318,"If new legislation or additional trade restrictions are adopted or geopolitical tensions were to increase and disrupt our operations in, or related to, China, such disruption could significantly impact our business and results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_319,Business,ITEM_1,0,10-K,319,"See Item 1A, ""Risk Factors-Risks Related to Our Operations-Reliance on third-party relationships and outsourcing arrangements could adversely affect our business"" and ""Risk Factors-Risks Related to Doing Business Internationally-Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results,"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_320,Business,ITEM_1,0,10-K,320,"We manage our supply chain (including our own facilities, contracted arrangements, and inventory) in a way that is intended to allow us to meet product demand while maintaining flexibility to reallocate manufacturing capacity to improve efficiency and respond to changes in supply and demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_321,Business,ITEM_1,0,10-K,321,"To maintain supply of our products, we use a variety of techniques, including comprehensive quality systems, inventory management, and back-up sites.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_322,Business,ITEM_1,0,10-K,322,"However, pharmaceutical production processes are complex, highly regulated, and vary widely from product to product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_323,Business,ITEM_1,0,10-K,323,"Shifting or adding manufacturing capacity is a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_324,Business,ITEM_1,0,10-K,324,"Accordingly, developments such as unanticipated demand, unplanned plant shutdowns, manufacturing or quality assurance difficulties at one of our facilities or contracted facilities, failure or refusal of a supplier or contract manufacturer to supply contracted quantities in a timely manner or at all, increases in demand on a supplier, or difficulties in predicting or variability in demand for and supply of our products and those of our competitors have led, and may in the future lead, to interruption or higher costs in the supply of certain products, product shortages, or pauses or discontinuations of product sales in one or more markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_325,Business,ITEM_1,0,10-K,325,"For example, in periods of 2024, demand for our incretin medicines exceeded production.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_326,Business,ITEM_1,0,10-K,326,Supply and channel dynamics in some cases also contribute to variability in financial results for our products from period to period.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_327,Business,ITEM_1,0,10-K,327,"Further, cost and wage inflation, availability of adequate capacity in global transportation, supply chain complexities, including consolidation therein, labor market issues, international tension and conflicts, uneven economic growth or downturns, an increase in overall demand in our industry for certain products and materials, and public health outbreaks, epidemics, or pandemics, have caused, and in the future may cause, delays or disruptions in and/or increased costs related to distribution of our medicines, the construction or acquisition of manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements, as well as other general business impacts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_328,Business,ITEM_1,0,10-K,328,"For more information on the additional risks we face in connection with any difficulties, disruptions, and shortages in the manufacturing, distribution, and sale of our products, see Item 1A, ""Risk Factors-Risks Related to Our Business-Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_329,Business,ITEM_1,0,10-K,329,Quality Assurance Our success depends in great measure on customer confidence in the quality of our products and in the integrity of the data that support their safety and effectiveness.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_330,Business,ITEM_1,0,10-K,330,"Product quality requires a total commitment to quality in all parts of our operations, including research and development, purchasing, facilities planning, manufacturing, distribution, and dissemination of information about our medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_331,Business,ITEM_1,0,10-K,331,"Quality of production processes involves strict control of ingredients, equipment, facilities, manufacturing methods, packaging materials, and labeling.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_332,Business,ITEM_1,0,10-K,332,We perform tests at various stages of production processes and on the final product in an effort to ensure that the product meets all applicable regulatory requirements and our internal standards.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_333,Business,ITEM_1,0,10-K,333,Additional testing for stability over the life of the product is also performed.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_334,Business,ITEM_1,0,10-K,334,"These tests may involve chemical and physical chemical analyses, microbiological testing, testing in animals, or a combination thereof.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_335,Business,ITEM_1,0,10-K,335,Additional assurance of quality is provided by quality assurance groups that audit and monitor all aspects of quality related to pharmaceutical manufacturing procedures and systems in company operations and at third-party suppliers.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_336,Business,ITEM_1,0,10-K,336,Executive Officers of the Company The following table sets forth certain information regarding our current executive officers.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_337,Business,ITEM_1,0,10-K,337,"The term of office for each executive officer expires on the date of the annual meeting of the board of directors, to be held on May 5, 2025 in connection with the company's annual meeting of shareholders, or on the date his or her successor is chosen and qualified.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_338,Business,ITEM_1,0,10-K,338,"No director or executive officer has a ""family relationship"" with any other director or executive officer of the company, as that term is defined for purposes of this disclosure requirement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_339,Business,ITEM_1,0,10-K,339,There is no understanding between any executive officer or director and any other person pursuant to which the executive officer was selected.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_340,Business,ITEM_1,0,10-K,340,"Name Age Titles and Business Experience David Ricks 57 Chair, President, and Chief Executive Officer (CEO) (since 2017).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_341,Business,ITEM_1,0,10-K,341,"Previously, Mr. Ricks held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_342,Business,ITEM_1,0,10-K,342,Mr. Ricks has 28 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_343,Business,ITEM_1,0,10-K,343,"Eric Dozier 58 Executive Vice President, Chief People Officer (since 2022).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_344,Business,ITEM_1,0,10-K,344,"Previously, Mr. Dozier held various leadership roles with Lilly, including senior vice president, chief commercial officer for Loxo@Lilly, and vice president, global ethics and compliance officer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_345,Business,ITEM_1,0,10-K,345,Mr. Dozier has 27 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_346,Business,ITEM_1,0,10-K,346,"Anat Hakim 55 Executive Vice President, General Counsel and Secretary (since 2020).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_347,Business,ITEM_1,0,10-K,347,"Prior to joining Lilly, Ms. Hakim was senior vice president, general counsel and secretary of WellCare Health Plans, Inc. (WellCare) from 2016 to 2018, and executive vice president, general counsel and secretary of WellCare from 2018 to 2020.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_348,Business,ITEM_1,0,10-K,348,"Prior to joining WellCare, she served as divisional vice president and associate general counsel of intellectual property litigation at Abbott Laboratories from 2010 to 2013 and divisional vice president and associate general counsel of litigation from 2013 to 2016.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_349,Business,ITEM_1,0,10-K,349,Ms. Hakim has five years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_350,Business,ITEM_1,0,10-K,350,"Edgardo Hernandez 50 Executive Vice President and President, Manufacturing Operations (since 2021).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_351,Business,ITEM_1,0,10-K,351,"Previously, Mr. Hernandez held various leadership roles with Lilly, including senior vice president, global parenteral drug product, delivery devices and regional manufacturing, and vice president, Fegersheim operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_352,Business,ITEM_1,0,10-K,352,Mr. Hernandez has 20 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_353,Business,ITEM_1,0,10-K,353,"Patrik Jonsson 58 Executive Vice President and President, Lilly Cardiometabolic Health and President, Lilly USA (since 2024).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_354,Business,ITEM_1,0,10-K,354,"Mr. Jonsson has held various leadership roles with Lilly, including, most recently, as Executive Vice President and President, Lilly Immunology and Lilly USA, and Chief Customer Officer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_355,Business,ITEM_1,0,10-K,355,"Previously, he served as senior vice president and president, Lilly Bio-Medicines and president and general manager, Lilly Japan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_356,Business,ITEM_1,0,10-K,356,Mr. Jonsson has 34 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_357,Business,ITEM_1,0,10-K,357,Lucas Montarce 47 Executive Vice President and Chief Financial Officer (since 2024).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_358,Business,ITEM_1,0,10-K,358,"Most recently, Mr. Montarce served as the president and general manager of Lilly's Spain, Portugal, and Greece hub, a position he assumed in 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_359,Business,ITEM_1,0,10-K,359,"Previously Mr. Montarce was group vice president, controller and chief financial officer of Lilly Research Laboratories, vice president, finance and chief financial officer, Lilly International, and vice president, finance and global chief financial officer, Elanco Health.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_360,Business,ITEM_1,0,10-K,360,Mr. Montarce has 23 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_361,Business,ITEM_1,0,10-K,361,Diogo Rau 50 Executive Vice President and Chief Information and Digital Officer (since 2021).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_362,Business,ITEM_1,0,10-K,362,"Prior to joining Lilly, Mr. Rau was senior director of information systems and technology for retail and online stores of Apple Inc. from 2011 to 2021.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_363,Business,ITEM_1,0,10-K,363,"Prior to his tenure at Apple, he served as a partner at McKinsey & Company.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_364,Business,ITEM_1,0,10-K,364,Mr. Rau has four years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_365,Business,ITEM_1,0,10-K,365,"Melissa Seymour 55 Executive Vice President, Global Quality (since 2024).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_366,Business,ITEM_1,0,10-K,366,"Prior to joining Lilly, Ms. Seymour was the chief quality officer for Bristol Myers Squibb from 2022 to 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_367,Business,ITEM_1,0,10-K,367,"Before joining Bristol Myers Squibb, Ms. Seymour was also the chief quality officer at Biogen.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_368,Business,ITEM_1,0,10-K,368,Ms. Seymour has one year of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_369,Business,ITEM_1,0,10-K,369,"Daniel Skovronsky, M.D., Ph.D. 51 Executive Vice President, Chief Scientific Officer and President, Lilly Research Laboratories and Lilly Immunology (since 2024).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_370,Business,ITEM_1,0,10-K,370,"Prior to assuming his current role, Dr. Skovronsky served as Executive Vice President, Chief Scientific and Medical Officer, and President, Lilly Research Laboratories since 2018.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_371,Business,ITEM_1,0,10-K,371,"Dr. Skovronsky has held other leadership roles with Lilly, including as senior vice president, clinical and product development and vice president, diabetes research.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_372,Business,ITEM_1,0,10-K,372,Dr. Skovronsky has 14 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_373,Business,ITEM_1,0,10-K,373,"Jacob Van Naarden 40 Executive Vice President and President, Lilly Oncology (since 2021).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_374,Business,ITEM_1,0,10-K,374,"Previously, Mr. Van Naarden served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_375,Business,ITEM_1,0,10-K,375,"Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_376,Business,ITEM_1,0,10-K,376,"In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_377,Business,ITEM_1,0,10-K,377,Mr. Van Naarden has six years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_378,Business,ITEM_1,0,10-K,378,"Anne White 56 Executive Vice President and President, Lilly Neuroscience (since 2021).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_379,Business,ITEM_1,0,10-K,379,"Previously, Ms. White held various leadership roles with Lilly, including senior vice president and president, Lilly Oncology, vice president of Portfolio Management, Chorus, and Next Generation Research and Development.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_380,Business,ITEM_1,0,10-K,380,Ms. White has 29 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_381,Business,ITEM_1,0,10-K,381,"Ilya Yuffa 50 Executive Vice President and President, Lilly International (since 2021).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_382,Business,ITEM_1,0,10-K,382,"Previously, Mr. Yuffa held various leadership roles with Lilly, including senior vice president and president, Lilly Bio-Medicines, vice president of U.S. Diabetes, general manager of Italy Hub, and vice president, global ethics and compliance officer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_383,Business,ITEM_1,0,10-K,383,Mr. Yuffa has 28 years of service with Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_384,Business,ITEM_1,0,10-K,384,"Human Capital Management Our core values-integrity, excellence, and respect for people-shape our approach to attracting, retaining, engaging, and developing a diverse and highly skilled and ethical workforce.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_385,Business,ITEM_1,0,10-K,385,"Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_386,Business,ITEM_1,0,10-K,386,We believe that fostering a positive culture that values the contributions of our talented colleagues helps drive our success.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_387,Business,ITEM_1,0,10-K,387,"We are committed to creating a safe, supportive, ethical, and rewarding work environment through intentional focus on our human capital management process, fairness and nondiscrimination in our employment practices, robust training and development opportunities, and competitive pay and benefits.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_388,Business,ITEM_1,0,10-K,388,We believe our dedication to promoting inclusion within our company makes Lilly a stronger and more innovative company.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_389,Business,ITEM_1,0,10-K,389,"At all times, we seek to hire the most qualified candidate for each open position.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_390,Business,ITEM_1,0,10-K,390,We regularly conduct confidential employee surveys to seek feedback from our workforce on a variety of topics.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_391,Business,ITEM_1,0,10-K,391,These results are reviewed and analyzed by our leaders to identify opportunities to adjust our practices and benefits to improve our employees' experience.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_392,Business,ITEM_1,0,10-K,392,"As a result of our efforts, we believe that we have a high performing, cohesive workforce and that our employee relations are good.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_393,Business,ITEM_1,0,10-K,393,"At the end of 2024, we employed approximately 47,000 people, including approximately 25,000 employees outside the U.S. Our employees include approximately 11,000 people engaged in research and development activities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_394,Business,ITEM_1,0,10-K,394,"Strategy and Oversight We are committed to fairness and nondiscrimination in our employment practices, and we deeply value diverse backgrounds, skills, and global perspectives.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_395,Business,ITEM_1,0,10-K,395,"Because dedication to human capital management is also a core component of our corporate governance, our board of directors regularly engages with management to monitor human capital management initiatives and progress as part of the overarching framework that guides how we attract, retain, engage, and develop a workforce that aligns with our values and mission.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_396,Business,ITEM_1,0,10-K,396,"Employee Health and Safety We strive to foster a healthy, vibrant work environment, which includes keeping our employees safe.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_397,Business,ITEM_1,0,10-K,397,We seek to create a companywide culture where best-in-class safety practices are consistently followed.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_398,Business,ITEM_1,0,10-K,398,"To do this, we assess and continuously attempt to improve our companywide safety performance to promote the well-being of employees and to help safeguard communities where we operate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_399,Business,ITEM_1,0,10-K,399,We believe a holistic approach and dedication to safety helps us be our best as we deliver on our company purpose to improve lives around the world.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_400,Business,ITEM_1,0,10-K,400,Information Available on Our Website Our company website is www.lilly.com.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_401,Business,ITEM_1,0,10-K,401,"None of the information accessible on or through our website is incorporated into this Annual Report on Form 10-K. We make available through the website, free of charge, our company filings with the Securities and Exchange Commission (SEC) as soon as reasonably practicable after we electronically file them with, or furnish them to, the SEC.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_402,Business,ITEM_1,0,10-K,402,"These include our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, registration statements, and any amendments to those documents.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_403,Business,ITEM_1,0,10-K,403,The link to our SEC filings is investor.lilly.com/financial-information/sec-filings.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_404,Business,ITEM_1,0,10-K,404,Paper copies of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that are filed with the SEC are available without charge upon written request to:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_405,Business,ITEM_1,0,10-K,405,"ELI LILLY AND COMPANY c/o General Counsel and Secretary Lilly Corporate Center Indianapolis, Indiana 46285 In addition, the ""Governance"" section of our website includes our corporate governance guidelines, board of directors and committee information (including committee charters), and our articles of incorporation and bylaws.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_406,Business,ITEM_1,0,10-K,406,The link to our corporate governance information is lilly.com/leadership/governance.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_407,Business,ITEM_1,0,10-K,407,"We routinely post important information for investors in the ""Investors"" section of our website, www.lilly.com.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_408,Business,ITEM_1,0,10-K,408,"We may use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_409,Business,ITEM_1,0,10-K,409,"Accordingly, investors should monitor the ""Investors"" section of our website, in addition to following our press releases, filings with the SEC, public conference calls, presentations, and webcasts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_410,Business,ITEM_1,0,10-K,410,"We and our executive officers may also use social media channels to communicate with investors and the public about our business, products and other matters, and those communications could be deemed to be material information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1_411,Business,ITEM_1,0,10-K,411,"The information contained on, or that may be accessed through, our website or our or our executive officers' social media channels, is not incorporated by reference into, and is not a part of, this Annual Report on Form 10-K.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_0,"Directors, Officers & Governance",ITEM_10,14,10-K,0,"Item 10Directors, Executive Officers, and Corporate Governance Directors and Executive Officers Information relating to our board of directors is found in our Definitive Proxy Statement, to be dated on or about March 21, 2025 (Proxy Statement), under ""Governance - How We Build an Effective Board"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_1,"Directors, Officers & Governance",ITEM_10,14,10-K,1,"Information relating to our insider trading procedure and processes is found in our Proxy Statement under ""Ownership of Company Stock - Common Stock Ownership by Directors and Executive Officers"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_2,"Directors, Officers & Governance",ITEM_10,14,10-K,2,"Information relating to our executive officers is found at Item 1, ""Business - Executive Officers of the Company"" and is incorporated by reference herein.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_3,"Directors, Officers & Governance",ITEM_10,14,10-K,3,"Code of Ethics Information relating to our code of ethics is found in our Proxy Statement under ""Governance - How We Operate an Effective Board - Governance Practices - Board Oversight - Key Areas of Oversight by the Board and Its Committees - Governance - Code of Ethics"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_4,"Directors, Officers & Governance",ITEM_10,14,10-K,4,"Corporate Governance Information about the procedures by which shareholders can recommend nominees to our board of directors is found in our Proxy Statement under ""Governance - How We Build an Effective Board - Director Nominations - Shareholder Director Candidates"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_5,"Directors, Officers & Governance",ITEM_10,14,10-K,5,The board of directors has appointed an audit committee consisting entirely of independent directors in accordance with applicable Securities and Exchange Commission and New York Stock Exchange requirements for audit committees.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_6,"Directors, Officers & Governance",ITEM_10,14,10-K,6,"Information about our audit committee is found in our Proxy Statement under ""Governance - How We Operate an Effective Board - Board Structure - Meetings of the Board and Its Committees - Committees of the Board - Audit Committee"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_10_7,"Directors, Officers & Governance",ITEM_10,14,10-K,7,"Section 16(a) Reporting Compliance Information about our compliance with Section 16(a) is found in our Proxy Statement under ""Ownership of Company Stock - Delinquent Section 16(a) Reports"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_11_0,Executive Compensation,ITEM_11,15,10-K,0,"Item 11Executive Compensation Information on director compensation, executive compensation, and talent and compensation committee matters can be found in the Proxy Statement under ""Governance - How We Build an Effective Board - Director Compensation,"" ""- How We Operate an Effective Board - Board Structure - Meetings of the Board and Its Committees - Committees of the Board - Talent and Compensation Committee,"" ""Compensation - Compensation Discussion and Analysis,"" ""- Talent and Compensation Committee Matters,"" and ""- Executive Compensation.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_11_1,Executive Compensation,ITEM_11,15,10-K,1,Such information is incorporated in this Annual Report on Form 10-K by reference.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_12_0,Security Ownership of Certain Beneficial Owners and Management,ITEM_12,16,10-K,0,Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_12_1,Security Ownership of Certain Beneficial Owners and Management,ITEM_12,16,10-K,1,"Security Ownership of Certain Beneficial Owners and Management Information relating to ownership of the company's common stock by management and by persons known by the company to be the beneficial owners of more than five percent of the outstanding shares of common stock is found in the Proxy Statement under ""Ownership of Company Stock"" and incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_12_2,Security Ownership of Certain Beneficial Owners and Management,ITEM_12,16,10-K,2,"Securities Authorized for Issuance Under Equity Compensation Plans The following table presents information as of December 31, 2024 regarding the company's compensation plans under which shares of the company's common stock have been authorized for issuance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_12_3,Security Ownership of Certain Beneficial Owners and Management,ITEM_12,16,10-K,3,"(1) 2,396,006 shares are underlying outstanding equity awards.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_13_0,Certain Relationships and Related Transactions,ITEM_13,17,10-K,0,"Item 13.Certain Relationships and Related Transactions, and Director Independence",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_13_1,Certain Relationships and Related Transactions,ITEM_13,17,10-K,1,"Related Person Transactions Information relating to the policies and procedures for approval of related person transactions by our board of directors can be found in the Proxy Statement under ""Governance - How We Operate an Effective Board - Board Alignment - Conflicts of Interest and Transactions with Related Persons.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_13_2,Certain Relationships and Related Transactions,ITEM_13,17,10-K,2,Such information is incorporated in this Annual Report on Form 10-K by reference.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_13_3,Certain Relationships and Related Transactions,ITEM_13,17,10-K,3,"Director Independence Information relating to director independence can be found in the Proxy Statement under ""Governance - How We Build an Effective Board - Director Qualifications - Independence"" and is incorporated in this Annual Report on Form 10-K by reference.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_14_0,Principal Accounting Fees and Services,ITEM_14,18,10-K,0,"Item 14Principal Accountant Fees and Services Information related to the fees and services of our principal independent accountants, Ernst & Young LLP, can be found in the Proxy Statement under ""Audit Matters - Item 3 Ratification of the Appointment of the Independent Auditor - Services Performed by the Independent Auditor"" and ""- Independent Auditor Fees.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_14_1,Principal Accounting Fees and Services,ITEM_14,18,10-K,1,Such information is incorporated in this Annual Report on Form 10-K by reference.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_0,Exhibits List,ITEM_15,19,10-K,0,Item 15Exhibits and Financial Statement Schedules (a)1. Financial Statements The following consolidated financial statements of the company and its subsidiaries are found at Item 8:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_1,Exhibits List,ITEM_15,19,10-K,1,"•Consolidated Statements of Operations-Years Ended December 31, 2024, 2023, and 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_2,Exhibits List,ITEM_15,19,10-K,2,"•Consolidated Statements of Comprehensive Income-Years Ended December 31, 2024, 2023, and 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_3,Exhibits List,ITEM_15,19,10-K,3,"•Consolidated Balance Sheets-December 31, 2024 and 2023 •Consolidated Statements of Shareholders' Equity-Years Ended December 31, 2024, 2023, and 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_4,Exhibits List,ITEM_15,19,10-K,4,"•Consolidated Statements of Cash Flows-Years Ended December 31, 2024, 2023, and 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_5,Exhibits List,ITEM_15,19,10-K,5,"•Notes to Consolidated Financial Statements (a)2. Financial Statement Schedules The consolidated financial statement schedules of the company and its subsidiaries have been omitted because they are not required, are inapplicable, or are adequately explained in the financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_6,Exhibits List,ITEM_15,19,10-K,6,"Financial statements of interests of 50 percent or less, which are accounted for by the equity method, have been omitted because they do not, considered in the aggregate as a single subsidiary, constitute a significant subsidiary.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_7,Exhibits List,ITEM_15,19,10-K,7,(a)3. Exhibits The following documents are filed as part of this Annual Report on Form 10-K:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_8,Exhibits List,ITEM_15,19,10-K,8,"Exhibit Description 3.1 Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_9,Exhibits List,ITEM_15,19,10-K,9,"3.2 Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_10,Exhibits List,ITEM_15,19,10-K,10,"4.1 Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee, incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, Registration No.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_11,Exhibits List,ITEM_15,19,10-K,11,333-186979,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_12,Exhibits List,ITEM_15,19,10-K,12,"4.2 Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1, incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_13,Exhibits List,ITEM_15,19,10-K,13,"4.3 Description of the Company's Common Stock, incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_14,Exhibits List,ITEM_15,19,10-K,14,"4.4 Description of the Company's 1.625% Notes due 2026 and 2.125% Notes due 2030, incorporated by reference to Exhibit 4.4 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_15,Exhibits List,ITEM_15,19,10-K,15,"4.5 Description of the Company's 6.77% Notes due 2036, incorporated by reference to Exhibit 4.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_16,Exhibits List,ITEM_15,19,10-K,16,"4.6 Description of the Company's 7 1/8% Notes due 2025, incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_17,Exhibits List,ITEM_15,19,10-K,17,"4.7 Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049, incorporated by reference to Exhibit 4.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_18,Exhibits List,ITEM_15,19,10-K,18,"4.8 Description of the Company's 0.500% Notes due 2033, 1.125% Notes due 2051, and 1.375% Notes due 2061, incorporated by reference to Exhibit 4.8 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_19,Exhibits List,ITEM_15,19,10-K,19,"4.9 Description of the Company's 1.625% Notes due 2043, incorporated by reference to Exhibit 4.9 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_20,Exhibits List,ITEM_15,19,10-K,20,"10.1 Amended and Restated 2002 Lilly Stock Plan(1), incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_21,Exhibits List,ITEM_15,19,10-K,21,"10.2 Form of Performance Award under the 2002 Lilly Stock Plan(1) incorporated by reference to Exhibit 10.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_22,Exhibits List,ITEM_15,19,10-K,22,10.3 Form of Shareholder Value Award under the 2002 Lilly Stock Plan(1)*,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_23,Exhibits List,ITEM_15,19,10-K,23,10.4 Form of Relative Value Award under the 2002 Lilly Stock Plan(1)*,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_24,Exhibits List,ITEM_15,19,10-K,24,10.5 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan(1)*,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_25,Exhibits List,ITEM_15,19,10-K,25,"10.6 Form of Non-Compete Payment Agreement(1), incorporated by reference to Exhibit 10.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2022",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_26,Exhibits List,ITEM_15,19,10-K,26,"10.7 The Lilly Deferred Compensation Plan, as amended(1)* 10.8 The Lilly Directors' Deferral Plan, as amended(1)* 10.9 The Eli Lilly and Company Bonus Plan, as amended(1), incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_27,Exhibits List,ITEM_15,19,10-K,27,"10.10 2007 Change in Control Severance Pay Plan for Select Employees, as amended(1), incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_28,Exhibits List,ITEM_15,19,10-K,28,"19 Trading Lilly Securities Global Procedure* 21 List of Subsidiaries* 23 Consent of Independent Registered Public Accounting Firm* 31.1 Rule 13a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_29,Exhibits List,ITEM_15,19,10-K,29,"31.2 Rule 13a-14(a) Certification of Lucas Montarce, Executive Vice President and Chief Financial Officer*",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_30,Exhibits List,ITEM_15,19,10-K,30,"32 Section 1350 Certification* 97 Executive Compensation Recovery Policy, incorporated by reference to Exhibit 97 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_31,Exhibits List,ITEM_15,19,10-K,31,101 Interactive Data File* 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)*,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_32,Exhibits List,ITEM_15,19,10-K,32,(1) Indicates management contract or compensatory plan.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_33,Exhibits List,ITEM_15,19,10-K,33,* Filed herewith.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_34,Exhibits List,ITEM_15,19,10-K,34,Long-term debt instruments under which the total amount of securities authorized does not exceed 10 percent of our consolidated assets are not filed as exhibits to this Annual Report.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_15_35,Exhibits List,ITEM_15,19,10-K,35,We will furnish a copy of these agreements to the Securities and Exchange Commission upon request.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_0,Risk Factors,ITEM_1A,1,10-K,0,"Item 1ARisk Factors In addition to the other information contained in this Annual Report on Form 10-K, the following risk factors should be considered carefully in evaluating our company.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_1,Risk Factors,ITEM_1A,1,10-K,1,"It is possible that our business, financial condition, liquidity, cash flows, results of operations, reputation, and prospects could be materially adversely affected by any of these risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_2,Risk Factors,ITEM_1A,1,10-K,2,"Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could also adversely affect our business, financial condition, liquidity, cash flows, results of operations, reputation, and prospects.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_3,Risk Factors,ITEM_1A,1,10-K,3,"Risks Related to Our Business and Industry •Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will lose intellectual property protection or are displaced by competing products or therapies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_4,Risk Factors,ITEM_1A,1,10-K,4,"There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products and indications, business development activities to enhance or refine our product pipeline, and commercialization of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_5,Risk Factors,ITEM_1A,1,10-K,5,There is a high rate of failure inherent in drug discovery and development.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_6,Risk Factors,ITEM_1A,1,10-K,6,To bring a product from the discovery phase to market takes considerable time and entails significant cost.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_7,Risk Factors,ITEM_1A,1,10-K,7,"Failure can occur at any point in the process, including in later stages after substantial investment and following meaningful cost for manufacturing capabilities and inventory to prepare for launch.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_8,Risk Factors,ITEM_1A,1,10-K,8,"As a result, a significant portion of funds invested in research and development programs will not generate direct financial returns.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_9,Risk Factors,ITEM_1A,1,10-K,9,"New product candidates that appear promising in development or prior to being acquired may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, failure to obtain placement on guidelines or recommendations published by third-party organizations that are commensurate with clinical data, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of newer, better, or more cost-effective competitive products, difficulty or excessive costs to manufacture, insufficient infrastructure to support detection, diagnostic or other requisites for treatment, ineffectiveness in connecting with healthcare professionals, including digitally through virtual engagements, or infringement of the patents or intellectual property rights of others.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_10,Risk Factors,ITEM_1A,1,10-K,10,"We may also fail to allocate research and development resources efficiently, fail to pursue or invest sufficiently in product candidates or indications that may have been successful, or fail to optimally balance trial design, conduct, and speed to accomplish desired outcomes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_11,Risk Factors,ITEM_1A,1,10-K,11,Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_12,Risk Factors,ITEM_1A,1,10-K,12,"Delay, uncertainty, unpredictability, and inconsistency in drug approval processes across markets and agencies can result in delays in product launches, lost market opportunities, impairment of inventories, and other negative impacts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_13,Risk Factors,ITEM_1A,1,10-K,13,"In addition, it can be very difficult to predict revenue growth rates of, or variability in demand for, new or future products and indications, which in some cases leads to difficulty meeting product demand or, on the other hand, lower volume growth, excess inventory and related financial charges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_14,Risk Factors,ITEM_1A,1,10-K,14,"We cannot state with certainty when or whether our products and indications now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates, indications, or products; or whether our products and indications, once launched, will be commercially successful.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_15,Risk Factors,ITEM_1A,1,10-K,15,"Through internal innovation and business development we must maintain a flow of successful products and indications or line extensions sufficient both to cover our substantial research and development costs and investments and to replace revenues that are lost as profitable products become subject to pricing controls, lose intellectual property exclusivity, or are displaced by competing products or therapies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_16,Risk Factors,ITEM_1A,1,10-K,16,"Failure to timely replenish our product portfolio and pipeline would have a material adverse effect on our business, results of operations, cash flows, and financial position.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_17,Risk Factors,ITEM_1A,1,10-K,17,"Our dependence on, or focus in, one or more key products or product classes exacerbates this risk.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_18,Risk Factors,ITEM_1A,1,10-K,18,"In addition, the growth of our business and revenue base increases the risk that products developed or acquired by us may not provide adequate value to sustain further long-term growth.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_19,Risk Factors,ITEM_1A,1,10-K,19,"We engage in various forms of business development activities to enhance or refine our product pipeline, including licensing arrangements, co-development agreements, co-promotion arrangements, distribution",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_20,Risk Factors,ITEM_1A,1,10-K,20,"and promotion agreements, joint ventures, acquisitions, equity investments, and divestitures.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_21,Risk Factors,ITEM_1A,1,10-K,21,There are substantial risks associated with identifying successful business development targets and consummating related transactions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_22,Risk Factors,ITEM_1A,1,10-K,22,"Continued regulatory focus on business combinations in our industry, including by the Federal Trade Commission and competition authorities in Europe and other jurisdictions, and heightened competition for attractive targets has and could continue to delay, jeopardize, or increase the costs of our business development activities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_23,Risk Factors,ITEM_1A,1,10-K,23,"In addition, failures or difficulties in integrating or retaining new personnel or the operations of the businesses, products, or assets we acquire (including related technology, commercial operations, compliance programs, information security, manufacturing, distribution, and general business operations and procedures) may affect our ability to realize the expected benefits of business development transactions and may result in our incurrence of substantial asset impairment or restructuring charges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_24,Risk Factors,ITEM_1A,1,10-K,24,"We also may fail to generate the expected revenue and pipeline enhancement from business development activities due to limited diligence opportunities, unsuccessful clinical trials, issues related to the quality, integrity, or broad applicability of data, regulatory impediments, and manufacturing or commercialization challenges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_25,Risk Factors,ITEM_1A,1,10-K,25,"Additionally, business development activity focused on new modalities may entail additional risks and costs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_26,Risk Factors,ITEM_1A,1,10-K,26,"Business development transactions may not be completed in a timely manner (if at all), may not result in successful development outcomes or successful commercialization of any product, may give rise to legal proceedings or regulatory scrutiny, and may result in charges that negatively impact our financial position or results of operations in any given period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_27,Risk Factors,ITEM_1A,1,10-K,27,"See Item 1, ""Business-Research and Development-Phases of New Drug Development,"" Item 7, ""Management's Discussion and Analysis-Executive Overview-Clinical Development Pipeline"" and Item 8, ""Financial Statements and Supplementary Data-Note 6: Inventories,"" for more details about our current product pipeline.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_28,Risk Factors,ITEM_1A,1,10-K,28,"•We and our products face intense competition, including from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_29,Risk Factors,ITEM_1A,1,10-K,29,"We compete with a large number of multinational pharmaceutical companies, biotechnology companies, and generic pharmaceutical companies and, in many cases, our products compete against the leading products of one or more of our competitors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_30,Risk Factors,ITEM_1A,1,10-K,30,"To compete successfully, we must continue to deliver innovative, cost-effective products through internal innovation or business development that meet important medical needs, provide improved outcomes and a positive consumer experience for patients, and deliver value to payers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_31,Risk Factors,ITEM_1A,1,10-K,31,"Our product revenues and prospects are adversely affected by patient access issues, the introduction by competitors of branded products that are first to market, have better marketplace access, have greater brand recognition or are perceived as superior by the marketplace, by generic or biosimilar versions of our branded products, and by generic or biosimilar versions of other products in the same therapeutic class as our branded products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_32,Risk Factors,ITEM_1A,1,10-K,32,"Our revenues are also adversely affected by treatment innovations, including new or superior modalities, that eliminate or minimize the need for treatment with our existing products, and our existing products could be subject to decreased sales volumes, realized price reductions, or both.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_33,Risk Factors,ITEM_1A,1,10-K,33,"In some cases, the introduction of our own innovative products results in these adverse impacts for our preexisting products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_34,Risk Factors,ITEM_1A,1,10-K,34,Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_35,Risk Factors,ITEM_1A,1,10-K,35,"Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_36,Risk Factors,ITEM_1A,1,10-K,36,"Given the importance to us of marketed biologic products and those in our clinical-stage pipeline, such regulation could have a material adverse effect on our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_37,Risk Factors,ITEM_1A,1,10-K,37,"See Item 1, ""Business-Competition"" and ""Business-Research and Development,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_38,Risk Factors,ITEM_1A,1,10-K,38,"Alternatively, actual or perceived failure of robust generic and biosimilar competition could propel governments to adopt additional policies and legislation that threaten our intellectual property, pricing of our products, or other aspects of our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_39,Risk Factors,ITEM_1A,1,10-K,39,Our success depends on a market that is observant of intellectual property rights and regulatory requirements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_40,Risk Factors,ITEM_1A,1,10-K,40,Developments that undermine that landscape can significantly impact our business and reputation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_41,Risk Factors,ITEM_1A,1,10-K,41,"For example, we have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins that could materially impact us.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_42,Risk Factors,ITEM_1A,1,10-K,42,Our actions intended to stop or prevent illegal sales of such medicines may be costly or ineffective.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_43,Risk Factors,ITEM_1A,1,10-K,43,"See Item 1, ""Business-Government Regulation of Our Operations and Products,"" for additional information on market risks related to counterfeit, misbranded, adulterated, and compounded medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_44,Risk Factors,ITEM_1A,1,10-K,44,"If inadequately regulated, e-",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_45,Risk Factors,ITEM_1A,1,10-K,45,"commerce may increase the prevalence of dangerous counterfeit or diverted products and scams, potentially exposing patients to significant risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_46,Risk Factors,ITEM_1A,1,10-K,46,"Our reputation and business could suffer harm as a result of counterfeit or diverted drugs sold under our brand name, which may also impact our business and financial results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_47,Risk Factors,ITEM_1A,1,10-K,47,"In addition, we rely on our ability to attract, engage, and retain highly qualified and skilled scientific, technical, management, and other personnel in order to compete effectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_48,Risk Factors,ITEM_1A,1,10-K,48,"To continue to commercialize our products, and advance the research, development, and commercialization of additional modalities, indications, and product candidates, we have expanded, and will likely need to further expand, our workforce, both in and outside the U.S. We continue to face intense competition for qualified individuals from numerous multinational pharmaceutical companies, biotechnology companies, academic and other research institutions, as well as employers near our manufacturing and other facilities, which has and may continue to increase our labor costs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_49,Risk Factors,ITEM_1A,1,10-K,49,"Our failure to compete effectively for talent could negatively affect sales of our current and any future approved products and indications, and could result in material financial, legal, commercial, or reputational harm to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_50,Risk Factors,ITEM_1A,1,10-K,50,"•Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_51,Risk Factors,ITEM_1A,1,10-K,51,"Public and private payers continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_52,Risk Factors,ITEM_1A,1,10-K,52,"These pressures have negatively affected, and we expect will continue to negatively affect, our consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_53,Risk Factors,ITEM_1A,1,10-K,53,"Governments and private payers worldwide have intensified their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products and are demanding greater commercial and clinical value from pharmaceutical companies in the form of strong product differentiation and demonstrated value.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_54,Risk Factors,ITEM_1A,1,10-K,54,"We continue to experience scrutiny on the pricing of current and potential diabetes, obesity, and Alzheimer's disease products due to payer concern over projected growth in these markets and, for certain of these drugs, the anticipated duration of treatment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_55,Risk Factors,ITEM_1A,1,10-K,55,We have also observed scrutiny of pricing and access disparities across jurisdictions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_56,Risk Factors,ITEM_1A,1,10-K,56,"Additional policies, regulations, legislation, or enforcement, including because of the regulatory priorities of the U.S. executive branch and regulatory authorities worldwide, could adversely impact our business and consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_57,Risk Factors,ITEM_1A,1,10-K,57,"For example, in August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices in Medicare effective in 2026.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_58,Risk Factors,ITEM_1A,1,10-K,58,"In August 2024, HHS announced the government-set prices for these first ten medicines with Jardiance subject to a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply and discounts for the other nine medicines ranging from approximately 38% to 79% below list price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_59,Risk Factors,ITEM_1A,1,10-K,59,"Given our product portfolio, we expect additional products will be selected in future years, which would have the effect of accelerating revenue erosion.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_60,Risk Factors,ITEM_1A,1,10-K,60,The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_61,Risk Factors,ITEM_1A,1,10-K,61,"Within the U.S., state level transparency initiatives, importation rules, reporting requirements, and mandated programs, including the establishment of drug affordability boards with the power to set upper payment limits on certain drugs in state-regulated plans, have also increased administrative costs, in some cases, compromised confidential business practices and otherwise detrimentally impacted our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_62,Risk Factors,ITEM_1A,1,10-K,62,"Certain states have also undertaken efforts to codify 340B contract pharmacies into statute or impose other state law mandates, which increase the cost of 340B programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_63,Risk Factors,ITEM_1A,1,10-K,63,"To date, several states have passed contract pharmacy legislation, which have been subject to various legal challenges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_64,Risk Factors,ITEM_1A,1,10-K,64,"For more details, see Item 1, ""Business-Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_65,Risk Factors,ITEM_1A,1,10-K,65,"Further, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, including in relation to the implementation of the IRA, reference pricing, and compulsory licensing, may adversely impact our business and financial results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_66,Risk Factors,ITEM_1A,1,10-K,66,"We continue to experience additional pricing pressures, rebates, clawbacks, and other changes in reimbursement policies and programs resulting from periods of uneven economic growth or downturns or uncertainty, and the emergence or escalation of, and responses to, international tension and conflicts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_67,Risk Factors,ITEM_1A,1,10-K,67,"In addition, government price reporting and payment regulations are complex, and require ongoing assessment of the methods by which we calculate and report pricing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_68,Risk Factors,ITEM_1A,1,10-K,68,Calculation methodologies are inherently subjective and are subject to review and challenge by government agencies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_69,Risk Factors,ITEM_1A,1,10-K,69,"If agencies disagree with our calculations, or the methodologies and assumptions underlying them, we may need to restate previously reported data and could be subject to financial and legal liability, which may be significant.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_70,Risk Factors,ITEM_1A,1,10-K,70,"In addition, changes to calculation methodologies could adversely affect our financial position or consolidated results of operations in any given period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_71,Risk Factors,ITEM_1A,1,10-K,71,"For more details, see Item 1, ""Business-Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access,"" Item 7, ""Management's Discussion and Analysis-Executive Overview-Other Matters-Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access and Certain Other Regulatory Developments"" and Item 8, ""Financial Statements and Supplementary Data-Note 16: Contingencies.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_72,Risk Factors,ITEM_1A,1,10-K,72,"•Pharmaceutical products can develop safety or efficacy concerns, which could have a material adverse effect on our revenues, income, and reputation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_73,Risk Factors,ITEM_1A,1,10-K,73,Pharmaceutical products receive regulatory approval based on data obtained in controlled clinical trials of fixed duration and defined populations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_74,Risk Factors,ITEM_1A,1,10-K,74,"After approval and launch, the products are used for longer periods of time by much larger numbers of patients, which may lead to identifying new safety or efficacy concerns.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_75,Risk Factors,ITEM_1A,1,10-K,75,We and others (including regulatory agencies and private payers) collect extensive information on the efficacy and safety of our marketed products by continuously monitoring the use of our products in the marketplace.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_76,Risk Factors,ITEM_1A,1,10-K,76,"In addition, we or others (including our competitors, in some cases) may conduct post-marketing clinical studies on efficacy and safety of our marketed products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_77,Risk Factors,ITEM_1A,1,10-K,77,"New safety or efficacy data may result in product label changes, or other measures that could reduce the product's market acceptance and result in declining sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_78,Risk Factors,ITEM_1A,1,10-K,78,"Relatedly, safety or efficacy concerns raised about a product in the same class, compounded or counterfeit versions of our products, or products with the same mechanism of action as one of our products or product candidates could be imputed and have an adverse impact on the availability or commercial viability of our products or approval of product candidates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_79,Risk Factors,ITEM_1A,1,10-K,79,"Serious safety or efficacy issues that arise after product approval have, and could in the future, result in voluntary or mandatory product recalls or withdrawals from the market.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_80,Risk Factors,ITEM_1A,1,10-K,80,"Safety issues have, and could in the future, result in costly product liability claims.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_81,Risk Factors,ITEM_1A,1,10-K,81,"Any of these outcomes could result in material financial, legal, commercial, or reputational harm to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_82,Risk Factors,ITEM_1A,1,10-K,82,"•We derive a significant percentage of our total revenue from relatively few products and sell our products through consolidated supply chain entities, which subjects us to various risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_83,Risk Factors,ITEM_1A,1,10-K,83,"We derived direct product and/or collaboration and other revenues of more than $3 billion for each of Mounjaro, Verzenio, Trulicity, Zepbound, Jardiance (including Glyxambi, Synjardy, and Trijardy XR), and Taltz that collectively accounted for 75 percent of our total revenues in 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_84,Risk Factors,ITEM_1A,1,10-K,84,"In particular, Mounjaro, Trulicity, and Zepbound accounted for 48 percent of our total revenues in 2024 and we expect cardiometabolic health products to represent a significant and growing portion of our business, revenues, and prospects.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_85,Risk Factors,ITEM_1A,1,10-K,85,"Loss of patent protection, changes in prescription rates, material product liability or pricing litigation, unexpected side effects or safety concerns, significant changes or fluctuations in demand, regulatory proceedings and investigations, negative publicity affecting doctor or patient confidence, pressure from existing or new competitive products, pipeline developments by us or our competitors, counterfeit and illegally compounded drugs, changes in labeling, pricing, and insufficient access, or reimbursement, or actual or perceived supply shortages or disruptions for these products or any of our other major products could materially impact our results of operations or result in significant and sudden declines or volatility in the trading price of our common stock and market capitalization.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_86,Risk Factors,ITEM_1A,1,10-K,86,"In addition, in the U.S., most of our products are distributed through a limited number of wholesalers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_87,Risk Factors,ITEM_1A,1,10-K,87,"If one of these significant wholesalers encounters financial or other difficulties or otherwise is unable to support distribution of our products, it could cause disruption to our supply chain or we might be unable to timely collect the amounts that the wholesaler owes us, which could negatively impact our results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_88,Risk Factors,ITEM_1A,1,10-K,88,"See Item 1, ""Business-Marketing and Distribution,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_89,Risk Factors,ITEM_1A,1,10-K,89,"Challenges to U.S. retail pharmacies due to pharmacy benefit manager reimbursement pressures, among other things, have resulted in financial difficulties for some pharmacies that may impact patient experiences, lead to determinations by certain pharmacies to not carry one or more of our significant products or threaten the viability of these pharmacies, which could negatively impact our business and results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_90,Risk Factors,ITEM_1A,1,10-K,90,"Moreover, the negotiating power of health plans, managed care organizations, pharmacy benefit managers, and other supply chain entities has increased due to consolidation, regulatory, and other market impacts, and they, along with governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion, or favorable formulary placement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_91,Risk Factors,ITEM_1A,1,10-K,91,Such stakeholders have also increasingly imposed utilization management tools to limit access to our products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_92,Risk Factors,ITEM_1A,1,10-K,92,"As these practices expand, including due to potential further consolidation of U.S. private third-party payers, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_93,Risk Factors,ITEM_1A,1,10-K,93,We expect that consolidation of supply chain entities will continue to increase competitive and pricing pressures on pharmaceutical manufacturers.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_94,Risk Factors,ITEM_1A,1,10-K,94,Pharmacy benefit manager practices have come under increased scrutiny from U.S. policymakers at the federal and state level who have proposed legislation intended to address concerns regarding the impact that these intermediaries have on drug pricing and patients' out of pocket costs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_95,Risk Factors,ITEM_1A,1,10-K,95,"If promulgated, such legislation could have resultant implications, costs, or consequences for our business and how we interact with these entities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_96,Risk Factors,ITEM_1A,1,10-K,96,"For additional information on pricing and reimbursement for our pharmaceutical products, see Item 1, ""Business-U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_97,Risk Factors,ITEM_1A,1,10-K,97,"Private Sector Dynamics"" and ""Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access-U.S.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_98,Risk Factors,ITEM_1A,1,10-K,98,"Risks Related to Our Intellectual Property •We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_99,Risk Factors,ITEM_1A,1,10-K,99,"In the ordinary course of their lifecycles, our products lose significant patent protection and/or data protection in the U.S., as well as in key jurisdictions outside the U.S., after a specified period of time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_100,Risk Factors,ITEM_1A,1,10-K,100,"For example, Trulicity will lose significant patent and remaining data protections in the next few years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_101,Risk Factors,ITEM_1A,1,10-K,101,Some products also lose patent protection as a result of successful third-party challenges.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_102,Risk Factors,ITEM_1A,1,10-K,102,"We have faced, and remain exposed to, generic competition following the expiration or loss of such intellectual property protection.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_103,Risk Factors,ITEM_1A,1,10-K,103,"For non-biologic products, loss of exclusivity typically results in the entry of one or more generic competitors, leading to a rapid and severe decline in revenues, especially in the U.S. Generic pharmaceutical companies have in some cases introduced a generic product before resolution of any related patent litigation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_104,Risk Factors,ITEM_1A,1,10-K,104,"For biologics, loss of exclusivity may or may not result in the near-term entry of competitor versions (i.e., biosimilars) due to many factors, including development timelines, manufacturing challenges, and/or uncertainties regarding the regulatory approval pathways.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_105,Risk Factors,ITEM_1A,1,10-K,105,Our success depends in part on our ability to obtain and defend patent rights and other intellectual property rights that are important to the commercialization of our products and product candidates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_106,Risk Factors,ITEM_1A,1,10-K,106,"The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_107,Risk Factors,ITEM_1A,1,10-K,107,There is no assurance that the patents we are seeking will be granted or that the patents we hold will be found valid and enforceable if challenged.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_108,Risk Factors,ITEM_1A,1,10-K,108,"Third parties may challenge, invalidate, or circumvent our patents and patent applications relating to our products, product candidates, and technologies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_109,Risk Factors,ITEM_1A,1,10-K,109,"In addition, our patent positions might not protect us against competitors with similar products or technologies because competing products or technologies may not be deemed to infringe our patents.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_110,Risk Factors,ITEM_1A,1,10-K,110,"Moreover, patents relating to particular products, uses, formulations, or processes may not preclude other manufacturers from employing alternative processes or marketing alternative products or formulations that compete with our patented products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_111,Risk Factors,ITEM_1A,1,10-K,111,"Patents held by third-parties have also contributed, and may in the future contribute, to a decision by us to not pursue all potential indications for a product candidate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_112,Risk Factors,ITEM_1A,1,10-K,112,"In addition, competitors or other third parties may assert claims that our activities infringe patents or other intellectual property rights held by them, or allege a third-party right of ownership in our existing intellectual property.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_113,Risk Factors,ITEM_1A,1,10-K,113,"See Item 7, ""Management's Discussion and Analysis-Executive Overview-Other Matters-Patent Matters"" and Item 1, ""Business-Patents, Trademarks, and Other Intellectual Property Rights,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_114,Risk Factors,ITEM_1A,1,10-K,114,Patents relating to pharmaceutical products are often obtained early in the development process.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_115,Risk Factors,ITEM_1A,1,10-K,115,"Given the limited duration of patent and data protections, the speed with which we develop products, complete clinical testing, receive regulatory approvals, supply commercial products to the market, and obtain public and private payer access are important factors in recouping our development costs and generating financial returns, particularly given regulatory and market dynamics that have and may continue to put pressure on pricing, exclusivity periods, and competition.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_116,Risk Factors,ITEM_1A,1,10-K,116,Delays in achieving these milestones in some cases may limit our ability to capitalize on the innovative medicines that we develop or acquire.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_117,Risk Factors,ITEM_1A,1,10-K,117,"•Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_118,Risk Factors,ITEM_1A,1,10-K,118,"Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_119,Risk Factors,ITEM_1A,1,10-K,119,"Without strong intellectual property protection, we would be unable to generate the returns necessary to support our significant investments in research and development, as well as the other expenditures required to bring new medicines and indications to the market.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_120,Risk Factors,ITEM_1A,1,10-K,120,"Intellectual property protection varies throughout the world and is subject to change over time, depending on local laws and regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_121,Risk Factors,ITEM_1A,1,10-K,121,"Changes to such laws, regulations, and enforcement practices could reduce protections for our innovative products and indications.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_122,Risk Factors,ITEM_1A,1,10-K,122,"For example, a proposal by the European Commission to revise the EU's general pharmaceutical legislation threatens the predictability and length of certain pharmaceutical intellectual property incentives, including by proposed reductions in data protection periods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_123,Risk Factors,ITEM_1A,1,10-K,123,"Changes proposed by the USPTO and by certain bills in Congress to limit the number of, and differences between, patents obtained could also affect the scope of patent protection for our products in the U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_124,Risk Factors,ITEM_1A,1,10-K,124,"In recent years, U.S. government officials have proposed the exercise of ""march-in-rights"" and various other measures that, if enacted, could have a negative impact on our patent rights.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_125,Risk Factors,ITEM_1A,1,10-K,125,"If any such proposals are adopted, our business and results of operations could be adversely affected.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_126,Risk Factors,ITEM_1A,1,10-K,126,"Also in the U.S., in addition to the process for challenging patents set forth in the BPCIA, which applies to biological products, the Hatch-Waxman Act provides generic companies substantial incentives to seek to invalidate our patents covering small molecule pharmaceutical products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_127,Risk Factors,ITEM_1A,1,10-K,127,"As a result, we expect that our U.S. patents on major pharmaceutical products, including biologics, will continue to be routinely challenged in litigation and may not be upheld.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_128,Risk Factors,ITEM_1A,1,10-K,128,"In addition, a separate IPR process currently allows competitors to seek invalidation of patents at the USPTO without the protections of the BPCIA or Hatch-Waxman Act.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_129,Risk Factors,ITEM_1A,1,10-K,129,The use of IPR proceedings after the institution of litigation pursuant to the BPCIA or Hatch-Waxman Act is currently a topic of debate among legislators and the future ability of our competitors to use IPR proceedings as an alternative to Hatch-Waxman Act or BPCIA litigation procedures to challenge our patents remains uncertain.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_130,Risk Factors,ITEM_1A,1,10-K,130,The USPTO issued an interim procedure regarding the use of discretionary denials of IPR proceedings when there is parallel district court litigation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_131,Risk Factors,ITEM_1A,1,10-K,131,"However, it is not clear how this interim procedure could affect the ability of our competitors to institute IPR proceedings after institution of litigation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_132,Risk Factors,ITEM_1A,1,10-K,132,"If our patents are challenged through this expedited review process, even if we prevail in demonstrating the validity of our patent, our win may not preclude future challenges at the PTAB and is not binding on federal district courts, meaning the same patent can be challenged by other competitors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_133,Risk Factors,ITEM_1A,1,10-K,133,We face many generic manufacturer challenges to our patents outside the U.S. as well.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_134,Risk Factors,ITEM_1A,1,10-K,134,The entry of generic competitors typically results in rapid and severe declines in revenues.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_135,Risk Factors,ITEM_1A,1,10-K,135,"In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_136,Risk Factors,ITEM_1A,1,10-K,136,"If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay significant damages for past infringement or royalties on future sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_137,Risk Factors,ITEM_1A,1,10-K,137,"In addition, intellectual property protection in certain jurisdictions is weak and we face heightened risks to our intellectual property rights in these jurisdictions, including competition with generic or counterfeit versions of our products at or relatively shortly after launch.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_138,Risk Factors,ITEM_1A,1,10-K,138,"See Item 1, ""Business-Patents, Trademarks, and Other Intellectual Property Rights"" and Item 8, ""Financial Statements and Supplementary Data-Note 16: Contingencies,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_139,Risk Factors,ITEM_1A,1,10-K,139,"Risks Related to Our Operations •Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could each result in material harm to our business and reputation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_140,Risk Factors,ITEM_1A,1,10-K,140,"Important confidential information owned by us, our business partners, or other third parties is stored in our information systems, networks, and facilities or those of third parties.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_141,Risk Factors,ITEM_1A,1,10-K,141,"This includes valuable trade secrets and intellectual property, clinical trial information, corporate strategic plans, marketing plans, customer information, and personal information, such as employee and patient information (collectively, confidential information).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_142,Risk Factors,ITEM_1A,1,10-K,142,"We also rely, to a large extent, on the efficient and uninterrupted operation of complex information technology systems, infrastructure, cloud technologies, and hardware (together, IT systems), some of which are within our control and some of which are within the control of third parties, to accumulate, process, store, and transmit large amounts of confidential information and other data.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_143,Risk Factors,ITEM_1A,1,10-K,143,"We are subject to a variety of evolving and developing laws and regulations around the world related to privacy, data protection, and data security.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_144,Risk Factors,ITEM_1A,1,10-K,144,"Maintaining the security, confidentiality, integrity, and availability of our IT systems and confidential information is vital to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_145,Risk Factors,ITEM_1A,1,10-K,145,"Our failure, or the failure of our third-party service providers, to protect and maintain the security, confidentiality, integrity, and availability of our (or their) IT systems and confidential information and other data could significantly harm our reputation as well as result in significant costs, including those related to fines, penalties, litigation, and obligations to comply with applicable data breach laws.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_146,Risk Factors,ITEM_1A,1,10-K,146,"A cybersecurity incident could also impose business costs through lost productivity, disruption to manufacturing, and costs to remediate and recover from the incident.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_147,Risk Factors,ITEM_1A,1,10-K,147,"IT systems are inherently vulnerable to system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware, or cyber-attacks from a variety of sources, which may remain undetected for significant periods of time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_148,Risk Factors,ITEM_1A,1,10-K,148,"From time to time, we update, transition, acquire, or expand use of our and third-party IT systems, which may result in heightened vulnerability.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_149,Risk Factors,ITEM_1A,1,10-K,149,Some third-party IT systems that are necessary for the operation of our business processes are maintained outside of our control but would impact business operations if compromised as a result of a cyber-attack.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_150,Risk Factors,ITEM_1A,1,10-K,150,"Vulnerabilities, inadequacies, or failures are in many cases more acute for IT systems associated with recently acquired businesses, and we may be unable to entirely address such vulnerabilities, inadequacies, or failures immediately after acquiring a business or ever.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_151,Risk Factors,ITEM_1A,1,10-K,151,"As a result, our newly acquired businesses are in some cases more vulnerable to failures, interruptions, breaches, intrusions, theft, exfiltration, or attacks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_152,Risk Factors,ITEM_1A,1,10-K,152,"Cyber-attacks are growing in their frequency, sophistication, and intensity, and are becoming increasingly difficult to detect, mitigate, or prevent.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_153,Risk Factors,ITEM_1A,1,10-K,153,"Cyber-attacks come in many forms, including the deployment of harmful malware, exploitation of vulnerabilities (including those of third-party software or systems), denial-of-service attacks, the use of social engineering (including phishing), and other means to compromise the confidentiality, integrity, and availability of IT systems, confidential information, and other data.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_154,Risk Factors,ITEM_1A,1,10-K,154,"Breaches resulting in the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, interference with, or attack of, our IT systems, products and services, can occur in a variety of ways, including negligent or wrongful conduct by employees or others with permitted access to our systems and information, or wrongful conduct by hackers, competitors, organized criminal groups, nation-states, state-sponsored or affiliated groups, current or former company personnel, and other actors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_155,Risk Factors,ITEM_1A,1,10-K,155,"Our third-party partners, including third-party providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third parties with whom we may share data, face similar risks, which could affect us directly or indirectly.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_156,Risk Factors,ITEM_1A,1,10-K,156,"Unassociated third parties present further risks, including by propagating and amplifying misinformation related to our products, business, and industry, including through social media.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_157,Risk Factors,ITEM_1A,1,10-K,157,"We and others in the healthcare industry have been and continue to be targets for cyber-attacks, and the number of threats has increased over time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_158,Risk Factors,ITEM_1A,1,10-K,158,"Numerous government agencies that monitor and regulate internet and cyber-crime have issued guidance, alerts and directives warning of software vulnerabilities that require immediate patching, malicious actors targeting healthcare-related systems and nation-state sponsored hacking designed to steal valuable information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_159,Risk Factors,ITEM_1A,1,10-K,159,"The failure, inadequacy, or breach of our IT systems or business processes or controls or procedures, the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized access to, disclosure or use of, confidential information, or the unauthorized access to, disruption of, or interference with our products and services that rely on IT systems or business processes, could impair",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_160,Risk Factors,ITEM_1A,1,10-K,160,"our ability to secure and maintain intellectual property rights; result in a product manufacturing interruption or failure, or in the interruption or failure of products or services that rely on IT systems or business processes; damage our operations, patient and other relationships, or reputation; undermine integration activities or otherwise delay or prevent the launch of products; result in unfavorable clinical trial results by virtue of incorrect or unreliable data; expose us to ransom payment, other demands, or paralyze our operations; give rise to legal liability and regulatory action under data protection and privacy laws; require disclosure to government authorities and/or regulators; expose us to civil and criminal investigations; and/or cause us to lose trade secrets or other competitive advantages, which effects could endure for a long period of time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_161,Risk Factors,ITEM_1A,1,10-K,161,"Unauthorized disclosure of personally identifiable information could further expose us to significant sanctions for violations of data privacy laws and regulations around the world, subject us to litigation, and damage public trust in our company.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_162,Risk Factors,ITEM_1A,1,10-K,162,"In addition, IT system security in jurisdictions outside the U.S. is weaker and may result in additional costs, uncertainties, and risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_163,Risk Factors,ITEM_1A,1,10-K,163,"We are subject to various laws and regulations globally regarding privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer, and security of personal information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_164,Risk Factors,ITEM_1A,1,10-K,164,The legislative and regulatory environment regarding privacy and data protection is continuously evolving and the subject of significant attention by regulators and private parties globally.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_165,Risk Factors,ITEM_1A,1,10-K,165,"Regulators are imposing new data privacy and security requirements, including new and greater monetary fines or penalties for privacy violations, and jurisdictions where we operate have passed, or continue to propose, data privacy legislation and/or regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_166,Risk Factors,ITEM_1A,1,10-K,166,"For example, we are subject to existing laws in the EU, United Kingdom, China, and U.S., all of which provide for substantial penalties for noncompliance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_167,Risk Factors,ITEM_1A,1,10-K,167,"Other jurisdictions where we operate have passed, or continue to propose, similar legislation and regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_168,Risk Factors,ITEM_1A,1,10-K,168,"Many jurisdictions, including the U.S., the EU, and China have passed, or expect to pass, restrictions on international data transfers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_169,Risk Factors,ITEM_1A,1,10-K,169,"Compliance with current and future laws and regulations requires implementing potentially costly new controls and processes and may restrict certain core activities, including impacting our ability to carry out research and clinical studies across multiple geographies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_170,Risk Factors,ITEM_1A,1,10-K,170,Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_171,Risk Factors,ITEM_1A,1,10-K,171,"To date, system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware, cyber-attacks, and the compromise, disruption, degradation, manipulation, loss, theft, exfiltration, destruction, or unauthorized disclosure or use of confidential information, or the unauthorized access to, disruption of, interference with, or attack of, our IT systems, products and services that we have encountered have not had a material impact on our business strategy, results of operations or financial condition.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_172,Risk Factors,ITEM_1A,1,10-K,172,"We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, operational, legal, business, or reputational losses that may result from an interruption or breach of our IT systems.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_173,Risk Factors,ITEM_1A,1,10-K,173,"We continue to implement measures in an effort to protect, detect, respond to, remediate, and minimize or prevent these risks and to enhance the resiliency of our IT systems; however, these measures may not be successful, and we may fail to detect or remediate system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware, cyber-attacks, or other compromises of our systems.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_174,Risk Factors,ITEM_1A,1,10-K,174,"Any of these events could result in material financial, operational, legal, business, or reputational harm to our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_175,Risk Factors,ITEM_1A,1,10-K,175,"For a discussion of our management of cybersecurity risks, see Item 1C, ""Cybersecurity-Risk Management and Strategy"" and ""-Governance.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_176,Risk Factors,ITEM_1A,1,10-K,176,"•Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_177,Risk Factors,ITEM_1A,1,10-K,177,We are continuing the significant expansion of our manufacturing capabilities and substantial investment in long-term supply agreements to fortify supply and support anticipated demand for our products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_178,Risk Factors,ITEM_1A,1,10-K,178,Pharmaceutical manufacturing is complex and highly regulated.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_179,Risk Factors,ITEM_1A,1,10-K,179,"Manufacturing or quality assurance difficulties at our facilities or those of our contractors and suppliers, the failure or refusal of a supplier or contract manufacturer to supply contracted quantities in a timely manner or at all, or increases in demand on a supplier with constrained capacity have resulted and may in the future result in delays and disruptions in the manufacturing, distribution, and sale of our products and/or product shortages, leading to lost revenue, reduced market opportunities, and the possibility of additional market entrants.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_180,Risk Factors,ITEM_1A,1,10-K,180,"In select cases, supply constraints may also lead to pauses, discontinuations, or other product availability issues in one or more markets, which could have a material adverse effect on our consolidated results of operations, cash flows, and reputation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_181,Risk Factors,ITEM_1A,1,10-K,181,"Further, cost inflation and global transportation and logistics",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_182,Risk Factors,ITEM_1A,1,10-K,182,"challenges, as well as tight labor markets, have caused, and in the future may cause, delays in, and/or increase costs related to, distribution of our medicines, the construction or other acquisition of additional manufacturing capacity, procurement activity, and supplier or contract manufacturer arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_183,Risk Factors,ITEM_1A,1,10-K,183,"These disruptions and challenges could result from actual or perceived quality, oversight, or regulatory compliance problems; natural disasters (including increased instances or severity of natural disasters or other events that may be due to climate change), public health outbreaks, epidemics, or pandemics; periods of uneven economic growth or downturns; emergence or escalation of, and responses to international tension and conflicts; equipment, mechanical, data, or IT system vulnerabilities, such as system inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware or other cyber-attacks from a variety of sources; labor shortages; challenges and complexities in manufacturing new drug modalities; contractual disputes with our suppliers and contract manufacturers; vertical integration by competitors within our supply chain; or inability to obtain single-source or other raw or intermediate materials.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_184,Risk Factors,ITEM_1A,1,10-K,184,Regional or single source dependencies may in some cases accentuate risks related to manufacturing and supply.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_185,Risk Factors,ITEM_1A,1,10-K,185,"For example, we, and the pharmaceutical industry generally, depend on China-based suppliers for portions of our supply chain, including integral chemical synthesis, reagents, starting materials, and ingredients.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_186,Risk Factors,ITEM_1A,1,10-K,186,Finding alternative suppliers if and as necessary due to geopolitical developments or otherwise may not be feasible or could take a significant amount of time and involve significant expense due to the nature of our products and the need to obtain regulatory approvals which would cause disruptions to patients and detrimentally impact our business.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_187,Risk Factors,ITEM_1A,1,10-K,187,"See, Item 1A, ""Risk Factors-Risks Related to Our Operations-Reliance on third-party relationships and outsourcing arrangements could adversely affect our business,"" and ""Risk Factors-Risks Related to Doing Business Internationally-Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_188,Risk Factors,ITEM_1A,1,10-K,188,Supply and channel dynamics in some cases also contribute to variability in financial results for our products from period to period.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_189,Risk Factors,ITEM_1A,1,10-K,189,"Difficulties in predicting or variability in demand and supply for our products and those of our competitors and the very long lead times necessary for the expansion and regulatory qualification of pharmaceutical manufacturing capacity have resulted, and in the future may result, in difficulty meeting demand, or disruptions, shortages, and higher costs in the supply of, our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_190,Risk Factors,ITEM_1A,1,10-K,190,"For example, at various times during 2024 demand for our incretin medicines exceeded production.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_191,Risk Factors,ITEM_1A,1,10-K,191,"While tirzepatide supply currently exceeds demand in the U.S., demand remains dynamic and could be impacted by a variety of factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_192,Risk Factors,ITEM_1A,1,10-K,192,Supply considerations will continue to influence the timing and approach (including available presentations) of tirzepatide launches in new markets.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_193,Risk Factors,ITEM_1A,1,10-K,193,"Despite our ongoing efforts to meet projected future demand by obtaining additional internal and contracted manufacturing capacity, there can be no assurances that such capacity increases that we expect will be needed to meet future demand will be realized as expected or that we will meet demand in launched markets in the future.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_194,Risk Factors,ITEM_1A,1,10-K,194,Delays or challenges in operationalizing additional manufacturing capacity could limit our ability to capitalize on demand for our products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_195,Risk Factors,ITEM_1A,1,10-K,195,"Conversely, unexpected events that limit demand for our products or anticipated demand for product candidates would undermine our ability to realize the full benefit of significant capital expenditures that we have incurred, and expect to continue to incur, to augment manufacturing capacity, may render built or in process manufacturing capacity unnecessary, and may also subject us to contractual payment obligations, which may be significant.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_196,Risk Factors,ITEM_1A,1,10-K,196,The foregoing risks and uncertainties could negatively impact our consolidated results of operations and reputation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_197,Risk Factors,ITEM_1A,1,10-K,197,"See Item 1, ""Business-Raw Materials and Product Supply"" and Item 7, ""Management's Discussion and Analysis-Financial Condition and Liquidity,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_198,Risk Factors,ITEM_1A,1,10-K,198,•Reliance on third-party relationships and outsourcing arrangements could adversely affect our business.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_199,Risk Factors,ITEM_1A,1,10-K,199,"We rely on third parties, including suppliers, distributors, alliances, and collaborations with other pharmaceutical and biotechnology companies, and third-party service providers, for selected aspects of product and clinical development, manufacturing, commercialization, hosting of, and support for, IT systems, product distribution, and certain financial transactional processes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_200,Risk Factors,ITEM_1A,1,10-K,200,"As examples, we outsource the day-to-day management and oversight of some of our clinical trials to contract research organizations, certain active ingredient manufacturing, finishing operations, and device or component production and assembly to contract manufacturing organizations, and the distribution of our products through logistics providers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_201,Risk Factors,ITEM_1A,1,10-K,201,"To support anticipated demand for our current and prospective products, we have expanded relationships with contract manufacturing organizations and other third parties in recent periods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_202,Risk Factors,ITEM_1A,1,10-K,202,"Outsourcing involves many risks, including the risk that third parties may not perform to our standards or legal requirements; may not produce reliable results; may not perform in a timely manner; may not maintain the confidentiality, integrity, and availability of confidential and proprietary information relating to us, our clinical trial subjects, or patients; may experience disruption or fail to perform due to IT system vulnerabilities, such as inadequacies, inadequate controls or procedures, operating failures, unauthorized access, service interruptions or failures, security breaches, malicious intrusions, theft, exfiltration, ransomware or other cyber-attacks; may be unable to satisfy their commitments to us in which case we may not be able to achieve acceptable alternative sourcing; or may fail to perform at all.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_203,Risk Factors,ITEM_1A,1,10-K,203,"The foregoing risks may be heightened in jurisdictions outside the U.S., where we may have fewer alternative providers as well as face additional costs, uncertainties, and risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_204,Risk Factors,ITEM_1A,1,10-K,204,"Among other third-party providers, we, and the pharmaceutical industry generally, depend on China-based suppliers for portions of our supply chain.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_205,Risk Factors,ITEM_1A,1,10-K,205,"U.S. officials are increasingly considering legislation or other actions that are intended to limit supply chain reliance on China, including the BIOSECURE Act.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_206,Risk Factors,ITEM_1A,1,10-K,206,"In February 2025, the U.S. presidential administration imposed new tariffs on Chinese goods and China responded with tariffs on select U.S. goods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_207,Risk Factors,ITEM_1A,1,10-K,207,"If enacted, additional measures could result in supply disruptions or delays, increase costs more significantly, or invite further retaliatory measures, any of which could negatively impact our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_208,Risk Factors,ITEM_1A,1,10-K,208,"See, Item 1A, ""Risk Factors-Risks Related to Doing Business Internationally-Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_209,Risk Factors,ITEM_1A,1,10-K,209,"In some cases, product or indication approvals depend on the outcome of regulatory inspections of third parties on which we rely.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_210,Risk Factors,ITEM_1A,1,10-K,210,Third-party inspection outcomes have and may in the future delay or prevent product launches and otherwise negatively affect our business.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_211,Risk Factors,ITEM_1A,1,10-K,211,"Failure of third parties to meet their contractual, regulatory, confidentiality, privacy, security, or other obligations to us, our clinical trial subjects, and our patients could have a material adverse effect on our business and could also result in non-compliance with legal or regulatory requirements or industry standards or subject us to reputational harm.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_212,Risk Factors,ITEM_1A,1,10-K,212,•Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_213,Risk Factors,ITEM_1A,1,10-K,213,We deploy AI and other emerging technologies in various facets of our operations and we continue to explore further use cases for AI.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_214,Risk Factors,ITEM_1A,1,10-K,214,"The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business endeavors but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, or that our competitors may more quickly or effectively adopt AI capabilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_215,Risk Factors,ITEM_1A,1,10-K,215,"Our use of AI or other emerging technologies could also exacerbate regulatory, cybersecurity and other significant risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_216,Risk Factors,ITEM_1A,1,10-K,216,"Effective development, management, and use of AI technologies is novel and complex, and there are technical challenges associated with achieving desired levels of accuracy, efficiency, and reliability.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_217,Risk Factors,ITEM_1A,1,10-K,217,"The algorithms and models utilized in AI systems may have limitations, including biases, errors, or inability to handle certain data types or scenarios or to render explainable outputs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_218,Risk Factors,ITEM_1A,1,10-K,218,"Furthermore, there are risks associated with the fact that the platforms providing AI models are in many cases owned and operated by emerging companies with less contractual and compliance sophistication.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_219,Risk Factors,ITEM_1A,1,10-K,219,These factors may undermine our ability to effectively utilize AI or create competitive disadvantages should our competitors more skillfully make use of AI capabilities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_220,Risk Factors,ITEM_1A,1,10-K,220,"Further, if we are unable to effectively manage the use of AI technologies by our employees, our confidential information, intellectual property, or reputation could be put at risk.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_221,Risk Factors,ITEM_1A,1,10-K,221,"The emergence of AI and other technologies may exacerbate other risks, including those related to regulation, litigation, compliance issues, ethical concerns, confidentiality, and data privacy or security.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_222,Risk Factors,ITEM_1A,1,10-K,222,"For example, regulatory uncertainty related to AI or other emerging technologies may require significant resources to adjust business practices to comply with developing laws.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_223,Risk Factors,ITEM_1A,1,10-K,223,"Several governmental authorities have already proposed or enacted laws and other guidance governing AI, such as the EU Artificial Intelligence Act.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_224,Risk Factors,ITEM_1A,1,10-K,224,"These and other developing obligations may prevent or make it harder for us to conduct or enhance our business using AI, or lead to regulatory fines, penalties, or other liability.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_225,Risk Factors,ITEM_1A,1,10-K,225,"Further, use of AI technologies could lead to unintended consequences, such as data leakage, healthcare fraud and abuse, cybersecurity incidents, intellectual property infringement, or unintended biases.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_226,Risk Factors,ITEM_1A,1,10-K,226,"Risks Related to Doing Business Internationally •Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_227,Risk Factors,ITEM_1A,1,10-K,227,"Economic slowdowns could lead to decreased utilization of our products, affecting our sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_228,Risk Factors,ITEM_1A,1,10-K,228,"Declining tax revenues and increased government spending on other programs attributable to uneven economic growth or downturns increase the pressure on governments to reduce healthcare spending, leading to increased control of drug prices or lower utilization.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_229,Risk Factors,ITEM_1A,1,10-K,229,"Additionally, some customers, including governments or other entities reliant upon government funding and cash-pay patients, may be unable to pay for our products fully or in a timely manner.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_230,Risk Factors,ITEM_1A,1,10-K,230,"Also, if our customers, suppliers, or collaboration partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or collaboration partners.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_231,Risk Factors,ITEM_1A,1,10-K,231,"Similarly, uneven economic growth or downturns could limit our ability to access capital markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_232,Risk Factors,ITEM_1A,1,10-K,232,"In addition, significant portions of our business are conducted in Europe, Asia, and other international geographies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_233,Risk Factors,ITEM_1A,1,10-K,233,"Trade and other global disputes and interruptions, including related to tariffs, trade protection measures, import or export licensing requirements, the imposition of trade sanctions or similar restrictions by the U.S. or other governments, international tension and conflicts, as well as economic stagnation, cost inflation, strains on global transportation, manufacturing, and labor markets, and public health outbreaks, epidemics, or pandemics affect our ability to do business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_234,Risk Factors,ITEM_1A,1,10-K,234,"Among other risks, the use of tariffs and other trade restrictions increase costs and may impact clinical trials or sales of our products, or otherwise complicate aspects of our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_235,Risk Factors,ITEM_1A,1,10-K,235,"In particular, tensions between the U.S. and China, which have already led to a series of tariffs and sanctions, as well as other business restrictions, could further escalate based on additional trade restrictions or retaliation thereto.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_236,Risk Factors,ITEM_1A,1,10-K,236,"In February 2025, the U.S. presidential administration imposed new tariffs on Chinese goods and China responded with tariffs on select U.S. goods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_237,Risk Factors,ITEM_1A,1,10-K,237,"Additionally, tariffs were proposed or threatened with respect to other jurisdictions, including Mexico, Canada and Europe.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_238,Risk Factors,ITEM_1A,1,10-K,238,"If geopolitical tensions were to increase and disrupt our operations in, or related to, China or other major international geographies, such disruption would significantly impact our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_239,Risk Factors,ITEM_1A,1,10-K,239,"See Item 1A, ""Risk Factors-Risks Related to Our Operations-Reliance on third-party relationships and outsourcing arrangements could adversely affect our business,"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_240,Risk Factors,ITEM_1A,1,10-K,240,"As a further example, the financial impact of higher energy prices, defense spending, and geopolitical and economic disruptions, has further exacerbated financial pressures on governments with single-payer or government funded healthcare systems, leading to increased impetus for increases in rebates, clawbacks, and other reforms to reimbursement systems, particularly in Europe.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_241,Risk Factors,ITEM_1A,1,10-K,241,"These and similar events have adversely affected, and may continue to adversely affect, us, our business partners, and our customers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_242,Risk Factors,ITEM_1A,1,10-K,242,"For more details, see Item 1, ""Business-Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_243,Risk Factors,ITEM_1A,1,10-K,243,"In addition to developments related to our business or financial results, or those of our competitors, uneven economic growth, downturns, or other negative global developments, could also undermine our growth or result in significant and sudden declines in the trading price of our common stock and market capitalization.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_244,Risk Factors,ITEM_1A,1,10-K,244,"•Changes in foreign currency rates, interest rate risks, and inflation or deflation affect our results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_245,Risk Factors,ITEM_1A,1,10-K,245,"As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, interest rate risk from our exposure to floating and variable interest rates, and existing and expected rates of inflation or deflation in the U.S. and other jurisdictions, each of which impacts our results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_246,Risk Factors,ITEM_1A,1,10-K,246,"In recent periods, significant fluctuations in currency rates and inflation have impacted our results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_247,Risk Factors,ITEM_1A,1,10-K,247,"We are a net receiver of foreign currencies, and our results of operations are adversely impacted when the U.S. dollar is strong compared to foreign currencies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_248,Risk Factors,ITEM_1A,1,10-K,248,"Further, in the event of an extreme devaluation of local currency in a particular market in which we operate, the price of our products could become unsustainable in the relevant market.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_249,Risk Factors,ITEM_1A,1,10-K,249,"Inflationary pressures in recent periods have also negatively impacted us and may continue to negatively impact us in various ways, including cost inflation, higher labor costs, and other higher expenses, with some of these higher expenses due in part to policy actions intended to curb inflation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_250,Risk Factors,ITEM_1A,1,10-K,250,"See Item 7, ""Management's Discussion and Analysis-Financial Condition and Liquidity"" and Item 8, ""Financial Statements and Supplementary Data-Note 1: Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_251,Risk Factors,ITEM_1A,1,10-K,251,"Risks Related to Litigation and Government Regulation •We are party to litigation and investigations related to our products, how we price or commercialize our products, and other aspects of our business, which could adversely affect our business, and we are self-insured for such matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_252,Risk Factors,ITEM_1A,1,10-K,252,"We are subject to a substantial number of claims, litigation, and investigations involving various current and historical products and practices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_253,Risk Factors,ITEM_1A,1,10-K,253,"These claims relate to how we commercialize and/or how we price our products, product safety, our operations as well as contractual matters and other disputes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_254,Risk Factors,ITEM_1A,1,10-K,254,We have also filed lawsuits and taken other legal actions to protect our intellectual property and address unlawful practices.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_255,Risk Factors,ITEM_1A,1,10-K,255,"See Item 8, ""Financial Statements and Supplementary Data-Note 16: Contingencies,"" for more information on certain matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_256,Risk Factors,ITEM_1A,1,10-K,256,"Like many companies in our industry, from time to time investigations into aspects of our business include inquiries, subpoenas, and other types of information demands from government and regulatory authorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_257,Risk Factors,ITEM_1A,1,10-K,257,"There continues to be a significant volume of government and regulatory investigations and litigation against companies operating in our industry, as well as robust regulatory enforcement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_258,Risk Factors,ITEM_1A,1,10-K,258,"Because of the nature of pharmaceutical products, we are, and could in the future become, subject to large numbers of product liability claims for our previous, current, or future products, or to further litigation or investigations, including related to product safety and pricing or other commercial practices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_259,Risk Factors,ITEM_1A,1,10-K,259,Some of these matters involve numerous plaintiffs and parties seeking large or indeterminate financial claims and may remain unresolved for several years.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_260,Risk Factors,ITEM_1A,1,10-K,260,"Such matters could negatively impact our reputation, affect our results of operations or require us to recognize substantial charges to resolve and, if involving marketed products, could adversely affect sales of the product and our consolidated results of operations in any given period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_261,Risk Factors,ITEM_1A,1,10-K,261,"Where we are the plaintiff or complainant, we may be unsuccessful in protecting our intellectual property or mitigating harm to us from unlawful practices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_262,Risk Factors,ITEM_1A,1,10-K,262,"Due to a very restrictive market for liability insurance, we are predominately self-insured for litigation liability losses for all of our products, as well as for litigation or investigations related to our pricing practices or other similar matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_263,Risk Factors,ITEM_1A,1,10-K,263,"•We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_264,Risk Factors,ITEM_1A,1,10-K,264,"We are subject to income taxes in the U.S. and numerous other jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_265,Risk Factors,ITEM_1A,1,10-K,265,"Changes in tax laws, regulations, administrative practices, principles, disclosure obligations, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_266,Risk Factors,ITEM_1A,1,10-K,266,"In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are expected to increase their scrutiny and examinations of cross-border tax issues, which could unfavorably impact our results of operations and cash flows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_267,Risk Factors,ITEM_1A,1,10-K,267,"Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development (OECD) and the European Commission could influence tax laws in countries in which we operate, such as the enactments by both EU and non-EU countries of a global minimum tax.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_268,Risk Factors,ITEM_1A,1,10-K,268,"Modifications to key elements of the U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_269,Risk Factors,ITEM_1A,1,10-K,269,"See Item 7, ""Management's Discussion and Analysis-Executive Overview-Other Matters-Tax Matters"" and Item 8, ""Financial Statements and Supplementary Data-Note 14: Income Taxes,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_270,Risk Factors,ITEM_1A,1,10-K,270,•Regulatory compliance problems could be damaging to the company.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_271,Risk Factors,ITEM_1A,1,10-K,271,"The marketing, promotional, and pricing practices of pharmaceutical manufacturers, as well as the manner in which manufacturers interact with purchasers, prescribers, and patients, are subject to extensive scrutiny and regulation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_272,Risk Factors,ITEM_1A,1,10-K,272,New business practices or commercial capabilities subject us to additional scrutiny over compliance with applicable regulatory schemes and compliance obligations or expose us to new regulatory schemes and compliance obligations entirely.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_273,Risk Factors,ITEM_1A,1,10-K,273,"Many companies, including us, are and have been subject to investigations, litigation, and claims related to these practices asserted by governmental authorities and other parties.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_274,Risk Factors,ITEM_1A,1,10-K,274,"These investigations, litigation, and claims have resulted in substantial expense and other significant consequences for pharmaceutical manufacturers, including criminal charges and fines, penalties, or other monetary or non-monetary remedies, including exclusion from U.S. federal and other healthcare programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_275,Risk Factors,ITEM_1A,1,10-K,275,"Such investigations, litigation, and claims remain intense as a result of evolving U.S. and foreign regulatory priorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_276,Risk Factors,ITEM_1A,1,10-K,276,"In addition, regulatory issues and evolving standards concerning compliance with cGMP and quality assurance, including increased scrutiny",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_277,Risk Factors,ITEM_1A,1,10-K,277,"around excipients, potential impurities such as nitrosamines, and chemicals important to pharmaceutical manufacturing, in some cases lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, delays or denials in new product approvals or line extensions or supplemental approvals of current products pending resolution of the issues, and reputational harm, any of which adversely affects our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_278,Risk Factors,ITEM_1A,1,10-K,278,"Regulatory oversight of the pharmaceutical industry entails judgment and interpretation, which can result in varying interpretations of laws and regulations by health and other authorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_279,Risk Factors,ITEM_1A,1,10-K,279,"In addition, changing political leadership, including the new presidential administration and regulatory leadership in the U.S., may propose, enact, or pursue policy, regulatory, and enforcement changes that create additional uncertainty for our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_280,Risk Factors,ITEM_1A,1,10-K,280,"Regulatory compliance and processes in jurisdictions outside the U.S. may be particularly unpredictable and result in additional costs, uncertainties, and risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_281,Risk Factors,ITEM_1A,1,10-K,281,U.S. and foreign governmental authorities are actively promulgating additional regulations and guidance that impact many aspects of our operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_282,Risk Factors,ITEM_1A,1,10-K,282,These regulations are in some cases advanced with short notice.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_283,Risk Factors,ITEM_1A,1,10-K,283,"New regulations may undermine our ability to achieve business objectives, may be costly to implement, may provide only limited time for compliance, may change accounting and reporting standards, and may carry significant penalties for non-compliance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_284,Risk Factors,ITEM_1A,1,10-K,284,"See Item 1, ""Business-Government Regulation of Our Operations and Products,"" for more details.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_285,Risk Factors,ITEM_1A,1,10-K,285,"We rely on the FDA and other regulatory bodies for appropriate oversight, administration and enforcement across our industry, anyone marketing or purporting to market medicines, and public health.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_286,Risk Factors,ITEM_1A,1,10-K,286,"Oversight, administrative, and enforcement changes, delays, inconsistencies, lapses, and failures could materiality impact our business and reputation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_287,Risk Factors,ITEM_1A,1,10-K,287,"See Item 1, ""Business-Government Regulation of Our Operations and Products,"" for additional information on regulatory risks, including as related to counterfeit, misbranded, adulterated, and compounded medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_288,Risk Factors,ITEM_1A,1,10-K,288,"Furthermore, there is an increased focus by foreign, federal, state, and local regulatory and legislative bodies on legislation and policies relating to climate change, regulating greenhouse gas emissions, carbon taxes, emissions trading schemes, sustainability, human rights and related due diligence, workforce matters, and disclosure regarding the foregoing, many of which may be ambiguous, inconsistent, dynamic or conflicting.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_289,Risk Factors,ITEM_1A,1,10-K,289,"We have experienced increased compliance costs, legal costs, and expenses related to such new or changing legal or regulatory requirements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_290,Risk Factors,ITEM_1A,1,10-K,290,"Moreover, compliance with any such legal or regulatory requirements requires us to devote time and attention, which may be substantial, to these matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_291,Risk Factors,ITEM_1A,1,10-K,291,"In addition, we may still be subject to penalties or potential litigation if such laws and regulations are interpreted or applied in a manner inconsistent with our practices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_292,Risk Factors,ITEM_1A,1,10-K,292,"Additionally, there is increased attention from the media, stockholders, activists, political leadership, regulatory authorities, and other stakeholders on climate, social, and other sustainability matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_293,Risk Factors,ITEM_1A,1,10-K,293,"The perception that we or others in our industry or supply chain have failed to act in an appropriate manner, whether or not valid, results in publicity that can negatively affect our business, brand, and reputation, as well as result in increased scrutiny from political leadership, legislators and regulatory authorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_294,Risk Factors,ITEM_1A,1,10-K,294,"For example, negative perception of inclusion initiatives, whether due to a perceived over- or under-pursuit of such initiatives, may result in issues hiring or retaining employees, as well as potential investigations, enforcement actions, litigation, reputational harm, or other adverse impacts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_295,Risk Factors,ITEM_1A,1,10-K,295,"Moreover, from time to time we establish and publicly announce goals, initiatives, and commitments, including on climate, social, and other sustainability matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_296,Risk Factors,ITEM_1A,1,10-K,296,"Our ability to achieve any of these stated goals, targets or objectives is subject to numerous factors and conditions, many of which are outside our control.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_297,Risk Factors,ITEM_1A,1,10-K,297,"Examples of such factors include evolving regulatory requirements affecting sustainability standards or disclosures or imposing different requirements, and the availability of suppliers that can meet our sustainability and other goals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_298,Risk Factors,ITEM_1A,1,10-K,298,"If we fail to achieve, are perceived to have failed or been delayed in achieving, or improperly report our progress toward achieving these goals, initiatives, and commitments, it could negatively affect our reputation, brand, or investor confidence, and expose us to investigations, enforcement actions and litigation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1A_299,Risk Factors,ITEM_1A,1,10-K,299,"Conversely, our pursuit or achievement of such goals, initiatives, and commitments may not be viewed favorably by certain stakeholders and could increase scrutiny of our business, negatively affect our reputation, or expose us to investigations, enforcement actions and litigation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_1B_0,Unresolved Staff Comments,ITEM_1B,2,10-K,0,Item 1BUnresolved Staff Comments None.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_0,Properties,ITEM_2,3,10-K,0,Item 2Properties Our principal domestic and international executive offices are located in Indianapolis.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_1,Properties,ITEM_2,3,10-K,1,"We own several production, distribution, and corporate administrative sites in the United States (U.S.), including Puerto Rico.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_2,Properties,ITEM_2,3,10-K,2,"Major production sites include facilities in Indiana, North Carolina, Puerto Rico, and New Jersey.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_3,Properties,ITEM_2,3,10-K,3,We own several production and distribution sites in Europe and Asia.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_4,Properties,ITEM_2,3,10-K,4,"Major production sites include facilities in Ireland, France, Spain, Italy, China, and Japan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_5,Properties,ITEM_2,3,10-K,5,Additional U.S. and international production facilities and expansions of production facilities are expected to come online in future periods.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_6,Properties,ITEM_2,3,10-K,6,"In the U.S., our research and development facilities primarily consist of owned facilities located in Indiana and leased sites in California, Massachusetts, New York, and Colorado.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_7,Properties,ITEM_2,3,10-K,7,"Outside the U.S., we own a small research and development facility in Spain and lease a small site in Singapore.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_8,Properties,ITEM_2,3,10-K,8,"We believe that none of our properties is subject to any encumbrance, easement, or other restriction that would detract materially from its value or impair its use in the operation of the business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_2_9,Properties,ITEM_2,3,10-K,9,The buildings we own are of varying ages and in good condition.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_3_0,Legal Proceedings,ITEM_3,4,10-K,0,"Item 3Legal Proceedings We are a party to various currently pending legal actions, government investigations, and environmental proceedings.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_3_1,Legal Proceedings,ITEM_3,4,10-K,1,"Information pertaining to legal proceedings is described in Item 8, ""Financial Statements and Supplementary Data - Note 16: Contingencies,"" and incorporated by reference herein.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_4_0,Mine Safety Disclosures,ITEM_4,5,10-K,0,Item 4Mine Safety Disclosures Not applicable.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_4_1,Mine Safety Disclosures,ITEM_4,5,10-K,1,Part II,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_0,Market for Stock,ITEM_5,6,10-K,0,"Item 5.Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_1,Market for Stock,ITEM_5,6,10-K,1,"Information relating to the principal market for our common stock, dividends, and related stockholder matters is described in Item 7, ""Management's Discussion and Analysis of Results of Operations and Financial Condition"" and Item 12, ""Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_2,Market for Stock,ITEM_5,6,10-K,2,This information is incorporated herein by reference.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_3,Market for Stock,ITEM_5,6,10-K,3,"As of February 14, 2025, there were approximately 17,903 holders of record of our common stock based on information provided by EQ Shareowner Services, our transfer agent.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_4,Market for Stock,ITEM_5,6,10-K,4,Our common stock is listed under the ticker symbol LLY on the New York Stock Exchange (NYSE).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_5,Market for Stock,ITEM_5,6,10-K,5,"The following table summarizes the activity related to repurchases of our equity securities during the three months ended December 31, 2024:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_6,Market for Stock,ITEM_5,6,10-K,6,"During the three months ended December 31, 2024, we repurchased the remaining $1.98 billion of shares under our $5.00 billion share repurchase program that our board authorized in May 2021.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_7,Market for Stock,ITEM_5,6,10-K,7,Our board authorized a $15.00 billion share repurchase program in December 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_8,Market for Stock,ITEM_5,6,10-K,8,"No shares were repurchased under this new program as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_9,Market for Stock,ITEM_5,6,10-K,9,PERFORMANCE GRAPH The following graph compares the return on Lilly stock with that of the Standard & Poor's (S&P) 500 Stock Index and our peer group for the years 2020 through 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_10,Market for Stock,ITEM_5,6,10-K,10,"The graph assumes that, on the last business day of 2019, a person invested $100 each in Lilly stock, the S&P 500 Stock Index, and the peer group's collective common stock.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_11,Market for Stock,ITEM_5,6,10-K,11,"The graph measures total shareholder return, which takes into account both stock price and dividends.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_12,Market for Stock,ITEM_5,6,10-K,12,It assumes that dividends paid by a company are immediately reinvested in that company's stock.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_13,Market for Stock,ITEM_5,6,10-K,13,"Value of $100 Invested on Last Business Day of 2019 Comparison of Five-Year Cumulative Total Shareholder Return Among Lilly, S&P 500 Stock Index, and Peer Group(1)",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_14,Market for Stock,ITEM_5,6,10-K,14,(1) We constructed the peer group as the industry index for this graph.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_15,Market for Stock,ITEM_5,6,10-K,15,"It is comprised of the following companies in the pharmaceutical and biotechnology industries: AbbVie Inc.; Amgen Inc.; AstraZeneca PLC; Biogen Inc.; Bristol-Myers Squibb Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Roche Holding AG; Sanofi S.A.; and Takeda Pharmaceutical Company Limited.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_5_16,Market for Stock,ITEM_5,6,10-K,16,The peer group used for performance benchmarking aligns with the peer group used for executive compensation purposes for 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_6_0,Selected Financial Data,ITEM_6,7,10-K,0,Item 6 [Reserved],2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_0,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,0,Item 7.Management's Discussion and Analysis of Results of Operations and Financial Condition,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_1,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,1,"(Tables present dollars in millions, except per-share data) General Management's discussion and analysis of results of operations and financial condition is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_2,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,2,"This discussion and analysis should be read in conjunction with Item 8, ""Financial Statements and Supplementary Data.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_3,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,3,Certain statements in this Item 7 constitute forward-looking statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_4,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,4,"Various risks and uncertainties, including those discussed in ""Forward-Looking Statements"" and Item 1A, ""Risk Factors,"" may cause our actual results, financial position, and cash generated from operations to differ from these forward-looking statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_5,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,5,"EXECUTIVE OVERVIEW This section provides an overview of our financial results, our clinical development pipeline, and other matters affecting our company and industry.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_6,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,6,"Financial Results The following table summarizes certain financial information: Revenue increased in 2024 driven by increased volume and, to a lesser extent, higher realized prices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_7,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,7,"The increase in revenue in 2024 was primarily driven by Mounjaro, Zepbound, and Verzenio, partially offset by Trulicity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_8,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,8,"Net income and earnings per share increased in 2024, primarily due to higher gross margin, partially offset by increased research and development expenses, marketing, selling, and administrative expenses, and asset impairment, restructuring, and other special charges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_9,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,9,"See ""Results of Operations"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_10,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,10,"Clinical Development Pipeline Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative medicines.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_11,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,11,"We currently have approximately 55 new medicine candidates in clinical development or under regulatory review, and a larger number of projects in the discovery phase.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_12,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,12,"The following select new molecular entities (NMEs) and new indication line extension (NILEX) products are currently in Phase 2 or Phase 3 clinical trials or have been submitted for regulatory review or have recently received regulatory approval in the United States (U.S.), European Union (EU), or Japan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_13,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,13,"The table reflects the status of these NMEs and NILEX products, including certain other developments, up to the time of the filing of this Annual Report on Form 10-K:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_14,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,14,"(1) In collaboration with Almirall, S.A. in Europe.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_15,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,15,(2) Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_16,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,16,(3) Continued approval may be contingent on verification and description of clinical benefit in confirmatory Phase 3 trials.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_17,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,17,"There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products and indications, business development activities to enhance or refine our product pipeline, and commercialization of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_18,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,18,There is a high rate of failure inherent in drug discovery and development.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_19,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,19,To bring a product from the discovery phase to market takes considerable time and entails significant cost.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_20,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,20,"See Item 1A, ""Risk Factors-Risks Related to Our Business and Industry-Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will lose intellectual property protection or are displaced by competing products or therapies,"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_21,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,21,We manage research and development spending across our portfolio of potential new medicines and indications.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_22,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,22,"A delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_23,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,23,"Due to the risks and uncertainties involved in the research and development process, we cannot reliably estimate the nature, timing, and costs of the efforts necessary to complete the development of our research and development projects, nor can we reliably estimate the future potential revenue that will be generated from any successful research and development project.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_24,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,24,"Each project represents only a portion of the overall pipeline, and none is individually material to our consolidated research and development expense.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_25,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,25,"While we do accumulate certain research and development costs on a project level for internal reporting purposes, we must make significant cost estimations and allocations, some of which rely on data that are neither reproducible nor validated through accepted control mechanisms.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_26,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,26,"Therefore, we do not have sufficiently reliable data to report on total research and development costs by project, by pre-clinical versus clinical spend, or by therapeutic category.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_27,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,27,"Other Matters Patent Matters We depend on patents or other forms of intellectual property protection for most of our revenue, cash flows, and earnings.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_28,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,28,See Note 16 to the consolidated financial statements for a description of legal proceedings currently pending regarding certain of our patents.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_29,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,29,"See Item 1, ""Business-Patents, Trademarks, and Other Intellectual Property Rights,"" for a discussion of the impacts of trends involving intellectual property on our business and results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_30,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,30,"Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access and Certain Other Regulatory Developments",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_31,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,31,"Reforms, including those that may stem from political initiatives, periods of uneven economic growth or downturns, or as a result of inflation or deflation, the emergence or escalation of, and responses to, international tension and conflicts, or government budgeting priorities, are expected to continue to result in added pressure on pricing and reimbursement for our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_32,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,32,"Global concern over access to, and affordability of, pharmaceutical products continues to drive regulatory and legislative debate and action, as well as cost containment efforts by governmental authorities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_33,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,33,"Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_34,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,34,"In 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_35,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,35,"Among other measures, the IRA requires the U.S. Department of Health and Human Services (HHS) to effectively set prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D. Generally, these government prices apply beginning at nine years (for medicines approved under a New Drug Application) or thirteen years (for medicines approved under a Biologics License Application) following FDA approval or licensure for the molecule and are set at a price that generally represents a significant discount from existing prices to wholesalers and direct purchasers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_36,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,36,"While the law specifies a maximum price that HHS can set, it does not set a minimum price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_37,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,37,"The Medicare price HHS determines may impact the product's best price determination under the Medicaid Drug Rebate Program and the 340B Drug Pricing Program, potentially leading to a negative impact on both Medicaid and 340B prices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_38,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,38,"In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices effective in 2026.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_39,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,39,"In August 2024, HHS announced the government-set prices for these medicines with Jardiance subject to a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply and discounts for the other nine medicines ranging from approximately 38% to 79% below list price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_40,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,40,"Given our product portfolio, we expect additional significant products will be selected in future years, which would have the effect of accelerating revenue erosion prior to expiry of exclusivities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_41,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,41,The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_42,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,42,Other IRA provisions require drug manufacturers to provide rebates for Medicare Part B and Part D medicines under certain circumstances.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_43,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,43,"Also, on January 1, 2025, the Part D benefit redesign replaced the Part D Coverage Gap Discount Program with a new manufacturer discount program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_44,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,44,"Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties, which could be significant.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_45,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,45,"The IRA has, and will continue to, meaningfully influence our business strategies and those of our competitors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_46,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,46,"In particular, the nine-year timeline to set prices for medicines approved under a New Drug Application reduces the attractiveness of investment in small molecule innovation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_47,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,47,The IRA can cause changes to development approach and timing and investments at-risk.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_48,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,48,"The full impact of the IRA on our business and the pharmaceutical industry, including the implications to us of a competitor's product being selected for price setting, remains uncertain.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_49,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,49,"Additional policies, regulations, legislation, or enforcement, including those proposed or pursued by lawmakers, regulators, and other authorities in the U.S. and worldwide, could adversely impact our business and consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_50,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,50,"For example, the U.S. House of Representatives recently passed the BIOSECURE Act, which is under consideration in the U.S. Senate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_51,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,51,"This legislation, if passed, could affect elements of the pharmaceutical supply chain; although as currently drafted we do not anticipate the bill would have a material impact on our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_52,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,52,Consolidation and integration of private payers and pharmacy benefit managers in the U.S. has also significantly impacted the market for pharmaceuticals by increasing payer leverage in negotiating manufacturer price or rebate concessions and pharmacy reimbursement rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_53,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,53,"Furthermore, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers may adversely impact our business and consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_54,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,54,"We expect that these actions may intensify and could particularly affect certain products, which could adversely affect our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_55,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,55,"In addition, we are engaged in litigation and investigations related to the 340B program, access to insulin, pricing, product safety, and other matters that, if resolved adversely to us, could negatively impact our business and consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_56,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,56,It is not currently possible to predict the overall potential adverse impact to us or the general pharmaceutical industry of continued cost containment efforts worldwide.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_57,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,57,"In addition, regulatory issues concerning compliance with current Good Manufacturing Practices, quality assurance, safety signals, evolving standards, and increased scrutiny around excipients and potential impurities such as nitrosamines, and similar regulations and standards (and comparable foreign regulations and standards) for our products in some cases lead to regulatory and legal actions, product recalls and seizures, fines and penalties, interruption of production leading to product shortages, import bans or denials of import certifications, inability to realize the benefit of capital expenditures, or delays or denials in new product approvals, line extensions or supplemental approvals of current products pending resolution of the issues, or other negative impacts, any of which result in reputational harm or adversely affect our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_58,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,58,"See Item 1, ""Business-Regulations and Private Payer Actions Affecting Pharmaceutical Pricing, Reimbursement, and Access,"" Item 1A, ""Risk Factors,"" and Note 16 to the consolidated financial statements for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_59,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,59,"Incretin Medicines At various times during 2024, demand for our incretin medicines exceeded production.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_60,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,60,Supply and channel dynamics have also contributed to variability in quarter-over-quarter revenue growth rates for tirzepatide.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_61,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,61,"Tirzepatide supply currently exceeds demand in the U.S. Demand in launched markets remains dynamic, and increases or changes in demand, by dose or overall, as well as the complex supply chain, may result in periodic unavailability of certain presentations and dose levels at certain locations even when total tirzepatide supply can meet demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_62,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,62,Supply considerations will continue to influence the timing and approach (including available presentations) of tirzepatide launches in new markets.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_63,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,63,"We continue to expand manufacturing capacity and progress efforts to bring tirzepatide to patients via different delivery presentations, such as single-use vials and multi-use pens.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_64,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,64,"Production increases will continue, and additional capacity is expected to be operational over the next several years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_65,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,65,"We have seen an increase in the production, marketing, and sale of counterfeit, misbranded, adulterated, and compounded incretins.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_66,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,66,These practices may impact patient safety and undermine regulatory drug approval processes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_67,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,67,"Lilly will continue to consider all options, including filing lawsuits where appropriate, to address unlawful practices and the patient safety risks of unapproved, untested, and manipulated drugs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_68,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,68,"See Item 1, ""Business-Government Regulation of Our Operations and Products"" and Item 1A, ""Risk -Risks Related to Our Business and Industry-We and our products face intense competition, including from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business,"" for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_69,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,69,"Tax Matters We are subject to income taxes and various other taxes in the U.S. and in many foreign jurisdictions; therefore, changes in both domestic and international tax laws or regulations have affected and may affect our effective tax rate, results of operations, and cash flows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_70,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,70,The U.S. and countries around the world are actively proposing and enacting tax law changes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_71,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,71,"Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development (OECD) and the European Commission could influence tax laws in countries in which we operate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_72,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,72,Tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are expected to increase their scrutiny of cross-border tax issues.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_73,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,73,Changes to existing U.S. and foreign tax laws and increased scrutiny by tax authorities in the U.S. and other jurisdictions could have a material adverse impact our future consolidated results of operations and cash flows.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_74,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,74,"Effective January 1, 2024, several EU and non-EU countries enacted legislation (known as ""Pillar Two"") that provided for a minimum level of taxation of multinational companies.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_75,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,75,The increase to income tax expense as a result of the global minimum tax was not material in 2024 and is not expected to be material in current and future years.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_76,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,76,Our assessment of the impact for 2025 and subsequent years could be affected by legislative guidance and future enactment of additional provisions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_77,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,77,Acquisitions We invest in external research and technologies and manufacturing capabilities that we believe complement and strengthen our own efforts.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_78,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,78,"These investments can take many forms, including acquisitions, collaborations, investments, and licensing arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_79,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,79,We view our business development activity as a way to enhance or refine our pipeline and strengthen our business.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_80,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,80,See Note 3 to the consolidated financial statements for further discussion regarding our recent acquisitions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_81,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,81,"Continued regulatory focus on business combinations in our industry, including by the Federal Trade Commission and competition authorities in Europe and other jurisdictions, could continue to delay, jeopardize, or increase the costs of our business development activities and may negatively impact our consolidated financial position or results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_82,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,82,"For discussion of risks related to business development activities, see Item 1A, ""Risk Factors-Risks Related to Our Business and Industry-Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will lose intellectual property protection or are displaced by competing products or therapies.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_83,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,83,"Foreign Currency Exchange Rates As a global company, we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_84,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,84,"While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our consolidated results of operations in any given period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_85,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,85,"There is uncertainty in the future movements in foreign currency exchange rates, and fluctuations in these rates have and could adversely impact our consolidated results of operations and cash flows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_86,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,86,"Other Factors Other factors have had, and may continue to have, an impact on our consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_87,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,87,"These factors include cost and wage inflation, supply chain and labor market complexities, international tension and conflicts, uneven economic growth or downturns or uncertainty, and an increase in overall demand in our industry for certain products and materials.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_88,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,88,"See Item 1A, ""Risk Factors,"" for additional information on risk factors that could impact our business and operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_89,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,89,RESULTS OF OPERATIONS Operating Results-2024 Revenue The following table summarizes our revenue activity by region:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_90,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,90,Numbers may not add due to rounding.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_91,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,91,The following are components of the change in revenue compared with the prior year:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_92,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,92,Numbers may not add due to rounding.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_93,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,93,"In the U.S. the increase in volume in 2024 was primarily driven by Zepbound and Mounjaro, partially offset by Trulicity. In the U.S. the higher realized prices in 2024 were primarily driven by Humalog, Mounjaro, Verzenio, and Zepbound.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_94,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,94,"Outside the U.S. the increase in volume in 2024 was primarily driven by Mounjaro and, to a lesser extent, Verzenio, as well as a one-time payment received of $300.0 million related to Jardiance associated with an amendment to our collaboration with Boehringer Ingelheim.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_95,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,95,Outside the U.S. the increase in volume in 2024 was partially offset by the 2023 sale of rights for the olanzapine portfolio.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_96,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,96,"The following table summarizes our revenue, including net product revenue and collaboration and other revenue, by product in 2024 compared with 2023:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_97,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,97,Numbers may not add due to rounding.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_98,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,98,"NM - not meaningful (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_99,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,99,(2) Humalog revenue includes insulin lispro.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_100,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,100,(3) Basaglar revenue includes Rezvoglar.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_101,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,101,(4) Zyprexa revenue includes sale of the rights for the olanzapine portfolio in 2023.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_102,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,102,"Revenue of Mounjaro increased 85 percent in the U.S., primarily driven by strong demand and increased supply.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_103,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,103,"Revenue outside of the U.S. was $2.59 billion in 2024 compared to $328.9 million in 2023, primarily driven by volume growth in launched markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_104,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,104,"Revenue of Verzenio increased 36 percent in the U.S., driven by increased demand, wholesaler buying patterns and, to a lesser extent, higher realized prices. Revenue outside the U.S. increased 39 percent, driven by increased demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_105,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,105,"Revenue of Trulicity decreased 32 percent in the U.S., driven by decreased volume primarily due to competitive dynamics and supply constraints during the first half of 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_106,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,106,"Revenue outside the U.S. decreased 8 percent, driven by decreased volume primarily due to competitive dynamics and actions we have taken to manage demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_107,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,107,"Revenue of Zepbound in the U.S. in 2024 was $4.93 billion, compared to $175.8 million in 2023. Zepbound launched in the U.S. for the treatment of adult patients with obesity or overweight with weight-related comorbidities in November 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_108,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,108,Revenue of Jardiance remained relatively flat in the U.S. as increased demand was offset by lower realized prices.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_109,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,109,"Revenue outside the U.S. increased 52 percent, driven by increased volume and a one-time payment received of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_110,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,110,"Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_111,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,111,See Note 4 to the consolidated financial statements for information regarding our collaboration with Boehringer Ingelheim involving Jardiance.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_112,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,112,"Revenue of Taltz increased 18 percent in the U.S., driven by higher realized prices due to changes in estimates for rebates and discounts, as well as increased demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_113,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,113,"Revenue outside the U.S. increased 19 percent, primarily driven by increased demand.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_114,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,114,"Gross Margin, Costs, and Expenses The following table summarizes our gross margin, costs, and expenses:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_115,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,115,"NM - not meaningful Gross margin as a percent of revenue in 2024 increased 2.1 percentage points compared with 2023, primarily driven by favorable product mix and higher realized prices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_116,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,116,"Research and development expenses increased 18 percent in 2024, primarily driven by continued investments in our early and late-stage portfolio.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_117,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,117,"Marketing, selling, and administrative expenses increased 16 percent in 2024, primarily driven by promotional efforts supporting ongoing and future launches.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_118,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,118,Acquired in-process research and development (IPR&D) charges recognized in 2024 primarily related to the acquisition of Morphic.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_119,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,119,"Acquired IPR&D charges recognized in 2023 primarily related to acquisitions of DICE Therapeutics, Inc., Versanis Bio, Inc., Emergence Therapeutics AG, and Mablink Biosciences SAS and from a business development transaction with Beam Therapeutics Inc. See Note 3 to the consolidated financial statements for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_120,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,120,"Asset impairment, restructuring, and other special charges recognized in 2024 primarily related to a $435.0 million litigation charge and an intangible asset impairment for Vitrakvi, driven by expected commercial projections.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_121,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,121,See Notes 5 and 16 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_122,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,122,"Our effective tax rate was 16.5 percent in 2024, compared with an effective tax rate of 20.1 percent in 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_123,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,123,"The effective tax rates for 2024 and 2023 were both unfavorably impacted by non-deductible acquired IPR&D charges, with a larger impact occurring in 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_124,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,124,See Note 14 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_125,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,125,"For additional information for other-net, (income) expense, see Note 18 to the consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_126,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,126,"Operating Results-2023 For a discussion of our results of operations pertaining to 2023 and 2022 see Item 7, ""Management's Discussion and Analysis of Results of Operations and Financial Condition"" in our Annual Report on Form 10-K for the year ended December 31, 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_127,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,127,"FINANCIAL CONDITION AND LIQUIDITY We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements, which include:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_128,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,128,"•working capital requirements, including related to employee payroll and benefits, clinical trials, manufacturing materials, and taxes;",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_129,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,129,"•capital expenditures; •share repurchases and dividends; •repayment of outstanding short-term and long-term borrowings; •milestone and royalty payments; •potential business development activities, including acquisitions, collaborations, investments, and licensing arrangements; and",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_130,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,130,•contributions to our defined benefit pension and retiree health benefit plans.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_131,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,131,"Our management continuously evaluates our liquidity and capital resources, including our access to external capital, to ensure we can adequately and efficiently finance our capital requirements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_132,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,132,"As of December 31, 2024, our material cash requirements primarily related to purchases of goods and services to produce our products and conduct our operations, income tax payments, capital expenditures, dividends, milestone and royalty payments, business development activities, share repurchases and repayment of outstanding borrowings (see Notes 14, 4, 3, 13, and 11 to the consolidated financial statements).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_133,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,133,We anticipate our cash requirements related to ordinary course purchases of goods and services will be consistent with our past levels relative to revenues.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_134,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,134,"Capital expenditures were $5.06 billion during 2024, compared to $3.45 billion in 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_135,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,135,We are making investments in global facilities to manufacture existing and future products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_136,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,136,"These investments, and other capital investments that support our operations, have increased our capital expenditures and will result in meaningfully higher capital expenditures over the next several years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_137,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,137,"As we expand our manufacturing capacity in order to meet existing and expected demand of our medicines, we have entered, and expect to continue to enter, into various agreements for contract manufacturing and for supply of materials.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_138,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,138,"The executed agreements could, under certain circumstances, require us to pay up to approximately $14 billion if we do not purchase specified amounts of goods or services primarily related to our incretin medicines, including medicines in development, over the durations of the agreements, which are generally up to 8 years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_139,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,139,"Cash and cash equivalents increased to $3.27 billion as of December 31, 2024, compared with $2.82 billion at December 31, 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_140,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,140,"Net cash provided by operating activities increased to $8.82 billion in 2024, compared with $4.24 billion in 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_141,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,141,"Refer to the consolidated statements of cash flows for additional information on the significant sources and uses of cash for the years ended December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_142,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,142,"In addition to our cash and cash equivalents, we held total investments of $3.37 billion and $3.16 billion as of December 31, 2024 and 2023, respectively. See Note 7 to the consolidated financial statements for additional information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_143,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,143,We paid $3.35 billion in 2024 for acquired IPR&D primarily related to the acquisition of Morphic.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_144,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,144,We paid $947.7 million in 2024 primarily related to the acquisition of a manufacturing site in Wisconsin.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_145,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,145,See Note 3 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_146,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,146,"As of December 31, 2024, total debt was $33.64 billion, an increase of $8.42 billion compared with $25.23 billion at December 31, 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_147,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,147,"In February 2025, we issued $6.5 billion of fixed-rate notes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_148,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,148,"We expect to use the net cash proceeds from the offering to fund potential business development activities, as well as general business purposes, including the repayment of outstanding commercial paper.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_149,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,149,See Note 11 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_150,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,150,"As of December 31, 2024, we had a total of $8.45 billion of unused committed bank credit facilities, $8.00 billion of which is available to support our commercial paper program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_151,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,151,See Note 11 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_152,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,152,We believe that amounts accessible through existing commercial paper markets should be adequate to fund short-term borrowing needs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_153,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,153,"Dividends of $5.20 per share and $4.52 per share were paid in 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_154,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,154,"The quarterly dividend was increased to $1.50 per share effective for the dividend to be paid in the first quarter of 2025, resulting in an indicated annual rate for 2025 of $6.00 per share.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_155,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,155,"In 2024, we repurchased $2.50 billion of shares, which completed our $5.00 billion share repurchase program that our board authorized in May 2021.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_156,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,156,Our board authorized a $15.00 billion share repurchase program in December 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_157,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,157,"No shares were repurchased under this new program as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_158,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,158,See Note 13 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_159,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,159,"See ""-Executive Overview-Other Matters-Patent Matters"" for information regarding losses of patent protection.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_160,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,160,"Both domestically and abroad, we monitor the potential impacts of the economic environment and international tension and conflicts; the creditworthiness of our wholesalers and other customers, including foreign government-backed agencies and suppliers; the uncertain impact of healthcare legislation; and various international government funding levels.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_161,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,161,"In the normal course of business, our operations are exposed to fluctuations in interest rates, currency values, and fair values of equity securities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_162,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,162,"These fluctuations impact the costs of financing, investing, and operating our business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_163,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,163,We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_164,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,164,The objective of this risk management program is to limit the impact on earnings of fluctuations in interest and currency exchange rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_165,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,165,All derivative activities are for purposes other than trading.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_166,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,166,Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_167,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,167,"In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt positions and in some cases we enter into interest rate derivatives to help maintain that balance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_168,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,168,"As of December 31, 2024, all of our total long-term debt is at a fixed rate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_169,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,169,We have converted approximately 5 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_170,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,170,"Based on our overall interest rate exposure at December 31, 2024 and 2023, including derivatives and other interest rate risk-sensitive instruments, a hypothetical 10 percent change in interest rates applied to the fair value of the instruments as of December 31, 2024 and 2023, respectively, would not have a material impact on earnings, cash flows, or fair values of interest rate risk-sensitive instruments over a one-year period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_171,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,171,"Our foreign currency risk exposure results from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and Chinese yuan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_172,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,172,We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_173,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,173,We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_174,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,174,"We in some cases enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates (primarily the euro, Chinese yuan, and Japanese yen).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_175,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,175,Our corporate risk-management policy outlines the minimum and maximum hedge coverage of such exposures.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_176,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,176,"Gains and losses on these derivative contracts offset, in part, the impact of currency fluctuations on the existing assets and liabilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_177,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,177,We periodically analyze the fair values of the outstanding foreign currency derivative contracts to determine their sensitivity to changes in foreign exchange rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_178,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,178,"A hypothetical 10 percent change in exchange rates (primarily against the U.S. dollar) applied to the fair values of our outstanding foreign currency derivative contracts as of December 31, 2024 and 2023, would not have a material impact on earnings, cash flows, or financial position over a one-year period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_179,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,179,This sensitivity analysis does not consider the impact that hypothetical changes in exchange rates would have on the underlying foreign currency denominated transactions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_180,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,180,Our fair value risk exposure relates primarily to our public equity investments and to our equity investments that do not have readily determinable fair values.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_181,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,181,"As of December 31, 2024 and 2023, our carrying values of these investments were $1.35 billion and $1.32 billion, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_182,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,182,"A hypothetical 20 percent change in fair value of the equity instruments would have impacted other-net, (income) expense by $269.9 million and $263.9 million as of December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_183,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,183,"We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_184,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,184,We acquire and collaborate on potential products still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_185,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,185,"Milestone payments may be required contingent upon the successful achievement of an important point in the development life cycle of the pharmaceutical product (e.g., approval for marketing by the appropriate regulatory agency or upon the achievement of certain sales levels).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_186,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,186,"If required by the arrangement, we may make royalty payments based upon a percentage of the sales of the product in the event that regulatory approval for marketing is obtained.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_187,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,187,"Individually, these arrangements are generally not material in any one annual reporting period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_188,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,188,"However, if milestones for multiple products covered by these arrangements were reached in the same reporting period, the aggregate expense or aggregate milestone payments made could be material to our results of operations or cash flows, respectively, in that period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_189,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,189,See Note 4 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_190,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,190,"These arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves milestone objectives.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_191,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,191,We view these payments as positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate cash flows from sales of products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_192,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,192,"APPLICATION OF CRITICAL ACCOUNTING ESTIMATES In preparing our financial statements in accordance with accounting principles generally accepted in the U.S., we must often make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_193,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,193,"Some of those judgments can be subjective and complex, and consequently actual results could differ from those estimates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_194,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,194,"For any given individual estimate or assumption we make, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_195,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,195,"We believe that, given current facts and circumstances, it is unlikely that applying any such other reasonable judgment would cause a material adverse effect on our consolidated results of operations, financial position, or liquidity for the periods presented in this Annual Report on Form 10-K. Our most critical accounting estimates have been discussed with our audit committee and are described below.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_196,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,196,"Revenue Recognition and Sales Return, Rebate, and Discount Accruals",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_197,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,197,"Background and Uncertainties We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_198,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,198,"For product sales to customers, provisions for returns, rebates and discounts are established in the same period the related product sales are recognized.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_199,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,199,"To determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_200,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,200,Significant judgments are required in making these estimates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_201,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,201,"The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_202,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,202,"In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_203,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,203,"Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to six months later.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_204,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,204,"Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_205,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,205,"Refer to Note 2 to the consolidated financial statements for further information on revenue recognition and sales return, rebate, and discount accruals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_206,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,206,"Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_207,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,207,"Financial Statement Impact We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_208,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,208,Our rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_209,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,209,Our sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_210,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,210,"As of December 31, 2024, a 5 percent change in our consolidated sales return, rebate, and discount liability would result in a change in revenue of approximately $600 million.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_211,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,211,"The portion of our consolidated sales return, rebate, and discount liability resulting from sales of our products in the U.S. was approximately 90 percent as of December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_212,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,212,"The following represents a roll-forward of our most significant U.S. sales return, rebate, and discount liability balances, including managed care, Medicare, Medicaid, chargeback, and patient assistance programs:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_213,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,213,"(1) Adjustments of the estimates for these returns, rebates, and discounts to actual results were less than 2 percent of consolidated revenue for each of the years presented.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_214,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,214,"Litigation Liabilities and Other Contingencies Background and Uncertainties Litigation liabilities and other contingencies are, by their nature, uncertain and based upon complex judgments and probabilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_215,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,215,"The factors we consider in developing our litigation liability reserves and other contingent liability amounts include the merits and jurisdiction of the litigation, the nature and the number of other similar current and past matters, the nature of the product and the current assessment of the science subject to the litigation, as applicable, and the likelihood of settlement and current state of settlement discussions, if any.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_216,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,216,"In addition, we accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs based primarily on historical claims experience and data regarding product usage.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_217,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,217,We also consider the insurance coverage we have to diminish the exposure for periods covered by insurance.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_218,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,218,"In assessing our insurance coverage, we consider the policy coverage limits and exclusions, the potential for denial of coverage by the insurance company, the financial condition of the insurers, and the possibility of and length of time for collection.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_219,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,219,"Due to a very restrictive market for liability insurance, we are predominantly self-insured for liability losses for all our currently and previously marketed products, as well as for litigation or investigations related to our pricing practices or other similar matters.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_220,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,220,"In addition to insurance coverage, we consider any third-party indemnification to which we are entitled or under which we are obligated.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_221,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,221,"With respect to our third-party indemnification rights, these considerations include the nature of the indemnification, the financial condition of the indemnifying party, and the possibility of and length of time for collection.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_222,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,222,"The litigation accruals and environmental liabilities and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_223,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,223,"Acquisitions Background and Uncertainties To determine whether acquisitions or licensing transactions should be accounted for as a business combination or as an asset acquisition, we make certain judgments, which include assessing whether the acquired set of activities and assets would meet the definition of a business under the relevant accounting rules.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_224,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,224,"If the acquired set of activities and assets meets the definition of a business, assets acquired and liabilities assumed are required to be recorded at their respective fair values on our consolidated balance sheet as of the acquisition date.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_225,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,225,"The excess of the purchase price over the fair value of the acquired net assets, where applicable, is recorded as goodwill.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_226,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,226,"If the acquired set of activities and assets does not meet the definition of a business, the transaction is recorded as an acquisition of assets and, therefore, any acquired IPR&D that does not have an alternative future use is charged to acquired IPR&D on our consolidated statement of operations at the acquisition date, and goodwill is not recorded.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_227,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,227,See Note 3 to the consolidated financial statements for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_228,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,228,"The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as estimated asset lives, can materially affect our consolidated results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_229,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,229,"The fair values of intangible assets, including acquired IPR&D, are determined using information available near the acquisition date based on estimates and assumptions that are deemed reasonable by management.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_230,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,230,"Significant estimates and assumptions include, but are not limited to, probability of technical success, revenue projections, and discount rate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_231,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,231,"Depending on the facts and circumstances, we may deem it necessary to engage an independent valuation expert to assist in valuing significant assets and liabilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_232,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,232,"The fair values of identifiable intangible assets are primarily determined using the ""income method,"" as described in Note 8 to the consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_233,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,233,"The fair value of any contingent consideration liability that results from a business combination is primarily determined using a discounted cash flow analysis, as described in Note 7 to the consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_234,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,234,"Estimating the fair value of contingent consideration requires the use of significant estimates and judgments, including, but not limited to, probability of technical success, timing of the potential milestone event, and the discount rate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_235,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,235,"Financial Statement Impact As of December 31, 2024, a 5 percent change in the contingent consideration liabilities would result in a change in income before income taxes of $1.6 million.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_236,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,236,Impairment of Indefinite-Lived and Long-Lived Assets Background and Uncertainties We review the carrying value of long-lived assets (both intangible and tangible) for potential impairment whenever events or changes in circumstances indicate the carrying value of an asset (or asset group) may not be recoverable.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_237,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,237,We identify impairment by comparing the projected undiscounted cash flows to be generated by the asset (or asset group) to its carrying value.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_238,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,238,"If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_239,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,239,"Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_240,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,240,"If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_241,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,241,"Several methods may be used to determine the estimated fair value of long-lived assets, all of which require multiple assumptions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_242,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,242,"When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the ""income method,"" as described in Note 8 to the consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_243,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,243,"For acquired IPR&D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product, as discussed previously in ""-Executive Overview-Clinical Development Pipeline.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_244,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,244,The nature of the pharmaceutical business is high-risk and requires that we invest in a large number of projects to maintain a successful portfolio of approved products.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_245,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,245,"As such, it is likely that some acquired IPR&D assets will become impaired in the future.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_246,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,246,"Estimates of future cash flows, based on what we believe to be reasonable and supportable assumptions and projections, require management's judgment. Actual results could vary materially from these estimates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_247,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,247,"Income Taxes Background and Uncertainties We file tax returns based upon our interpretation of tax laws and regulations, and we record estimates in our financial statements based upon these interpretations at the applicable tax rates in the jurisdictions in which we operate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_248,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,248,"Our tax returns are routinely subject to examination by taxing authorities, which could result in future tax, interest, and penalty assessments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_249,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,249,Inherent uncertainties also exist in estimates of many tax positions due to the complexity of tax laws.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_250,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,250,"We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_251,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,251,The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_252,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,252,"The amount of unrecognized tax benefits is adjusted for changes in facts and circumstances such as changes to existing tax law, the issuance of regulations by taxing authorities, new information obtained during a tax examination, or resolution of a tax examination.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_253,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,253,"We believe our estimates for uncertain tax positions are both appropriate and sufficient to pay assessments that may result from examinations of our tax returns; however, given the uncertainty of positions that could be taken by taxing authorities during the examinations of our tax returns, the ultimate outcome of any tax matters may result in liabilities that are greater than amounts accrued.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_254,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,254,We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_255,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,255,"We have recorded valuation allowances against certain of our deferred tax assets, primarily those that have been generated from net operating losses, tax credits, and other tax carryforwards in certain taxing jurisdictions, when the amount of future taxable income is unlikely to support their utilization.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_256,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,256,"Financial Statement Impact As of December 31, 2024, a 5 percent change in the amount of uncertain tax positions and the valuation allowance would result in a change in net income of $131.3 million and $48.2 million, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_257,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,257,"Retirement Benefits Assumptions Background and Uncertainties Defined benefit pension plan and retiree health benefit plan costs include assumptions for the discount rate, expected return on plan assets, and retirement age.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_258,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,258,These assumptions have a significant effect on the amounts reported.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_259,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,259,"In addition to the analysis below, see Note 15 to the consolidated financial statements for additional information regarding our retirement benefits.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_260,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,260,"Annually, we evaluate the discount rate and the expected return on plan assets in our defined benefit pension and retiree health benefit plans.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_261,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,261,"We use an actuarially determined, plan-specific yield curve of high quality, fixed income debt instruments to determine the discount rates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_262,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,262,"In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions, asset returns and asset allocations (approximately 75 percent of which are growth investments), and the views of leading financial advisers and economists.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_263,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,263,"We may also review our historical assumptions compared with actual results, as well as the discount rates and expected return on plan assets of other companies, where applicable.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_264,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,264,"In evaluating our expected retirement age assumption, we consider the retirement ages of our past employees eligible for pension and medical benefits together with our expectations of future retirement ages.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_265,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,265,"Financial Statement Impact If the 2024 discount rate for the U.S. defined benefit pension and retiree health benefit plans (U.S. plans) were to change by a quarter percentage point, income before income taxes would change by $15.0 million.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_266,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,266,"If the 2024 expected return on plan assets for U.S. plans were to change by a quarter percentage point, income before income taxes would change by $33.2 million.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_267,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,267,"If our assumption regarding the 2024 expected age of future retirees for U.S. plans were adjusted by one year, our income before income taxes would be affected by $35.9 million.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_268,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,268,"The U.S. plans, including Puerto Rico, represent approximately 80 percent for total projected benefit obligation and 85 percent for total plan assets at December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7_269,Management’s Discussion and Analysis (MD&A),ITEM_7,8,10-K,269,LEGAL AND REGULATORY MATTERS Information relating to certain legal proceedings can be found in Note 16 to the consolidated financial statements and is incorporated here by reference.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7A_0,Quantitative and Qualitative Disclosures About Market Risk,ITEM_7A,9,10-K,0,"Item 7AQuantitative and Qualitative Disclosures About Market Risk You can find quantitative and qualitative disclosures about market risk (e.g., interest rate risk) at Item 7, ""Management's Discussion and Analysis - Financial Condition and Liquidity.""",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_7A_1,Quantitative and Qualitative Disclosures About Market Risk,ITEM_7A,9,10-K,1,That information is incorporated by reference herein.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_0,Financial Statements and Supplementary Data,ITEM_8,10,10-K,0,"Item 8Financial Statements and Supplementary Data Consolidated Statements of Operations ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, except per-share data, and shares in thousands)",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_1,Financial Statements and Supplementary Data,ITEM_8,10,10-K,1,See notes to consolidated financial statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_2,Financial Statements and Supplementary Data,ITEM_8,10,10-K,2,Consolidated Statements of Comprehensive Income ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions) See notes to consolidated financial statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_3,Financial Statements and Supplementary Data,ITEM_8,10,10-K,3,"Consolidated Balance Sheets ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions, shares in thousands) See notes to consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_4,Financial Statements and Supplementary Data,ITEM_8,10,10-K,4,Consolidated Statements of Shareholders' Equity ELI LILLY AND COMPANY AND SUBSIDIARIES See notes to consolidated financial statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_5,Financial Statements and Supplementary Data,ITEM_8,10,10-K,5,Consolidated Statements of Cash Flows ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions) See notes to consolidated financial statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_6,Financial Statements and Supplementary Data,ITEM_8,10,10-K,6,Notes to Consolidated Financial Statements ELI LILLY AND COMPANY AND SUBSIDIARIES (Tables present dollars in millions) Note 1: Summary of Significant Accounting Policies and Implementation of New Financial Accounting Standards,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_7,Financial Statements and Supplementary Data,ITEM_8,10,10-K,7,Basis of Presentation The accompanying consolidated financial statements include Eli Lilly and Company and all subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (GAAP).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_8,Financial Statements and Supplementary Data,ITEM_8,10,10-K,8,"We consider majority voting interests, as well as effective economic or other control over an entity when deciding whether or not to consolidate an entity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_9,Financial Statements and Supplementary Data,ITEM_8,10,10-K,9,We generally do not have control by means other than voting interests.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_10,Financial Statements and Supplementary Data,ITEM_8,10,10-K,10,"Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders' interests are reflected as a separate component of equity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_11,Financial Statements and Supplementary Data,ITEM_8,10,10-K,11,All intercompany balances and transactions have been eliminated.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_12,Financial Statements and Supplementary Data,ITEM_8,10,10-K,12,"The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_13,Financial Statements and Supplementary Data,ITEM_8,10,10-K,13,Actual results could differ from those estimates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_14,Financial Statements and Supplementary Data,ITEM_8,10,10-K,14,We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing of this Annual Report on Form 10-K.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_15,Financial Statements and Supplementary Data,ITEM_8,10,10-K,15,"We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_16,Financial Statements and Supplementary Data,ITEM_8,10,10-K,16,"A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_17,Financial Statements and Supplementary Data,ITEM_8,10,10-K,17,"Our commercial organizations market, distribute, and sell the products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_18,Financial Statements and Supplementary Data,ITEM_8,10,10-K,18,The business is also supported by global corporate staff functions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_19,Financial Statements and Supplementary Data,ITEM_8,10,10-K,19,See Note 19 for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_20,Financial Statements and Supplementary Data,ITEM_8,10,10-K,20,Research and Development Expenses and Acquired In-Process Research and Development (IPR&D),2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_21,Financial Statements and Supplementary Data,ITEM_8,10,10-K,21,Research and development costs are expensed as incurred.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_22,Financial Statements and Supplementary Data,ITEM_8,10,10-K,22,"Research and development costs consist of expenses incurred in performing research and development activities, including but not limited to, compensation and benefits, facilities and overhead expense, clinical trial expense and fees paid to contract research organizations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_23,Financial Statements and Supplementary Data,ITEM_8,10,10-K,23,"Acquired IPR&D includes the initial costs and development milestones incurred related to externally developed IPR&D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_24,Financial Statements and Supplementary Data,ITEM_8,10,10-K,24,Development milestones are milestone payment obligations that are incurred prior to regulatory approval of the compound and are expensed when the event triggering an obligation to pay the milestone occurs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_25,Financial Statements and Supplementary Data,ITEM_8,10,10-K,25,"Earnings Per Share (EPS) All per-share amounts, unless otherwise stated in the notes to the consolidated financial statements, are presented on a diluted basis.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_26,Financial Statements and Supplementary Data,ITEM_8,10,10-K,26,We calculate basic EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from potential participating securities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_27,Financial Statements and Supplementary Data,ITEM_8,10,10-K,27,We calculate diluted EPS based on the weighted-average number of common shares outstanding plus the effect of incremental shares from our stock-based compensation programs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_28,Financial Statements and Supplementary Data,ITEM_8,10,10-K,28,Foreign Currency Translation Operations in our subsidiaries outside the United States (U.S.) are recorded in the functional currency of each subsidiary which is determined by a review of the environment where each subsidiary primarily generates and expends cash.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_29,Financial Statements and Supplementary Data,ITEM_8,10,10-K,29,The results of operations for our subsidiaries outside the U.S. are translated from functional currencies into U.S. dollars using the weighted-average currency rate for the period.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_30,Financial Statements and Supplementary Data,ITEM_8,10,10-K,30,Assets and liabilities are translated using the period end exchange rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_31,Financial Statements and Supplementary Data,ITEM_8,10,10-K,31,The U.S. dollar effects that arise from translating the net assets of these subsidiaries are recorded in other comprehensive income (loss).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_32,Financial Statements and Supplementary Data,ITEM_8,10,10-K,32,"Advertising Expenses Costs associated with advertising are expensed as incurred and are included in marketing, selling, and administrative expenses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_33,Financial Statements and Supplementary Data,ITEM_8,10,10-K,33,"Global advertising expenses, comprised primarily of online marketing and television advertising, totaled $1.44 billion, $1.12 billion, and $966.8 million in 2024, 2023, and 2022, respectively, which were less than 5 percent of revenue each year.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_34,Financial Statements and Supplementary Data,ITEM_8,10,10-K,34,Other Significant Accounting Policies Our other significant accounting policies are described in the remaining appropriate notes to the consolidated financial statements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_35,Financial Statements and Supplementary Data,ITEM_8,10,10-K,35,Reclassifications Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_36,Financial Statements and Supplementary Data,ITEM_8,10,10-K,36,"Implementation of New Financial Accounting Standards Effective January 1, 2024, we adopted Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosures about significant segment expenses and additional interim disclosure requirements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_37,Financial Statements and Supplementary Data,ITEM_8,10,10-K,37,This standard also requires a single reportable segment company to provide all disclosures required by Topic 280.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_38,Financial Statements and Supplementary Data,ITEM_8,10,10-K,38,"See Note 19 for the segment disclosures as required by Topic 280, as amended by ASU 2023-07.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_39,Financial Statements and Supplementary Data,ITEM_8,10,10-K,39,"ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_40,Financial Statements and Supplementary Data,ITEM_8,10,10-K,40,"This standard is effective for fiscal years beginning after December 15, 2024, and requires prospective application with the option to apply it retrospectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_41,Financial Statements and Supplementary Data,ITEM_8,10,10-K,41,"We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_42,Financial Statements and Supplementary Data,ITEM_8,10,10-K,42,We are currently evaluating the potential impact of adopting this standard on our disclosures.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_43,Financial Statements and Supplementary Data,ITEM_8,10,10-K,43,"ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_44,Financial Statements and Supplementary Data,ITEM_8,10,10-K,44,"This standard is effective for annual reporting periods beginning after December 15, 2026, and requires prospective application with the option to apply it retrospectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_45,Financial Statements and Supplementary Data,ITEM_8,10,10-K,45,"We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2027.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_46,Financial Statements and Supplementary Data,ITEM_8,10,10-K,46,We are currently evaluating the potential impact of adopting this standard on our disclosures.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_47,Financial Statements and Supplementary Data,ITEM_8,10,10-K,47,Note 2: Revenue The following table summarizes our revenue recognized in our consolidated statements of operations:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_48,Financial Statements and Supplementary Data,ITEM_8,10,10-K,48,"We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_49,Financial Statements and Supplementary Data,ITEM_8,10,10-K,49,"Revenue recognized from collaborations and other arrangements includes our share of profits from the collaborations, as well as royalties, upfront and milestone payments we receive under these types of contracts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_50,Financial Statements and Supplementary Data,ITEM_8,10,10-K,50,See Note 4 for additional information related to our collaborations and other arrangements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_51,Financial Statements and Supplementary Data,ITEM_8,10,10-K,51,"Collaboration and other revenue disclosed above includes the revenue resulting from our collaboration with Boehringer Ingelheim, as well as from the 2023 sales of rights for the olanzapine portfolio, including Zyprexa, and for Baqsimi, all of which are discussed in Note 4.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_52,Financial Statements and Supplementary Data,ITEM_8,10,10-K,52,Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_53,Financial Statements and Supplementary Data,ITEM_8,10,10-K,53,"Collaboration and other revenue associated with intellectual property licensed in prior periods was not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_54,Financial Statements and Supplementary Data,ITEM_8,10,10-K,54,"Net Product Revenue Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_55,Financial Statements and Supplementary Data,ITEM_8,10,10-K,55,"Payment terms differ by jurisdiction and customer, but payment terms in most of our major jurisdictions typically range from 30 to 70 days from date of shipment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_56,Financial Statements and Supplementary Data,ITEM_8,10,10-K,56,"Revenue for our product sales has not been adjusted for the effects of a financing component as we expect, at contract inception, that the period between when we transfer control of the product and when we receive payment will be one year or less.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_57,Financial Statements and Supplementary Data,ITEM_8,10,10-K,57,Any exceptions are either not material or we collect interest for payments made after the due date.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_58,Financial Statements and Supplementary Data,ITEM_8,10,10-K,58,"Provisions for rebates, discounts, and returns are established in the same period the related product sales are recognized.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_59,Financial Statements and Supplementary Data,ITEM_8,10,10-K,59,"We generally ship product shortly after orders are received; therefore, we generally only have a few days of orders received but not yet shipped at the end of any reporting period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_60,Financial Statements and Supplementary Data,ITEM_8,10,10-K,60,Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_61,Financial Statements and Supplementary Data,ITEM_8,10,10-K,61,We exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are imposed on our sales of product and collected from a customer.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_62,Financial Statements and Supplementary Data,ITEM_8,10,10-K,62,"Most of our products are sold to wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_63,Financial Statements and Supplementary Data,ITEM_8,10,10-K,63,"For the years ended December 31, 2024, 2023, and 2022, our three largest wholesalers each accounted for between 16 percent and 24 percent of consolidated revenue.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_64,Financial Statements and Supplementary Data,ITEM_8,10,10-K,64,"Further, they each accounted for between 21 percent and 29 percent of accounts receivable as of December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_65,Financial Statements and Supplementary Data,ITEM_8,10,10-K,65,"Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts, and returns. The following describe the most significant of these judgments:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_66,Financial Statements and Supplementary Data,ITEM_8,10,10-K,66,Sales Rebates and Discounts - Background and Uncertainties •We initially invoice our customers at contractual list prices.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_67,Financial Statements and Supplementary Data,ITEM_8,10,10-K,67,Contracts with direct and indirect customers may provide for various rebates and discounts that may differ in each contract.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_68,Financial Statements and Supplementary Data,ITEM_8,10,10-K,68,"As a consequence, to determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_69,Financial Statements and Supplementary Data,ITEM_8,10,10-K,69,Significant judgments are required in making these estimates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_70,Financial Statements and Supplementary Data,ITEM_8,10,10-K,70,•The rebate and discount amounts are recorded as a deduction to arrive at our net product revenue.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_71,Financial Statements and Supplementary Data,ITEM_8,10,10-K,71,"Sales rebates and discounts that require the use of judgment in the establishment of the accrual include managed care, Medicare, Medicaid, chargebacks, long-term care, hospital, patient assistance programs, and various other programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_72,Financial Statements and Supplementary Data,ITEM_8,10,10-K,72,We estimate these accruals using an expected value approach.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_73,Financial Statements and Supplementary Data,ITEM_8,10,10-K,73,"•The largest of our sales rebate and discount amounts include rebates associated with sales covered by managed care, Medicare, Medicaid, and chargeback programs, as well as reductions in revenue related to our patient assistance programs, in the U.S.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_74,Financial Statements and Supplementary Data,ITEM_8,10,10-K,74,"In determining the appropriate accrual amount, we consider our historical rebate payments for these programs, as well as patient assistance program costs, by product as a percentage of our historical sales as well as any significant changes in sales trends (e.g., patent expiries and product launches), an evaluation of the current contracts for these programs, the percentage of our products that are sold via these programs, and our product pricing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_75,Financial Statements and Supplementary Data,ITEM_8,10,10-K,75,"Although we accrue a liability for revenue reductions related to these programs at the time we record the sale, the reduction related to that sale is typically paid up to six months later.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_76,Financial Statements and Supplementary Data,ITEM_8,10,10-K,76,"Because of this time lag, in any particular period our net product revenue may incorporate revisions of accruals for several periods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_77,Financial Statements and Supplementary Data,ITEM_8,10,10-K,77,•Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_78,Financial Statements and Supplementary Data,ITEM_8,10,10-K,78,"In some large European countries, government rebates are based on the anticipated budget for pharmaceutical payments in the country.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_79,Financial Statements and Supplementary Data,ITEM_8,10,10-K,79,"An estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_80,Financial Statements and Supplementary Data,ITEM_8,10,10-K,80,"Sales Returns - Background and Uncertainties •When product sales occur, to determine the appropriate transaction price for our sales, we estimate a reserve for future product returns related to those sales using an expected value approach.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_81,Financial Statements and Supplementary Data,ITEM_8,10,10-K,81,"This estimate is based on several factors, including: historical return rates, expiration date by product (on average, approximately 24 months after the initial sale of a product to our customer), and estimated levels of inventory in the wholesale and retail channels, as well as any other specifically identified anticipated returns due to known factors such as the loss of patent exclusivity, product recalls and discontinuations, or a changing competitive environment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_82,Financial Statements and Supplementary Data,ITEM_8,10,10-K,82,We maintain a returns policy that allows most U.S. customers to return most of our products for dating issues within a specified period prior to and subsequent to the product's expiration date.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_83,Financial Statements and Supplementary Data,ITEM_8,10,10-K,83,"Following the loss of exclusivity for a patent-dependent product, we expect to experience an elevated level of product returns as product inventory remaining in the wholesale and retail channels expires.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_84,Financial Statements and Supplementary Data,ITEM_8,10,10-K,84,Adjustments to the returns reserve have been and may in the future be required based on revised estimates to our assumptions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_85,Financial Statements and Supplementary Data,ITEM_8,10,10-K,85,We record the return amounts as a deduction to arrive at our net product revenue.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_86,Financial Statements and Supplementary Data,ITEM_8,10,10-K,86,"Once the product is returned, it is destroyed; we do not record a right of return asset.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_87,Financial Statements and Supplementary Data,ITEM_8,10,10-K,87,Our returns policies outside the U.S. are generally more restrictive than in the U.S. as returns are not allowed for reasons other than failure to meet product specifications in many countries.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_88,Financial Statements and Supplementary Data,ITEM_8,10,10-K,88,Our reserve for future product returns for product sales outside the U.S. is not material.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_89,Financial Statements and Supplementary Data,ITEM_8,10,10-K,89,"•As a part of our process to estimate a reserve for product returns, we regularly review the supply levels of our significant products at the major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_90,Financial Statements and Supplementary Data,ITEM_8,10,10-K,90,We attempt to maintain U.S. wholesaler inventory levels at an average of approximately one month or less.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_91,Financial Statements and Supplementary Data,ITEM_8,10,10-K,91,"Causes of unusual wholesaler buying patterns include actual or anticipated product-supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_92,Financial Statements and Supplementary Data,ITEM_8,10,10-K,92,"In the U.S., the current structure of our arrangements provides us with data on inventory levels at our wholesalers; however, our data on inventory levels in the retail channel is more limited.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_93,Financial Statements and Supplementary Data,ITEM_8,10,10-K,93,Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_94,Financial Statements and Supplementary Data,ITEM_8,10,10-K,94,"•Actual U.S. product returns have been less than 1 percent of our U.S. revenue during each of the past three years and have not fluctuated significantly as a percentage of revenue, although fluctuations are more likely in periods following loss of patent exclusivity for major products in the U.S. market.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_95,Financial Statements and Supplementary Data,ITEM_8,10,10-K,95,"Adjustments to Revenue Adjustments to revenue recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were less than 3 percent of U.S. revenue during the year ended December 31, 2024, and less than 1 percent of U.S. revenue during each of the years ended December 31, 2023 and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_96,Financial Statements and Supplementary Data,ITEM_8,10,10-K,96,"Collaboration and Other Arrangements We recognize several types of revenue from our collaborations and other arrangements, which we discuss in general terms immediately below and more specifically in Note 4 for each of our significant collaborations and other arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_97,Financial Statements and Supplementary Data,ITEM_8,10,10-K,97,"Our collaborations and other arrangements are evaluated to determine if the arrangements in their entirety, or contain aspects that, are contracts with customers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_98,Financial Statements and Supplementary Data,ITEM_8,10,10-K,98,•Revenue related to products we sell pursuant to these arrangements is included in net product revenue at the earlier of when control of the asset transfers to the other party or when the product has no alternative use to us and we have right to payment.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_99,Financial Statements and Supplementary Data,ITEM_8,10,10-K,99,"•Profit-sharing due from our collaboration partners, which is based upon gross margins reported to us by our partners, is recognized as collaboration and other revenue as earned.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_100,Financial Statements and Supplementary Data,ITEM_8,10,10-K,100,"•Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third parties of licensed products and technology, is recorded when the third-party sale occurs and the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_101,Financial Statements and Supplementary Data,ITEM_8,10,10-K,101,This royalty revenue is included in collaboration and other revenue.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_102,Financial Statements and Supplementary Data,ITEM_8,10,10-K,102,•The net gain or loss related to the sale of rights of a product is included in collaboration and other revenue when control of the asset transfers to the other party.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_103,Financial Statements and Supplementary Data,ITEM_8,10,10-K,103,"•For arrangements that involve variable consideration where we have sold intellectual property, we recognize revenue based on estimates of the amount of consideration we believe we will be entitled to receive from the other party, but only to the extent a significant reversal in the amount of revenue recognized is not probable of occurring when the uncertainties associated with the variable consideration are subsequently resolved.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_104,Financial Statements and Supplementary Data,ITEM_8,10,10-K,104,These estimates are adjusted to reflect the actual amounts to be collected when those facts and circumstances become known.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_105,Financial Statements and Supplementary Data,ITEM_8,10,10-K,105,Significant judgments must be made in determining the transaction price for our sales of intellectual property.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_106,Financial Statements and Supplementary Data,ITEM_8,10,10-K,106,"Because of the risk that products in development will not receive regulatory approval, we generally do not recognize any contingent payments that would be due to us upon or after regulatory approval.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_107,Financial Statements and Supplementary Data,ITEM_8,10,10-K,107,"•For arrangements involving multiple goods or services (e.g., research and development, marketing and selling, manufacturing, and distribution), each required good or service is evaluated to determine whether it is distinct.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_108,Financial Statements and Supplementary Data,ITEM_8,10,10-K,108,"If a good or service does not qualify as distinct, it is combined with the other non-distinct goods or services within the arrangement and these combined goods or services are treated as a single performance obligation for accounting purposes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_109,Financial Statements and Supplementary Data,ITEM_8,10,10-K,109,The arrangement's transaction price is then allocated to each performance obligation based on the relative standalone selling price of each performance obligation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_110,Financial Statements and Supplementary Data,ITEM_8,10,10-K,110,"Contract Liabilities Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_111,Financial Statements and Supplementary Data,ITEM_8,10,10-K,111,Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_112,Financial Statements and Supplementary Data,ITEM_8,10,10-K,112,The following table summarizes contract liability balances at December 31:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_113,Financial Statements and Supplementary Data,ITEM_8,10,10-K,113,"The contract liabilities balances disclosed above as of December 31, 2024 and 2023 were primarily related to the remaining license period of symbolic intellectual property and obligations to supply product for a defined period of time.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_114,Financial Statements and Supplementary Data,ITEM_8,10,10-K,114,"During the years ended December 31, 2024, 2023, and 2022, revenue recognized from contract liabilities as of the beginning of the respective year was not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_115,Financial Statements and Supplementary Data,ITEM_8,10,10-K,115,Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_116,Financial Statements and Supplementary Data,ITEM_8,10,10-K,116,"Disaggregation of Revenue The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_117,Financial Statements and Supplementary Data,ITEM_8,10,10-K,117,Numbers may not add due to rounding.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_118,Financial Statements and Supplementary Data,ITEM_8,10,10-K,118,"(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_119,Financial Statements and Supplementary Data,ITEM_8,10,10-K,119,(2) Humalog revenue includes insulin lispro.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_120,Financial Statements and Supplementary Data,ITEM_8,10,10-K,120,(3) Basaglar revenue includes Rezvoglar.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_121,Financial Statements and Supplementary Data,ITEM_8,10,10-K,121,(4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_122,Financial Statements and Supplementary Data,ITEM_8,10,10-K,122,(5) Zyprexa revenue includes sale of rights for the olanzapine portfolio in July 2023.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_123,Financial Statements and Supplementary Data,ITEM_8,10,10-K,123,"(6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_124,Financial Statements and Supplementary Data,ITEM_8,10,10-K,124,The following table summarizes revenue by geographical area: Numbers may not add due to rounding.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_125,Financial Statements and Supplementary Data,ITEM_8,10,10-K,125,(1) Revenue is attributed to the countries based on the location of the customer or other party.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_126,Financial Statements and Supplementary Data,ITEM_8,10,10-K,126,"Note 3: Acquisitions We engage in various forms of business development activities to enhance or refine our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_127,Financial Statements and Supplementary Data,ITEM_8,10,10-K,127,"In connection with these arrangements, our partners may be entitled to future royalties and/or commercial milestones based on sales should products be approved for commercialization and/or milestones based on the successful progress of compounds through the development process.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_128,Financial Statements and Supplementary Data,ITEM_8,10,10-K,128,We account for each arrangement as either a business combination or an asset acquisition in accordance with GAAP.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_129,Financial Statements and Supplementary Data,ITEM_8,10,10-K,129,"Business Combinations When an acquisition met the definition of a business under GAAP, the assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_130,Financial Statements and Supplementary Data,ITEM_8,10,10-K,130,The determination of estimated fair value required management to make significant estimates and assumptions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_131,Financial Statements and Supplementary Data,ITEM_8,10,10-K,131,The excess of the purchase price over the fair value of the acquired net assets was recorded as goodwill.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_132,Financial Statements and Supplementary Data,ITEM_8,10,10-K,132,The results of operations of the acquisition are included in our consolidated financial statements from the date of acquisition.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_133,Financial Statements and Supplementary Data,ITEM_8,10,10-K,133,"Manufacturing Facility Acquisition Overview of Transaction In May 2024, we acquired all outstanding membership interests of NexPharm Parent HoldCo, LLC and Isopro Holdings, LLC, which together own the assets of a manufacturing site in Wisconsin, for a purchase price of $924.7 million, net of cash acquired.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_134,Financial Statements and Supplementary Data,ITEM_8,10,10-K,134,The facility is intended to further expand our global parenteral (injectable) product manufacturing network.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_135,Financial Statements and Supplementary Data,ITEM_8,10,10-K,135,Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_136,Financial Statements and Supplementary Data,ITEM_8,10,10-K,136,"(1) The goodwill recognized from this acquisition is primarily attributable to the synergies between the manufacturing capabilities of the site and our products as well as the assembled workforce of the site, which is deductible for tax purposes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_137,Financial Statements and Supplementary Data,ITEM_8,10,10-K,137,"The results of operations attributable to this acquisition for the year ended December 31, 2024 were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_138,Financial Statements and Supplementary Data,ITEM_8,10,10-K,138,"Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_139,Financial Statements and Supplementary Data,ITEM_8,10,10-K,139,"POINT Acquisition Overview of Transaction In December 2023, we acquired all shares of POINT Biopharma Global Inc. (POINT) for a purchase price of $12.50 per share in cash (or an aggregate of $1.04 billion, net of cash acquired).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_140,Financial Statements and Supplementary Data,ITEM_8,10,10-K,140,"POINT has capabilities in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_141,Financial Statements and Supplementary Data,ITEM_8,10,10-K,141,Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_142,Financial Statements and Supplementary Data,ITEM_8,10,10-K,142,"(1) The goodwill recognized from this acquisition is primarily attributable to the radiopharmaceutical discovery, development, and manufacturing capabilities and the assembled workforce for POINT, which is not deductible for tax purposes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_143,Financial Statements and Supplementary Data,ITEM_8,10,10-K,143,"The results of operations attributable to POINT for the years ended December 31, 2024 and 2023 were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_144,Financial Statements and Supplementary Data,ITEM_8,10,10-K,144,"Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_145,Financial Statements and Supplementary Data,ITEM_8,10,10-K,145,"Akouos Acquisition Overview of Transaction In December 2022, we acquired all shares of Akouos, Inc. (Akouos) for a purchase price that included $12.50 per share in cash (or an aggregate of $327.2 million, net of cash acquired) plus one non-tradable contingent value right (CVR) per share.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_146,Financial Statements and Supplementary Data,ITEM_8,10,10-K,146,"The CVR entitles the Akouos shareholders up to an additional $3.00 per share in cash (or an aggregate of approximately $122 million) payable, subject to certain terms and conditions, upon the achievement of certain specified milestones prior to December 2028.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_147,Financial Statements and Supplementary Data,ITEM_8,10,10-K,147,"Under the terms of the agreement, we acquired potential gene therapy treatments for hearing loss and other inner ear conditions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_148,Financial Statements and Supplementary Data,ITEM_8,10,10-K,148,"The lead gene therapies in clinical development that we acquired included GJB2 (which encodes connexin 26) for a common form of monogenic deafness and hearing loss; AK-OTOF for hearing loss due to mutations in the otoferlin gene; AK-CLRN1 for Usher Type 3A, an autosomal recessive disorder characterized by progressive loss of both hearing and vision; and AK-antiVEGF for vestibular schwannoma.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_149,Financial Statements and Supplementary Data,ITEM_8,10,10-K,149,Assets Acquired and Liabilities Assumed The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_150,Financial Statements and Supplementary Data,ITEM_8,10,10-K,150,(1) Acquired IPR&D intangibles primarily relate to GJB2.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_151,Financial Statements and Supplementary Data,ITEM_8,10,10-K,151,(2) The goodwill recognized from this acquisition is primarily attributable to future unidentified projects and products and the assembled workforce for Akouos and is not deductible for tax purposes.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_152,Financial Statements and Supplementary Data,ITEM_8,10,10-K,152,(3) See Note 7 for a discussion on the estimation of the CVR liability.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_153,Financial Statements and Supplementary Data,ITEM_8,10,10-K,153,"The results of operations attributable to Akouos for the years ended December 31, 2024, 2023 and 2022 were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_154,Financial Statements and Supplementary Data,ITEM_8,10,10-K,154,"Pro forma information has not been included as this acquisition did not have a material impact on our consolidated statements of operations for the year ended December 31, 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_155,Financial Statements and Supplementary Data,ITEM_8,10,10-K,155,"Asset Acquisitions Upon each asset acquisition, the cost allocated to acquired IPR&D was immediately expensed as acquired IPR&D if the compound has no alternative future use.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_156,Financial Statements and Supplementary Data,ITEM_8,10,10-K,156,Milestone payment obligations incurred prior to regulatory approval of the compound were expensed when the event triggering an obligation to pay the milestone occurred.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_157,Financial Statements and Supplementary Data,ITEM_8,10,10-K,157,"We recognized acquired IPR&D charges of $3.28 billion, $3.80 billion, and $908.5 million for the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_158,Financial Statements and Supplementary Data,ITEM_8,10,10-K,158,"The following table summarizes our significant asset acquisitions during 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_159,Financial Statements and Supplementary Data,ITEM_8,10,10-K,159,"(1) The phase of development presented is as of the date of the arrangement and represents the phase of development of the most advanced asset acquired, where applicable.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_160,Financial Statements and Supplementary Data,ITEM_8,10,10-K,160,"(2) In 2024, we discontinued development of this molecule in favor of another molecule in development.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_161,Financial Statements and Supplementary Data,ITEM_8,10,10-K,161,"In connection with our acquisition of Petra Pharma Corporation (Petra) in 2020, we were required to make milestone payments to Petra shareholders contingent upon the occurrence of certain future events linked to the success of the mutant-selective PI3Kα inhibitor.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_162,Financial Statements and Supplementary Data,ITEM_8,10,10-K,162,"In 2022, we entered into agreements with substantially all Petra shareholders to acquire their rights to receive any future milestone payments in exchange for a one-time payment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_163,Financial Statements and Supplementary Data,ITEM_8,10,10-K,163,"As a result of these agreements, we recognized a charge of $333.8 million as acquired IPR&D in 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_164,Financial Statements and Supplementary Data,ITEM_8,10,10-K,164,Any remaining contingent milestones payments linked to the success of the mutant-selective PI3Kα inhibitor are not expected to be material.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_165,Financial Statements and Supplementary Data,ITEM_8,10,10-K,165,"We recognized no other significant acquired IPR&D charges during the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_166,Financial Statements and Supplementary Data,ITEM_8,10,10-K,166,Note 4: Collaborations and Other Arrangements We often enter into collaborative and other arrangements to develop and commercialize drug candidates or to sell the rights of a product.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_167,Financial Statements and Supplementary Data,ITEM_8,10,10-K,167,See Note 2 for a discussion of our recognition of revenue from our collaborations and other arrangements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_168,Financial Statements and Supplementary Data,ITEM_8,10,10-K,168,"Collaborative activities may include research and development, marketing and selling, manufacturing, and distribution for which we may receive from or pay to the collaboration partner expense reimbursements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_169,Financial Statements and Supplementary Data,ITEM_8,10,10-K,169,"Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_170,Financial Statements and Supplementary Data,ITEM_8,10,10-K,170,"Each arrangement is unique in nature, and our more significant arrangements are discussed below.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_171,Financial Statements and Supplementary Data,ITEM_8,10,10-K,171,Boehringer Ingelheim Collaboration We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of compounds.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_172,Financial Statements and Supplementary Data,ITEM_8,10,10-K,172,Significant product families included in the collaboration are Boehringer Ingelheim's Jardiance product family and our Basaglar product family.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_173,Financial Statements and Supplementary Data,ITEM_8,10,10-K,173,"Glyxambi, Synjardy, and Trijardy XR are included in the Jardiance product family.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_174,Financial Statements and Supplementary Data,ITEM_8,10,10-K,174,Rezvoglar is included in the Basaglar product family.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_175,Financial Statements and Supplementary Data,ITEM_8,10,10-K,175,"For the Jardiance product family, we and Boehringer Ingelheim generally share equally the ongoing development and commercialization costs in the most significant markets, and we record our portion of the development and commercialization costs as research and development expense and marketing, selling, and administrative expense, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_176,Financial Statements and Supplementary Data,ITEM_8,10,10-K,176,We receive a royalty on net sales of the Jardiance product family in the most significant markets and recognize the royalty as collaboration and other revenue.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_177,Financial Statements and Supplementary Data,ITEM_8,10,10-K,177,"Boehringer Ingelheim is entitled to potential performance payments depending on the net sales of the Jardiance product family; therefore, our reported revenue for Jardiance may be reduced by any potential performance payments we make related to this product family.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_178,Financial Statements and Supplementary Data,ITEM_8,10,10-K,178,The royalty received by us related to the Jardiance product family may also be increased or decreased depending on whether net sales for this product family exceed or fall below certain thresholds.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_179,Financial Statements and Supplementary Data,ITEM_8,10,10-K,179,We pay to Boehringer Ingelheim a royalty on net sales for the Basaglar product family in the U.S. We record our sales of the Basaglar product family to third parties as net product revenue with the royalty payments made to Boehringer Ingelheim recorded as cost of sales.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_180,Financial Statements and Supplementary Data,ITEM_8,10,10-K,180,The following table summarizes our revenue recognized:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_181,Financial Statements and Supplementary Data,ITEM_8,10,10-K,181,"2024 revenue from Jardiance included a one-time payment received of $300.0 million associated with an amendment to our collaboration with Boehringer Ingelheim. Pursuant to the amendment, we and Boehringer Ingelheim adjusted commercialization responsibilities for Jardiance within certain smaller markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_182,Financial Statements and Supplementary Data,ITEM_8,10,10-K,182,"Olumiant We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte), which provides us the development and commercialization rights to baricitinib, which is branded and trademarked as Olumiant, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases and COVID-19.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_183,Financial Statements and Supplementary Data,ITEM_8,10,10-K,183,"Incyte has the right to receive tiered, double digit royalty payments on worldwide net sales with rates ranging up to 20 percent.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_184,Financial Statements and Supplementary Data,ITEM_8,10,10-K,184,Incyte has the right to receive an additional royalty ranging up to the low teens on worldwide net sales for the treatment of COVID-19 that exceed a specified aggregate worldwide net sales threshold.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_185,Financial Statements and Supplementary Data,ITEM_8,10,10-K,185,"We record our sales of Olumiant, including sales of baricitinib that were made pursuant to EUA or similar regulatory authorizations, to third parties as net product revenue with the royalty payments made to Incyte recorded as cost of sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_186,Financial Statements and Supplementary Data,ITEM_8,10,10-K,186,The following table summarizes our net product revenue recognized:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_187,Financial Statements and Supplementary Data,ITEM_8,10,10-K,187,"Tyvyt We have a collaboration agreement with Innovent Biologics, Inc. (Innovent) to jointly develop and commercialize sintilimab injection in China, where it is branded and trademarked as Tyvyt.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_188,Financial Statements and Supplementary Data,ITEM_8,10,10-K,188,"We record our sales of Tyvyt to third parties as net product revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_189,Financial Statements and Supplementary Data,ITEM_8,10,10-K,189,We report as collaboration and other revenue our portion of the gross margin for Tyvyt sales made by Innovent to third parties.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_190,Financial Statements and Supplementary Data,ITEM_8,10,10-K,190,The following table summarizes our revenue recognized:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_191,Financial Statements and Supplementary Data,ITEM_8,10,10-K,191,"Ebglyss We have a license agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. (collectively, Roche), which provides us the worldwide development and commercialization rights to lebrikizumab, which is branded and trademarked as Ebglyss.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_192,Financial Statements and Supplementary Data,ITEM_8,10,10-K,192,"Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_193,Financial Statements and Supplementary Data,ITEM_8,10,10-K,193,"As of December 31, 2024, Roche is eligible to receive additional payments from us, including up to $1.03 billion in potential sales-based milestones.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_194,Financial Statements and Supplementary Data,ITEM_8,10,10-K,194,"During the years ended December 31, 2024, 2023, and 2022, milestone payments to Roche were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_195,Financial Statements and Supplementary Data,ITEM_8,10,10-K,195,"We have a license agreement with Almirall, S.A. (Almirall), under which Almirall licensed the rights to develop and commercialize Ebglyss for the treatment or prevention of dermatology indications, including, but not limited to, atopic dermatitis in Europe.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_196,Financial Statements and Supplementary Data,ITEM_8,10,10-K,196,"We receive tiered royalty payments on net sales in Europe ranging in percentages from low double digits to low twenties, which we recognize as collaboration and other revenue.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_197,Financial Statements and Supplementary Data,ITEM_8,10,10-K,197,"During the years ended December 31, 2024, 2023, and 2022, collaboration and other revenue recognized under this license agreement was not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_198,Financial Statements and Supplementary Data,ITEM_8,10,10-K,198,"As of December 31, 2024, we are eligible to receive additional payments up to $1.25 billion in a series of sales-based milestones.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_199,Financial Statements and Supplementary Data,ITEM_8,10,10-K,199,"Orforglipron We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us with the worldwide development and commercialization rights to orforglipron.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_200,Financial Statements and Supplementary Data,ITEM_8,10,10-K,200,Chugai has the right to receive tiered royalty payments on future worldwide net sales from mid single digits to low teens if the product is successfully commercialized.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_201,Financial Statements and Supplementary Data,ITEM_8,10,10-K,201,"As of December 31, 2024, Chugai is eligible to receive up to $140.0 million contingent upon the achievement of success-based regulatory milestones and up to $250.0 million in a series of sales-based milestones, contingent upon the commercial success of orforglipron.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_202,Financial Statements and Supplementary Data,ITEM_8,10,10-K,202,"During the years ended December 31, 2024, 2023, and 2022, milestone payments to Chugai were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_203,Financial Statements and Supplementary Data,ITEM_8,10,10-K,203,"COVID-19 Antibodies We have a worldwide license and collaboration agreement with AbCellera Biologics Inc. (AbCellera) to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, including bamlanivimab and bebtelovimab, for which we hold development and commercialization rights.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_204,Financial Statements and Supplementary Data,ITEM_8,10,10-K,204,"AbCellera received royalty payments, recorded as cost of sales, in the mid-teens to mid-twenties on worldwide net sales of bamlanivimab and bebtelovimab.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_205,Financial Statements and Supplementary Data,ITEM_8,10,10-K,205,"Pursuant to EUAs or similar regulatory authorizations, we recognized net product revenue associated with our sales of our COVID-19 antibodies of $2.02 billion during 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_206,Financial Statements and Supplementary Data,ITEM_8,10,10-K,206,"We had no sales of our COVID-19 antibodies during the years ended December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_207,Financial Statements and Supplementary Data,ITEM_8,10,10-K,207,"Divestitures Olanzapine Portfolio (including Zyprexa) In July 2023, we sold the rights for the olanzapine portfolio, including Zyprexa, to Cheplapharm Arzneimittel GmbH (Cheplapharm), a European company.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_208,Financial Statements and Supplementary Data,ITEM_8,10,10-K,208,"Under the terms of the agreement, we received $1.05 billion in cash in 2023 and an additional $305.0 million in cash in 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_209,Financial Statements and Supplementary Data,ITEM_8,10,10-K,209,We included both in the transaction price in 2023.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_210,Financial Statements and Supplementary Data,ITEM_8,10,10-K,210,We entered into a supply agreement with Cheplapharm that obligates Cheplapharm to purchase Zyprexa product we are manufacturing at an amount which represents a standalone selling price.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_211,Financial Statements and Supplementary Data,ITEM_8,10,10-K,211,"As the product we are manufacturing under this supply agreement has no alternative use to us and we have right to payment, we recognize net product revenue over time as we manufacture the product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_212,Financial Statements and Supplementary Data,ITEM_8,10,10-K,212,"During the year ended December 31, 2023, we recognized $1.45 billion in revenue primarily related to the net gain on the sale of rights for the olanzapine portfolio.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_213,Financial Statements and Supplementary Data,ITEM_8,10,10-K,213,"Baqsimi In June 2023, we sold the rights for Baqsimi to Amphastar Pharmaceuticals, Inc. (Amphastar).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_214,Financial Statements and Supplementary Data,ITEM_8,10,10-K,214,"Under the terms of the agreement, we received $500.0 million in cash in 2023 and an additional $125.0 million in cash in 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_215,Financial Statements and Supplementary Data,ITEM_8,10,10-K,215,We included both in the transaction price in 2023.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_216,Financial Statements and Supplementary Data,ITEM_8,10,10-K,216,"We are eligible to receive payments of up to $450.0 million in a series of sales-based milestones, that have not been included in the transaction price as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_217,Financial Statements and Supplementary Data,ITEM_8,10,10-K,217,We entered into a supply agreement with Amphastar that obligates Amphastar to purchase Baqsimi product we are manufacturing at an amount which represents a standalone selling price.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_218,Financial Statements and Supplementary Data,ITEM_8,10,10-K,218,"As the product we are manufacturing under this supply agreement has no alternative use to us and we have right to payment, we recognize net product revenue over time as we manufacture the product.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_219,Financial Statements and Supplementary Data,ITEM_8,10,10-K,219,"During the year ended December 31, 2023, we recognized $579.0 million in revenue primarily related to the net gain on the sale of rights for Baqsimi.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_220,Financial Statements and Supplementary Data,ITEM_8,10,10-K,220,"Note 5: Asset Impairment, Restructuring, and Other Special Charges",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_221,Financial Statements and Supplementary Data,ITEM_8,10,10-K,221,"Asset impairment, restructuring, and other special charges were $860.6 million, $67.7 million, and $244.6 million for the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_222,Financial Statements and Supplementary Data,ITEM_8,10,10-K,222,"Asset impairment, restructuring, and other special charges recognized during the year ended December 31, 2024 were primarily related to a $435.0 million litigation charge and an intangible asset impairment for Vitrakvi, driven by expected commercial projections.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_223,Financial Statements and Supplementary Data,ITEM_8,10,10-K,223,See Note 16 for additional information related to the litigation charge.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_224,Financial Statements and Supplementary Data,ITEM_8,10,10-K,224,"Asset impairment, restructuring, and other special charges recognized during the year ended December 31, 2022 were primarily related to an intangible asset impairment driven by delays in estimated launch timing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_225,Financial Statements and Supplementary Data,ITEM_8,10,10-K,225,"Note 6: Inventories We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_226,Financial Statements and Supplementary Data,ITEM_8,10,10-K,226,FIFO cost approximates current replacement cost.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_227,Financial Statements and Supplementary Data,ITEM_8,10,10-K,227,Inventories measured using LIFO must be valued at the lower of cost or market.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_228,Financial Statements and Supplementary Data,ITEM_8,10,10-K,228,Inventories measured using FIFO must be valued at the lower of cost or net realizable value.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_229,Financial Statements and Supplementary Data,ITEM_8,10,10-K,229,"Inventories at December 31 consisted of the following: Inventories valued under the LIFO method comprised $2.70 billion and $1.77 billion of total inventories at December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_230,Financial Statements and Supplementary Data,ITEM_8,10,10-K,230,"When we believe that future commercialization is probable and the future economic benefit is expected to be realized, we capitalize pre-launch inventory prior to regulatory approval.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_231,Financial Statements and Supplementary Data,ITEM_8,10,10-K,231,"A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, viability of commercialization, and marketplace trends.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_232,Financial Statements and Supplementary Data,ITEM_8,10,10-K,232,"Pre-launch inventory capitalized as of December 31, 2024 was $548.1 million, primarily related to orforglipron.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_233,Financial Statements and Supplementary Data,ITEM_8,10,10-K,233,Note 7: Financial Instruments Investments in Equity and Debt Securities Our equity investments are accounted for using three different methods depending on the type of equity investment:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_234,Financial Statements and Supplementary Data,ITEM_8,10,10-K,234,"•Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method, with our share of earnings or losses reported in other-net, (income) expense.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_235,Financial Statements and Supplementary Data,ITEM_8,10,10-K,235,"•For equity investments that do not have readily determinable fair values, we measure these investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_236,Financial Statements and Supplementary Data,ITEM_8,10,10-K,236,"Any change in recorded value is recorded in other-net, (income) expense.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_237,Financial Statements and Supplementary Data,ITEM_8,10,10-K,237,"•Our public equity investments are measured and carried at fair value. Any change in fair value is recognized in other-net, (income) expense.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_238,Financial Statements and Supplementary Data,ITEM_8,10,10-K,238,We adjust our equity investments without readily determinable fair values based upon changes in the equity instruments' values resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_239,Financial Statements and Supplementary Data,ITEM_8,10,10-K,239,"Downward adjustments resulting from an impairment are recorded based upon impairment considerations, including the financial condition and near-term prospects of the issuer, general market conditions, and industry specific factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_240,Financial Statements and Supplementary Data,ITEM_8,10,10-K,240,"Adjustments recorded for the years ended December 31, 2024, 2023, and 2022 were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_241,Financial Statements and Supplementary Data,ITEM_8,10,10-K,241,"The net losses recognized in our consolidated statements of operations for equity securities were $49.5 million, $20.2 million, and $410.7 million for the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_242,Financial Statements and Supplementary Data,ITEM_8,10,10-K,242,"The net gains (losses) recognized for the years ended December 31, 2024, 2023, and 2022 on equity securities sold during the respective periods were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_243,Financial Statements and Supplementary Data,ITEM_8,10,10-K,243,"As of December 31, 2024, we had approximately $899 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_244,Financial Statements and Supplementary Data,ITEM_8,10,10-K,244,"We record our available-for-sale debt securities at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_245,Financial Statements and Supplementary Data,ITEM_8,10,10-K,245,We periodically assess our investment in available-for-sale securities for impairment losses and credit losses.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_246,Financial Statements and Supplementary Data,ITEM_8,10,10-K,246,The amount of credit losses is determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_247,Financial Statements and Supplementary Data,ITEM_8,10,10-K,247,"Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_248,Financial Statements and Supplementary Data,ITEM_8,10,10-K,248,"Impairment and credit losses related to available-for-sale securities were not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_249,Financial Statements and Supplementary Data,ITEM_8,10,10-K,249,"The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2024:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_250,Financial Statements and Supplementary Data,ITEM_8,10,10-K,250,A summary of the amount of unrealized gains and losses in accumulated other comprehensive loss and the fair value of available-for-sale securities in an unrealized gain or loss position follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_251,Financial Statements and Supplementary Data,ITEM_8,10,10-K,251,"As of December 31, 2024, the available-for-sale securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities, which are sensitive to changes in the yield curve and other market conditions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_252,Financial Statements and Supplementary Data,ITEM_8,10,10-K,252,Substantially all of the fixed-rate debt securities in a loss position are investment-grade debt securities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_253,Financial Statements and Supplementary Data,ITEM_8,10,10-K,253,"As of December 31, 2024, we do not intend to sell, and it is not more likely than not that we will be required to sell, the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of a material default on interest or principal payments for our debt securities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_254,Financial Statements and Supplementary Data,ITEM_8,10,10-K,254,"Realized gains and losses on sales of available-for-sale investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings and were not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_255,Financial Statements and Supplementary Data,ITEM_8,10,10-K,255,"Proceeds from sales of available-for-sale investments were $98.0 million, $145.6 million, and $132.9 million for the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_256,Financial Statements and Supplementary Data,ITEM_8,10,10-K,256,"Fair Value of Investments The following table summarizes certain fair value information at December 31, 2024 and 2023 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_257,Financial Statements and Supplementary Data,ITEM_8,10,10-K,257,"(1) For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_258,Financial Statements and Supplementary Data,ITEM_8,10,10-K,258,(2) We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_259,Financial Statements and Supplementary Data,ITEM_8,10,10-K,259,(3) Fair value disclosures are not applicable for equity method investments and investments accounted for under the measurement alternative for equity investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_260,Financial Statements and Supplementary Data,ITEM_8,10,10-K,260,"We determine our Level 1 and Level 2 fair value measurements based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_261,Financial Statements and Supplementary Data,ITEM_8,10,10-K,261,"Level 3 fair value measurements for other investment securities are determined using unobservable inputs, including the investments' cost adjusted for impairments and price changes from orderly transactions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_262,Financial Statements and Supplementary Data,ITEM_8,10,10-K,262,Fair values are not readily available for certain equity investments measured under the measurement alternative.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_263,Financial Statements and Supplementary Data,ITEM_8,10,10-K,263,Debt Fair Value of Debt The following table summarizes certain fair value information for our short-term and long-term debt:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_264,Financial Statements and Supplementary Data,ITEM_8,10,10-K,264,Risk Management and Related Financial Instruments Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_265,Financial Statements and Supplementary Data,ITEM_8,10,10-K,265,Wholesale distributors of our products account for a substantial portion of our trade receivables; collateral is generally not required.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_266,Financial Statements and Supplementary Data,ITEM_8,10,10-K,266,We seek to mitigate the risk associated with this concentration through our ongoing credit-review procedures and insurance.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_267,Financial Statements and Supplementary Data,ITEM_8,10,10-K,267,The majority of our cash is held by a few major financial institutions that have been identified as Global Systemically Important Banks (G-SIBs) by the Financial Stability Board.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_268,Financial Statements and Supplementary Data,ITEM_8,10,10-K,268,G-SIBs are subject to rigorous regulatory testing and oversight and must meet certain capital requirements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_269,Financial Statements and Supplementary Data,ITEM_8,10,10-K,269,We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_270,Financial Statements and Supplementary Data,ITEM_8,10,10-K,270,"In accordance with documented corporate risk-management policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer based on credit rating of our counterparty.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_271,Financial Statements and Supplementary Data,ITEM_8,10,10-K,271,We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect significant counterparties to fail to meet their obligations given their investment grade credit ratings.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_272,Financial Statements and Supplementary Data,ITEM_8,10,10-K,272,We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_273,Financial Statements and Supplementary Data,ITEM_8,10,10-K,273,"These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over, and risk related to, the receivables to the buyers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_274,Financial Statements and Supplementary Data,ITEM_8,10,10-K,274,"We derecognized $421.6 million and $431.9 million of accounts receivable as of December 31, 2024 and 2023, respectively, under these factoring arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_275,Financial Statements and Supplementary Data,ITEM_8,10,10-K,275,"The costs of factoring such accounts receivable as well as estimated credit losses were not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_276,Financial Statements and Supplementary Data,ITEM_8,10,10-K,276,"Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and are intended to offset losses and gains on the assets, liabilities, and transactions being hedged.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_277,Financial Statements and Supplementary Data,ITEM_8,10,10-K,277,Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_278,Financial Statements and Supplementary Data,ITEM_8,10,10-K,278,"For derivative instruments that are designated and qualify as fair value hedges, the derivative instrument is marked to market, with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_279,Financial Statements and Supplementary Data,ITEM_8,10,10-K,279,"For derivative instruments that are designated and qualify as cash flow hedges, gains and losses are reported as a component of accumulated other comprehensive income (loss) (see Note 17) and reclassified into earnings in the same period the hedged transaction affects earnings.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_280,Financial Statements and Supplementary Data,ITEM_8,10,10-K,280,"For derivative and non-derivative instruments that are designated and qualify as net investment hedges, the foreign currency translation gains or losses due to spot rate fluctuations are reported as a component of accumulated other comprehensive income (loss) (see Note 17).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_281,Financial Statements and Supplementary Data,ITEM_8,10,10-K,281,Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in earnings during the period of change.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_282,Financial Statements and Supplementary Data,ITEM_8,10,10-K,282,"Foreign currency exchange risk is managed through the use of foreign currency debt, cross-currency interest rate swaps, and foreign currency forward contracts.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_283,Financial Statements and Supplementary Data,ITEM_8,10,10-K,283,"Our foreign currency-denominated notes had carrying amounts of $6.03 billion and $7.14 billion as of December 31, 2024 and 2023, respectively, of which $5.34 billion and $5.67 billion have been designated as, and are effective as, hedges of net investments in certain of our foreign operations as of December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_284,Financial Statements and Supplementary Data,ITEM_8,10,10-K,284,"At December 31, 2024, we had outstanding cross-currency interest rate swaps with notional amounts of $218.0 million swapping U.S. dollars to euro and 402.0 million Swiss francs swapping to U.S. dollars, with settlement dates ranging through 2028.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_285,Financial Statements and Supplementary Data,ITEM_8,10,10-K,285,"Our cross-currency interest rate swaps have been designated as, and are effective as, net investment and cash flow hedges, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_286,Financial Statements and Supplementary Data,ITEM_8,10,10-K,286,"At December 31, 2024, we had outstanding foreign currency forward contracts to sell 7.59 billion euro and to sell 4.20 billion Chinese yuan, with settlement dates ranging through 2025, which have been designated as, and are effective as, hedges of net investments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_287,Financial Statements and Supplementary Data,ITEM_8,10,10-K,287,We may also enter into foreign currency forward or option contracts as economic hedges to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies (primarily the euro and Japanese yen).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_288,Financial Statements and Supplementary Data,ITEM_8,10,10-K,288,Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_289,Financial Statements and Supplementary Data,ITEM_8,10,10-K,289,"These contracts are recorded at fair value with the gain or loss recognized in other-net, (income) expense.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_290,Financial Statements and Supplementary Data,ITEM_8,10,10-K,290,Forward contracts generally have maturities not exceeding 12 months.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_291,Financial Statements and Supplementary Data,ITEM_8,10,10-K,291,"At December 31, 2024, our significant outstanding foreign currency forward commitments were as follows, all of which have settlement dates within 180 days:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_292,Financial Statements and Supplementary Data,ITEM_8,10,10-K,292,"In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_293,Financial Statements and Supplementary Data,ITEM_8,10,10-K,293,We seek to address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_294,Financial Statements and Supplementary Data,ITEM_8,10,10-K,294,The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_295,Financial Statements and Supplementary Data,ITEM_8,10,10-K,295,Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_296,Financial Statements and Supplementary Data,ITEM_8,10,10-K,296,"In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_297,Financial Statements and Supplementary Data,ITEM_8,10,10-K,297,Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_298,Financial Statements and Supplementary Data,ITEM_8,10,10-K,298,Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_299,Financial Statements and Supplementary Data,ITEM_8,10,10-K,299,Interest expense on the debt is adjusted to include the payments made or received under the swap agreements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_300,Financial Statements and Supplementary Data,ITEM_8,10,10-K,300,Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated statements of cash flows.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_301,Financial Statements and Supplementary Data,ITEM_8,10,10-K,301,"At December 31, 2024, all of our total long-term debt is at a fixed rate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_302,Financial Statements and Supplementary Data,ITEM_8,10,10-K,302,We have converted approximately 5 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_303,Financial Statements and Supplementary Data,ITEM_8,10,10-K,303,"We also may enter into forward-starting interest rate swaps and treasury locks, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_304,Financial Statements and Supplementary Data,ITEM_8,10,10-K,304,"The change in fair value of these instruments is recorded as part of other comprehensive income (loss) (see Note 17) and, upon completion of a debt issuance and termination of the instrument, is amortized to interest expense over the life of the underlying debt.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_305,Financial Statements and Supplementary Data,ITEM_8,10,10-K,305,Cash proceeds or payments from the termination of these instruments are classified as operating activities in our consolidated statements of cash flows.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_306,Financial Statements and Supplementary Data,ITEM_8,10,10-K,306,The Effect of Risk Management Instruments on the Consolidated Statements of Operations,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_307,Financial Statements and Supplementary Data,ITEM_8,10,10-K,307,"The following effects of risk-management instruments were recognized in other-net, (income) expense:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_308,Financial Statements and Supplementary Data,ITEM_8,10,10-K,308,"During the years ended December 31, 2024, 2023, and 2022, the amortization of losses related to the portion of our risk management hedging instruments, fair value hedges, and cash flow hedges that was excluded from the assessment of effectiveness was not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_309,Financial Statements and Supplementary Data,ITEM_8,10,10-K,309,The Effect of Risk-Management Instruments on Other Comprehensive Income (Loss),2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_310,Financial Statements and Supplementary Data,ITEM_8,10,10-K,310,The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_311,Financial Statements and Supplementary Data,ITEM_8,10,10-K,311,"During the years ended December 31, 2024, 2023, and 2022, the amounts excluded from the assessment of hedge effectiveness recognized in other comprehensive income (loss) were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_312,Financial Statements and Supplementary Data,ITEM_8,10,10-K,312,"As of December 31, 2024, the amount of pre-tax gains or losses on cash flow hedges expected to be reclassified from accumulated other comprehensive income (loss) to other-net, (income) expense over the next 12 months is not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_313,Financial Statements and Supplementary Data,ITEM_8,10,10-K,313,"Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at December 31, 2024 and 2023 for risk-management assets and liabilities measured at fair value on a recurring basis:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_314,Financial Statements and Supplementary Data,ITEM_8,10,10-K,314,Risk-management instruments above are disclosed on a gross basis.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_315,Financial Statements and Supplementary Data,ITEM_8,10,10-K,315,There are various rights of setoff associated with certain of the risk-management instruments above that are subject to enforceable master netting arrangements or similar agreements.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_316,Financial Statements and Supplementary Data,ITEM_8,10,10-K,316,"Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_317,Financial Statements and Supplementary Data,ITEM_8,10,10-K,317,Contingent consideration liabilities relate to our liabilities arising in connection with the CVRs issued as a result of acquisitions of businesses.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_318,Financial Statements and Supplementary Data,ITEM_8,10,10-K,318,"The fair values of the CVR liabilities were estimated using a discounted cash flow analysis and Level 3 inputs, including projections representative of a market participant's view of the expected cash payments associated with the agreed upon regulatory milestones based on probabilities of technical success, timing of the potential milestone events for the compounds, and estimated discount rates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_319,Financial Statements and Supplementary Data,ITEM_8,10,10-K,319,Note 8: Goodwill and Other Intangibles Goodwill Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_320,Financial Statements and Supplementary Data,ITEM_8,10,10-K,320,"Goodwill is not amortized but is reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_321,Financial Statements and Supplementary Data,ITEM_8,10,10-K,321,"If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value to its carrying value is performed to determine the amount of any impairment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_322,Financial Statements and Supplementary Data,ITEM_8,10,10-K,322,The change in goodwill during 2024 was primarily related to our acquisition of a manufacturing site in Wisconsin.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_323,Financial Statements and Supplementary Data,ITEM_8,10,10-K,323,See Note 3 for additional information.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_324,Financial Statements and Supplementary Data,ITEM_8,10,10-K,324,"No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_325,Financial Statements and Supplementary Data,ITEM_8,10,10-K,325,Other Intangibles The components of intangible assets other than goodwill at December 31 were as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_326,Financial Statements and Supplementary Data,ITEM_8,10,10-K,326,"Marketed products consist primarily of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_327,Financial Statements and Supplementary Data,ITEM_8,10,10-K,327,"For transactions other than a business combination, we capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_328,Financial Statements and Supplementary Data,ITEM_8,10,10-K,328,"Acquired IPR&D consists of the fair values of acquired IPR&D projects acquired in business combinations, adjusted for subsequent impairments, if any.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_329,Financial Statements and Supplementary Data,ITEM_8,10,10-K,329,"The costs of acquired IPR&D projects acquired directly in a transaction other than a business combination are capitalized as other intangible assets if the projects have an alternative future use; otherwise, they are expensed immediately.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_330,Financial Statements and Supplementary Data,ITEM_8,10,10-K,330,See Note 3 for significant acquired IPR&D projects that had no alternative future use.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_331,Financial Statements and Supplementary Data,ITEM_8,10,10-K,331,Several methods may be used to determine the estimated fair value of other intangibles acquired in a business combination.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_332,Financial Statements and Supplementary Data,ITEM_8,10,10-K,332,"We utilize the ""income method,"" which is a Level 3 fair value measurement and applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected revenues and estimated costs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_333,Financial Statements and Supplementary Data,ITEM_8,10,10-K,333,"These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, analyst expectations, and expected industry trends.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_334,Financial Statements and Supplementary Data,ITEM_8,10,10-K,334,The estimated future net cash flows are then discounted to the present value using an appropriate discount rate.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_335,Financial Statements and Supplementary Data,ITEM_8,10,10-K,335,This analysis is performed for each asset independently.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_336,Financial Statements and Supplementary Data,ITEM_8,10,10-K,336,"The acquired IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_337,Financial Statements and Supplementary Data,ITEM_8,10,10-K,337,"Indefinite-lived intangible assets are reviewed for impairment at least annually, or more frequently if impairment indicators are present, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_338,Financial Statements and Supplementary Data,ITEM_8,10,10-K,338,"If we conclude it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the intangible asset to its carrying value is performed to determine the amount of any impairment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_339,Financial Statements and Supplementary Data,ITEM_8,10,10-K,339,Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_340,Financial Statements and Supplementary Data,ITEM_8,10,10-K,340,"When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_341,Financial Statements and Supplementary Data,ITEM_8,10,10-K,341,"When determining the fair value of indefinite-lived acquired IPR&D as well as the fair value of finite-lived intangible assets for impairment testing purposes, we utilize the ""income method"" discussed above.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_342,Financial Statements and Supplementary Data,ITEM_8,10,10-K,342,"Intangible assets with finite lives are capitalized and are amortized primarily to cost of sales over their estimated useful lives, ranging from one to 20 years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_343,Financial Statements and Supplementary Data,ITEM_8,10,10-K,343,"As of December 31, 2024, the remaining weighted-average amortization period for finite-lived intangible assets was approximately 12 years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_344,Financial Statements and Supplementary Data,ITEM_8,10,10-K,344,Amortization expense related to finite-lived intangible assets was as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_345,Financial Statements and Supplementary Data,ITEM_8,10,10-K,345,"The estimated amortization expense for each of the next five years associated with our finite-lived intangible assets as of December 31, 2024 is as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_346,Financial Statements and Supplementary Data,ITEM_8,10,10-K,346,Note 9: Property and Equipment Property and equipment is stated on the basis of cost.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_347,Financial Statements and Supplementary Data,ITEM_8,10,10-K,347,Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and three to 25 years for equipment).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_348,Financial Statements and Supplementary Data,ITEM_8,10,10-K,348,We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_349,Financial Statements and Supplementary Data,ITEM_8,10,10-K,349,Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_350,Financial Statements and Supplementary Data,ITEM_8,10,10-K,350,"If an impairment is identified, a loss is recorded equal to the excess of the asset's net book value over its fair value, and the cost basis is adjusted.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_351,Financial Statements and Supplementary Data,ITEM_8,10,10-K,351,"At December 31, property and equipment consisted of the following:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_352,Financial Statements and Supplementary Data,ITEM_8,10,10-K,352,Depreciation expense related to property and equipment was as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_353,Financial Statements and Supplementary Data,ITEM_8,10,10-K,353,"Capitalized interest costs were not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_354,Financial Statements and Supplementary Data,ITEM_8,10,10-K,354,The following table summarizes long-lived assets by geographical area:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_355,Financial Statements and Supplementary Data,ITEM_8,10,10-K,355,"(1) Long-lived assets consist of property and equipment, net, operating lease assets, and unamortized computer software costs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_356,Financial Statements and Supplementary Data,ITEM_8,10,10-K,356,Note 10: Leases We determine if an arrangement is a lease at inception.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_357,Financial Statements and Supplementary Data,ITEM_8,10,10-K,357,"We have leases with terms up to 15 years primarily for corporate offices, research and development facilities, vehicles, and equipment, including some of which have options to extend and/or early-terminate the leases.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_358,Financial Statements and Supplementary Data,ITEM_8,10,10-K,358,We determine the lease term by assuming the exercise of any renewal and/or early-termination options that are reasonably assured.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_359,Financial Statements and Supplementary Data,ITEM_8,10,10-K,359,"Operating lease right-of-use assets are presented as other noncurrent assets in our consolidated balance sheets, and the current and long-term portions of operating lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, in our consolidated balance sheets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_360,Financial Statements and Supplementary Data,ITEM_8,10,10-K,360,"Short-term leases, which are deemed at inception to have a lease term of 12 months or less, are not recorded on the consolidated balance sheets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_361,Financial Statements and Supplementary Data,ITEM_8,10,10-K,361,"Operating lease assets represent our right to use an underlying asset for the lease term, and operating lease liabilities represent our obligation to make lease payments arising from the lease.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_362,Financial Statements and Supplementary Data,ITEM_8,10,10-K,362,Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_363,Financial Statements and Supplementary Data,ITEM_8,10,10-K,363,"As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_364,Financial Statements and Supplementary Data,ITEM_8,10,10-K,364,"Lease expense for operating lease assets, which is recognized on a straight-line basis over the lease term, was $209.6 million, $171.2 million, and $148.8 million during the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_365,Financial Statements and Supplementary Data,ITEM_8,10,10-K,365,"Variable lease payments, which represent non-lease components such as maintenance, insurance and taxes, and which vary due to changes in facts or circumstances occurring after the commencement date other than the passage of time, are expensed in the period in which the payment obligation is incurred and were not material during the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_366,Financial Statements and Supplementary Data,ITEM_8,10,10-K,366,"Short-term lease expense was not material during the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_367,Financial Statements and Supplementary Data,ITEM_8,10,10-K,367,Supplemental balance sheet information related to operating leases as of December 31 was as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_368,Financial Statements and Supplementary Data,ITEM_8,10,10-K,368,Supplemental cash flow information related to operating leases was as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_369,Financial Statements and Supplementary Data,ITEM_8,10,10-K,369,"The annual minimum lease payments of our operating lease liabilities as of December 31, 2024 were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_370,Financial Statements and Supplementary Data,ITEM_8,10,10-K,370,"Finance leases are included in property and equipment, short-term borrowings and current maturities of long-term debt, and long-term debt in our consolidated balance sheets. Finance leases are not material to our consolidated financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_371,Financial Statements and Supplementary Data,ITEM_8,10,10-K,371,"Note 11: Borrowings Debt at December 31 consisted of the following: The weighted-average effective borrowing rates on short-term commercial paper borrowings were 4.61 percent and 5.39 percent at December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_372,Financial Statements and Supplementary Data,ITEM_8,10,10-K,372,The following table summarizes long-term notes at December 31:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_373,Financial Statements and Supplementary Data,ITEM_8,10,10-K,373,The weighted-average effective borrowing rate for each issuance of the long term-notes approximates the stated interest rate.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_374,Financial Statements and Supplementary Data,ITEM_8,10,10-K,374,"At December 31, 2024, we had a total of $8.45 billion of unused committed bank credit facilities, which consisted primarily of a $3.00 billion credit facility that expires in December 2028 and a $5.00 billion 364-day facility that expires in September 2025, both of which are available to support our commercial paper program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_375,Financial Statements and Supplementary Data,ITEM_8,10,10-K,375,"We have not drawn against the $3.00 billion and $5.00 billion facilities as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_376,Financial Statements and Supplementary Data,ITEM_8,10,10-K,376,"Of the remaining committed bank credit facilities, the outstanding balances as of December 31, 2024 and 2023 were not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_377,Financial Statements and Supplementary Data,ITEM_8,10,10-K,377,"Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_378,Financial Statements and Supplementary Data,ITEM_8,10,10-K,378,"In February 2025, we issued $1.00 billion of 4.550 percent fixed-rate notes due in 2028, $1.25 billion of 4.750 percent fixed-rate notes due in 2030, $1.00 billion of 4.900 percent fixed-rate notes due in 2032, $1.25 billion of 5.100 percent fixed-rate notes due in 2035, $1.25 billion of 5.500 percent fixed-rate notes due in 2055, and $750.0 million of 5.600 percent fixed-rate notes due in 2065, all with interest to be paid semi-annually.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_379,Financial Statements and Supplementary Data,ITEM_8,10,10-K,379,"We expect to use the net cash proceeds from the offering to fund potential business development activities, as well as general business purposes, including the repayment of outstanding commercial paper.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_380,Financial Statements and Supplementary Data,ITEM_8,10,10-K,380,"In August 2024, we issued $750.0 million of 4.150 percent fixed-rate notes due in 2027, $1.00 billion of 4.200 percent fixed-rate notes due in 2029, $1.25 billion of 4.600 percent fixed-rate notes due in 2034, $1.25 billion of 5.050 percent fixed-rate notes due in 2054, and $750.0 million of 5.200 percent fixed-rate notes due in 2064, all with interest to be paid semi-annually.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_381,Financial Statements and Supplementary Data,ITEM_8,10,10-K,381,"We used a portion of the net cash proceeds from the offering of $4.96 billion to fund the acquisition of Morphic and related fees and expenses, with any remaining funds used for general business purposes, including the repayment of outstanding commercial paper.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_382,Financial Statements and Supplementary Data,ITEM_8,10,10-K,382,"In February 2024, we issued $1.00 billion of 4.500 percent fixed-rate notes due in 2027, $1.00 billion of 4.500 percent fixed-rate notes due in 2029, $1.50 billion of 4.700 percent fixed-rate notes due in 2034, $1.50 billion of 5.000 percent fixed-rate notes due in 2054, and $1.50 billion of 5.100 percent fixed-rate notes due in 2064, all with interest to be paid semi-annually.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_383,Financial Statements and Supplementary Data,ITEM_8,10,10-K,383,"We used, or may be using, the net cash proceeds from the offering of $6.45 billion for general business purposes, including the repayment of outstanding commercial paper, repayment of current maturities of long-term debt, and repayment of the $750.0 million of 5.000 percent fixed-rate notes due in 2026.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_384,Financial Statements and Supplementary Data,ITEM_8,10,10-K,384,"In February 2023, we issued $750.0 million of 5.000 percent fixed-rate notes due in 2026, $1.00 billion of 4.700 percent fixed-rate notes due in 2033, $1.25 billion of 4.875 percent fixed-rate notes due in 2053, and $1.00 billion of 4.950 percent fixed-rate notes due in 2063, all with interest to be paid semi-annually.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_385,Financial Statements and Supplementary Data,ITEM_8,10,10-K,385,"We used the net cash proceeds from the offering of $3.96 billion for general business purposes, including the repayment of outstanding commercial paper.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_386,Financial Statements and Supplementary Data,ITEM_8,10,10-K,386,The aggregate amounts of maturities on long-term debt for the next five years are as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_387,Financial Statements and Supplementary Data,ITEM_8,10,10-K,387,We have converted approximately 5 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_388,Financial Statements and Supplementary Data,ITEM_8,10,10-K,388,"The weighted-average effective borrowing rates based on long-term debt obligations and interest rates at December 31, 2024 and 2023, including the effects of interest rate swaps for hedged debt obligations, were 3.95 percent and 3.37 percent, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_389,Financial Statements and Supplementary Data,ITEM_8,10,10-K,389,"The aggregate amount of cash payments for interest on borrowings, net of capitalized interest, are as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_390,Financial Statements and Supplementary Data,ITEM_8,10,10-K,390,"In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged as a fair value hedge is reflected in the consolidated balance sheets as an amount equal to the sum of the debt's carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_391,Financial Statements and Supplementary Data,ITEM_8,10,10-K,391,"Note 12: Stock-Based Compensation Our stock-based compensation expense consists of restricted stock units (RSUs), shareholder value awards (SVAs), performance awards (PAs), and relative value awards (RVAs).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_392,Financial Statements and Supplementary Data,ITEM_8,10,10-K,392,"We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_393,Financial Statements and Supplementary Data,ITEM_8,10,10-K,393,"We provide newly issued shares of our common stock and treasury stock to satisfy the issuance of RSU, SVA, PA, and RVA shares.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_394,Financial Statements and Supplementary Data,ITEM_8,10,10-K,394,Stock-based compensation expense and the related tax benefits were as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_395,Financial Statements and Supplementary Data,ITEM_8,10,10-K,395,"At December 31, 2024, stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 48.8 million additional shares.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_396,Financial Statements and Supplementary Data,ITEM_8,10,10-K,396,Restricted Stock Units RSUs are granted to certain employees and are payable in shares of our common stock.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_397,Financial Statements and Supplementary Data,ITEM_8,10,10-K,397,RSU shares are accounted for at fair value based upon the closing stock price on the date of grant.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_398,Financial Statements and Supplementary Data,ITEM_8,10,10-K,398,"The corresponding expense is amortized over the vesting period, typically three years.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_399,Financial Statements and Supplementary Data,ITEM_8,10,10-K,399,"The weighted-average fair values of RSU awards granted during the years ended December 31, 2024, 2023, and 2022 were $749.74, $339.30, and $239.88, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_400,Financial Statements and Supplementary Data,ITEM_8,10,10-K,400,The number of shares ultimately issued for the RSU program remains constant with the number of shares originally granted less forfeitures.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_401,Financial Statements and Supplementary Data,ITEM_8,10,10-K,401,"Pursuant to this program, 0.9 million, 1.0 million, and 1.0 million shares were granted and approximately 0.3 million, 0.5 million, and 0.8 million shares were issued during the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_402,Financial Statements and Supplementary Data,ITEM_8,10,10-K,402,We expect to issue approximately 0.5 million shares in 2025.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_403,Financial Statements and Supplementary Data,ITEM_8,10,10-K,403,"As of December 31, 2024, the total estimated remaining unrecognized compensation cost related to nonvested RSUs was $485.1 million, which will be amortized over the weighted-average remaining requisite service period of 23 months.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_404,Financial Statements and Supplementary Data,ITEM_8,10,10-K,404,Shareholder Value Award Program SVAs are granted to officers and management and are payable in shares of our common stock.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_405,Financial Statements and Supplementary Data,ITEM_8,10,10-K,405,"The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_406,Financial Statements and Supplementary Data,ITEM_8,10,10-K,406,We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_407,Financial Statements and Supplementary Data,ITEM_8,10,10-K,407,The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_408,Financial Statements and Supplementary Data,ITEM_8,10,10-K,408,"Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_409,Financial Statements and Supplementary Data,ITEM_8,10,10-K,409,"Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_410,Financial Statements and Supplementary Data,ITEM_8,10,10-K,410,The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_411,Financial Statements and Supplementary Data,ITEM_8,10,10-K,411,"The weighted-average fair values of the SVA units granted during the years ended December 31, 2024, 2023, and 2022 were $1,030.87, $349.63, and $203.88, respectively, determined using the following assumptions:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_412,Financial Statements and Supplementary Data,ITEM_8,10,10-K,412,"Pursuant to this program, approximately 0.2 million, 0.3 million, and 0.5 million shares were issued during the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_413,Financial Statements and Supplementary Data,ITEM_8,10,10-K,413,We expect to issue approximately 0.3 million shares in 2025.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_414,Financial Statements and Supplementary Data,ITEM_8,10,10-K,414,"As of December 31, 2024, the total estimated remaining unrecognized compensation cost related to nonvested SVAs was $61.4 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_415,Financial Statements and Supplementary Data,ITEM_8,10,10-K,415,Performance Award Program PAs were granted to officers and management prior to 2024 and are payable in shares of our common stock.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_416,Financial Statements and Supplementary Data,ITEM_8,10,10-K,416,"The number of PA shares actually issued, if any, varied depending on the achievement of certain pre-established earnings-per-share targets over a two-year period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_417,Financial Statements and Supplementary Data,ITEM_8,10,10-K,417,PA shares were accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement period.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_418,Financial Statements and Supplementary Data,ITEM_8,10,10-K,418,"The fair values of PAs granted for the years ended December 31, 2023 and 2022 were, $335.86 and $234.93, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_419,Financial Statements and Supplementary Data,ITEM_8,10,10-K,419,"Pursuant to this program, approximately 0.4 million, 0.5 million, and 0.7 million shares were issued during the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_420,Financial Statements and Supplementary Data,ITEM_8,10,10-K,420,We expect to issue approximately 0.6 million shares in 2025.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_421,Financial Statements and Supplementary Data,ITEM_8,10,10-K,421,"As of December 31, 2024, there was no remaining unrecognized compensation cost related to PAs, as we discontinued the program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_422,Financial Statements and Supplementary Data,ITEM_8,10,10-K,422,Relative Value Award Program RVAs are granted to officers and management and are payable in shares of our common stock.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_423,Financial Statements and Supplementary Data,ITEM_8,10,10-K,423,"The number of shares actually issued, if any, varies depending on the growth of our stock price at the end of the three-year vesting period compared to our peers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_424,Financial Statements and Supplementary Data,ITEM_8,10,10-K,424,We measure the fair value of the RVA unit on the grant date using a Monte Carlo simulation model.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_425,Financial Statements and Supplementary Data,ITEM_8,10,10-K,425,The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_426,Financial Statements and Supplementary Data,ITEM_8,10,10-K,426,"Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price and our peers' stock price, and other factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_427,Financial Statements and Supplementary Data,ITEM_8,10,10-K,427,"Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_428,Financial Statements and Supplementary Data,ITEM_8,10,10-K,428,The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_429,Financial Statements and Supplementary Data,ITEM_8,10,10-K,429,"The weighted-average fair value of the RVA units granted during the years ended December 31, 2024, 2023 and 2022 were $1,106.40, $397.95, and $230.00, respectively, determined using the following assumptions:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_430,Financial Statements and Supplementary Data,ITEM_8,10,10-K,430,"Pursuant to this program, approximately 0.1 million shares were issued during each of the years ended December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_431,Financial Statements and Supplementary Data,ITEM_8,10,10-K,431,We expect to issue approximately 0.1 million shares in 2025.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_432,Financial Statements and Supplementary Data,ITEM_8,10,10-K,432,"As of December 31, 2024, the total estimated remaining unrecognized compensation cost related to nonvested RVAs was $27.5 million, which will be amortized over the weighted-average remaining requisite service period of 22 months.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_433,Financial Statements and Supplementary Data,ITEM_8,10,10-K,433,"Note 13: Shareholders' Equity In 2024, 2023, and 2022, we repurchased $2.50 billion, $750.0 million, and $1.50 billion, respectively, of shares associated with our share repurchase programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_434,Financial Statements and Supplementary Data,ITEM_8,10,10-K,434,"In 2024, we repurchased $2.50 billion of shares, which completed our $5.00 billion share repurchase program that our board authorized in May 2021.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_435,Financial Statements and Supplementary Data,ITEM_8,10,10-K,435,Our board authorized a $15.00 billion share repurchase program in December 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_436,Financial Statements and Supplementary Data,ITEM_8,10,10-K,436,"No shares were repurchased under this new program as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_437,Financial Statements and Supplementary Data,ITEM_8,10,10-K,437,"We have 5.0 million authorized shares of preferred stock. As of December 31, 2024 and 2023, no preferred stock was issued.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_438,Financial Statements and Supplementary Data,ITEM_8,10,10-K,438,"We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2024 and 2023, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_439,Financial Statements and Supplementary Data,ITEM_8,10,10-K,439,"The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2024 and 2023, and is shown as a reduction of shareholders' equity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_440,Financial Statements and Supplementary Data,ITEM_8,10,10-K,440,Any dividend transactions between us and the trust are eliminated.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_441,Financial Statements and Supplementary Data,ITEM_8,10,10-K,441,Stock held by the trust is not considered outstanding in the computation of EPS.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_442,Financial Statements and Supplementary Data,ITEM_8,10,10-K,442,"The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_443,Financial Statements and Supplementary Data,ITEM_8,10,10-K,443,Note 14: Income Taxes Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_444,Financial Statements and Supplementary Data,ITEM_8,10,10-K,444,Deferred taxes related to global intangible low-taxed income (GILTI) are also recognized for the future tax effects of temporary differences.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_445,Financial Statements and Supplementary Data,ITEM_8,10,10-K,445,"We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position, based on its technical merits, will be sustained upon examination by the taxing authority.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_446,Financial Statements and Supplementary Data,ITEM_8,10,10-K,446,The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_447,Financial Statements and Supplementary Data,ITEM_8,10,10-K,447,"Following is the composition of income tax expense: (1) The 2024, 2023, and 2022 current tax expense includes $129.9 million, $69.3 million, and $189.5 million of tax benefit, respectively, from utilization of net operating loss and other tax carryforwards.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_448,Financial Statements and Supplementary Data,ITEM_8,10,10-K,448,Significant components of our deferred tax assets and liabilities as of December 31 were as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_449,Financial Statements and Supplementary Data,ITEM_8,10,10-K,449,"The deferred tax asset and related valuation allowance amounts for U.S. federal, international, and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_450,Financial Statements and Supplementary Data,ITEM_8,10,10-K,450,"At December 31, 2024, based on filed tax returns we have tax credit carryforwards and carrybacks of $1.13 billion available to reduce future income taxes; $148.8 million, if unused, will expire in 2026, and $53.6 million, if unused, will expire between 2030 and 2044.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_451,Financial Statements and Supplementary Data,ITEM_8,10,10-K,451,"The remaining portion of the tax credit carryforwards is related to federal tax credits of $68.0 million, international tax credits of $109.4 million, and state tax credits of $754.8 million, all of which are fully reserved.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_452,Financial Statements and Supplementary Data,ITEM_8,10,10-K,452,"At December 31, 2024, based on filed tax returns we have net operating losses and other carryforwards for U.S. federal and international tax purposes of $1.74 billion available to reduce future income taxes: $5.8 million will expire by 2029, $355.7 million will expire between 2030 and 2044, and $861.5 million of the carryforwards will never expire.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_453,Financial Statements and Supplementary Data,ITEM_8,10,10-K,453,"The remaining net operating losses and other carryforwards for U.S. federal and international tax purposes of $481.0 million and $32.4 million, respectively, are fully reserved.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_454,Financial Statements and Supplementary Data,ITEM_8,10,10-K,454,"Deferred tax assets related to state net operating losses and other carryforwards of $282.6 million are fully reserved as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_455,Financial Statements and Supplementary Data,ITEM_8,10,10-K,455,"At December 31, 2024 and 2023, prepaid expenses included prepaid taxes of $7.13 billion and $4.26 billion, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_456,Financial Statements and Supplementary Data,ITEM_8,10,10-K,456,"Domestic and Puerto Rican companies contributed approximately 20 percent, 14 percent, and 33 percent for the years ended December 31, 2024, 2023, and 2022, respectively, to consolidated income before income taxes.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_457,Financial Statements and Supplementary Data,ITEM_8,10,10-K,457,Substantially all of the unremitted earnings of our foreign subsidiaries are considered not to be indefinitely reinvested for continued use in our foreign operations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_458,Financial Statements and Supplementary Data,ITEM_8,10,10-K,458,"At December 31, 2024 and 2023, we accrued an immaterial amount of foreign withholding taxes and state income taxes that would be owed upon future distributions of unremitted earnings of our foreign subsidiaries that are not indefinitely reinvested.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_459,Financial Statements and Supplementary Data,ITEM_8,10,10-K,459,"For the amount considered to be indefinitely reinvested, it is not practicable to determine the amount of the related deferred income tax liability due to the complexities in the tax laws and assumptions we would have to make.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_460,Financial Statements and Supplementary Data,ITEM_8,10,10-K,460,"Cash payments of U.S. federal, state, and foreign income taxes, net of refunds, were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_461,Financial Statements and Supplementary Data,ITEM_8,10,10-K,461,"As of December 31, 2024, we have noncurrent income tax payables of $490.7 million that we expect to pay in 2026 and $3.57 billion that we cannot reasonably estimate the timing of future cash outflows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_462,Financial Statements and Supplementary Data,ITEM_8,10,10-K,462,Following is a reconciliation of the consolidated income tax expense applying the U.S. federal statutory rate to income before income taxes to reported consolidated income tax expense:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_463,Financial Statements and Supplementary Data,ITEM_8,10,10-K,463,"(1) Non-deductible acquired IPR&D was primarily related to the acquisitions of Morphic in 2024, and DICE, Versanis, and Emergence in 2023. See Note 3 for additional information related to acquisitions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_464,Financial Statements and Supplementary Data,ITEM_8,10,10-K,464,"(2) Includes the impact of GILTI tax, Puerto Rico Excise Tax (for 2022), and other U.S. taxation of foreign income.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_465,Financial Statements and Supplementary Data,ITEM_8,10,10-K,465,(3) Includes excess tax benefits from stock-based compensation and non-deductible stock-based compensation.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_466,Financial Statements and Supplementary Data,ITEM_8,10,10-K,466,A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_467,Financial Statements and Supplementary Data,ITEM_8,10,10-K,467,"The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $2.62 billion at December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_468,Financial Statements and Supplementary Data,ITEM_8,10,10-K,468,"We file U.S. federal, foreign, and various state and local income tax returns.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_469,Financial Statements and Supplementary Data,ITEM_8,10,10-K,469,We are no longer subject to U.S. federal income tax examination for years before 2016.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_470,Financial Statements and Supplementary Data,ITEM_8,10,10-K,470,"In most major foreign and state jurisdictions, we are no longer subject to income tax examination for years before 2014.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_471,Financial Statements and Supplementary Data,ITEM_8,10,10-K,471,The U.S. examination of tax years 2019-2021 began in 2023 and remains ongoing.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_472,Financial Statements and Supplementary Data,ITEM_8,10,10-K,472,"For tax years 2016-2018, we are pursuing competent authority assistance through the Mutual Agreement Procedure (MAP) process for the pricing of certain intercompany transactions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_473,Financial Statements and Supplementary Data,ITEM_8,10,10-K,473,The resolution of both audit periods will likely extend beyond the next 12 months.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_474,Financial Statements and Supplementary Data,ITEM_8,10,10-K,474,"Interest and penalties related to unrecognized tax benefits are recognized in income tax expense and were not material for the years ended December 31, 2024, 2023, and 2022.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_475,Financial Statements and Supplementary Data,ITEM_8,10,10-K,475,"Our accrued interest and penalties related to unrecognized tax benefits were $594.2 million and $414.9 million at December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_476,Financial Statements and Supplementary Data,ITEM_8,10,10-K,476,"Note 15: Retirement Benefits We use a measurement date of December 31 to determine the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_477,Financial Statements and Supplementary Data,ITEM_8,10,10-K,477,"The unrecognized net actuarial (gain) loss and unrecognized prior service (benefit) cost have not yet been recognized in net periodic pension costs and were included in accumulated other comprehensive loss at December 31, 2024 and 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_478,Financial Statements and Supplementary Data,ITEM_8,10,10-K,478,Unrecognized net actuarial (gain) loss for the U.S. and Puerto Rico defined benefit pension and retiree health benefit plans are amortized over the average remaining service period of active employees in the plan.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_479,Financial Statements and Supplementary Data,ITEM_8,10,10-K,479,The amortization of actuarial (gains) losses for U.S. and Puerto Rico defined benefit pension plans are determined by using a 10% corridor of the greater of the market related value of assets or the projected benefit obligations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_480,Financial Statements and Supplementary Data,ITEM_8,10,10-K,480,The $930.1 million decrease in benefit obligation in 2024 was primarily driven by increases in the discount rates. The $1.09 billion increase in benefit obligation in 2023 was primarily driven by decreases in the discount rates.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_481,Financial Statements and Supplementary Data,ITEM_8,10,10-K,481,The following represents our weighted-average assumptions: We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_482,Financial Statements and Supplementary Data,ITEM_8,10,10-K,482,"In evaluating the expected return on plan assets, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_483,Financial Statements and Supplementary Data,ITEM_8,10,10-K,483,"In U.S. and Puerto Rico, the expected return on plan assets uses a market-related value of assets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_484,Financial Statements and Supplementary Data,ITEM_8,10,10-K,484,"For U.S. dollar denominated investment grade debt securities and derivatives, the market-related value of assets is the actual fair value.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_485,Financial Statements and Supplementary Data,ITEM_8,10,10-K,485,"For all other asset categories, the market-related value of assets uses a method that recognizes investment gains and losses arising from the difference between expected and actual returns on plan assets over a five-year period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_486,Financial Statements and Supplementary Data,ITEM_8,10,10-K,486,"We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_487,Financial Statements and Supplementary Data,ITEM_8,10,10-K,487,"Given the design of our retiree health benefit plans, healthcare-cost trend rates do not have a material impact on our financial condition or results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_488,Financial Statements and Supplementary Data,ITEM_8,10,10-K,488,"Expected benefit payments, which reflect expected future service, are as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_489,Financial Statements and Supplementary Data,ITEM_8,10,10-K,489,Amounts relating to defined benefit pension plans with projected benefit obligations in excess of plan assets were as follows at December 31:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_490,Financial Statements and Supplementary Data,ITEM_8,10,10-K,490,Amounts relating to defined benefit pension plans and retiree health benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_491,Financial Statements and Supplementary Data,ITEM_8,10,10-K,491,"The total accumulated benefit obligation for our defined benefit pension plans was $12.18 billion and $12.74 billion at December 31, 2024 and 2023, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_492,Financial Statements and Supplementary Data,ITEM_8,10,10-K,492,Net periodic (benefit) cost included the following components: The following represents the amounts recognized in other comprehensive income (loss) for the years ended December 31:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_493,Financial Statements and Supplementary Data,ITEM_8,10,10-K,493,We have defined contribution savings plans that cover our eligible employees worldwide.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_494,Financial Statements and Supplementary Data,ITEM_8,10,10-K,494,The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_495,Financial Statements and Supplementary Data,ITEM_8,10,10-K,495,Our contributions to the plans are based on employee contributions and the level of our match.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_496,Financial Statements and Supplementary Data,ITEM_8,10,10-K,496,"Expenses under the plans totaled $249.7 million, $222.6 million, and $170.6 million for the years ended December 31, 2024, 2023, and 2022, respectively.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_497,Financial Statements and Supplementary Data,ITEM_8,10,10-K,497,Benefit Plan Investments Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_498,Financial Statements and Supplementary Data,ITEM_8,10,10-K,498,U.S. and Puerto Rico plans represent approximately 85 percent of our global investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_499,Financial Statements and Supplementary Data,ITEM_8,10,10-K,499,"Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_500,Financial Statements and Supplementary Data,ITEM_8,10,10-K,500,"At the investment-policy level, there are no specifically prohibited investments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_501,Financial Statements and Supplementary Data,ITEM_8,10,10-K,501,"However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_502,Financial Statements and Supplementary Data,ITEM_8,10,10-K,502,"We manage our portfolio to minimize concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_503,Financial Statements and Supplementary Data,ITEM_8,10,10-K,503,Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_504,Financial Statements and Supplementary Data,ITEM_8,10,10-K,504,"Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_505,Financial Statements and Supplementary Data,ITEM_8,10,10-K,505,The plans utilize both exchange-traded and over-the-counter instruments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_506,Financial Statements and Supplementary Data,ITEM_8,10,10-K,506,"The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_507,Financial Statements and Supplementary Data,ITEM_8,10,10-K,507,We expect all of our counterparties to meet their obligations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_508,Financial Statements and Supplementary Data,ITEM_8,10,10-K,508,"The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_509,Financial Statements and Supplementary Data,ITEM_8,10,10-K,509,The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 80 percent growth investments and 20 percent fixed-income investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_510,Financial Statements and Supplementary Data,ITEM_8,10,10-K,510,"The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_511,Financial Statements and Supplementary Data,ITEM_8,10,10-K,511,"These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_512,Financial Statements and Supplementary Data,ITEM_8,10,10-K,512,Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_513,Financial Statements and Supplementary Data,ITEM_8,10,10-K,513,"Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, bank loans, mortgage-backed securities, commercial mortgage-backed obligations, and any related repurchase agreements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_514,Financial Statements and Supplementary Data,ITEM_8,10,10-K,514,Hedge funds are privately owned institutional investment funds that generally have moderate liquidity.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_515,Financial Statements and Supplementary Data,ITEM_8,10,10-K,515,"Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_516,Financial Statements and Supplementary Data,ITEM_8,10,10-K,516,"Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.)",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_517,Financial Statements and Supplementary Data,ITEM_8,10,10-K,517,using a very broad range of trading activities to manage portfolio risks.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_518,Financial Statements and Supplementary Data,ITEM_8,10,10-K,518,Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_519,Financial Statements and Supplementary Data,ITEM_8,10,10-K,519,"Common groupings of hedge fund strategies include relative value, tactical, and event driven.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_520,Financial Statements and Supplementary Data,ITEM_8,10,10-K,520,"Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_521,Financial Statements and Supplementary Data,ITEM_8,10,10-K,521,Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_522,Financial Statements and Supplementary Data,ITEM_8,10,10-K,522,"Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_523,Financial Statements and Supplementary Data,ITEM_8,10,10-K,523,Our hedge fund investments are made through limited partnership interests in fund-of-funds structures and directly into hedge funds.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_524,Financial Statements and Supplementary Data,ITEM_8,10,10-K,524,"Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_525,Financial Statements and Supplementary Data,ITEM_8,10,10-K,525,Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_526,Financial Statements and Supplementary Data,ITEM_8,10,10-K,526,"Underlying investments include venture capital (early stage investing), buyout, special situations, private debt, and private real estate investments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_527,Financial Statements and Supplementary Data,ITEM_8,10,10-K,527,Private equity management firms typically acquire and then reorganize private companies to create increased long term value.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_528,Financial Statements and Supplementary Data,ITEM_8,10,10-K,528,"Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_529,Financial Statements and Supplementary Data,ITEM_8,10,10-K,529,Our private equity-like investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_530,Financial Statements and Supplementary Data,ITEM_8,10,10-K,530,"Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_531,Financial Statements and Supplementary Data,ITEM_8,10,10-K,531,Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_532,Financial Statements and Supplementary Data,ITEM_8,10,10-K,532,"Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_533,Financial Statements and Supplementary Data,ITEM_8,10,10-K,533,The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_534,Financial Statements and Supplementary Data,ITEM_8,10,10-K,534,Real estate is composed of public holdings.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_535,Financial Statements and Supplementary Data,ITEM_8,10,10-K,535,Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_536,Financial Statements and Supplementary Data,ITEM_8,10,10-K,536,Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as such.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_537,Financial Statements and Supplementary Data,ITEM_8,10,10-K,537,"These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_538,Financial Statements and Supplementary Data,ITEM_8,10,10-K,538,Other assets include cash and cash equivalents and mark-to-market value of derivatives.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_539,Financial Statements and Supplementary Data,ITEM_8,10,10-K,539,The cash value of the trust-owned insurance contract is primarily invested in investment-grade publicly traded equity and fixed-income securities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_540,Financial Statements and Supplementary Data,ITEM_8,10,10-K,540,"Other than hedge funds, private equity-like investments, and a portion of the real estate holdings, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_541,Financial Statements and Supplementary Data,ITEM_8,10,10-K,541,"The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2024 by asset category were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_542,Financial Statements and Supplementary Data,ITEM_8,10,10-K,542,(1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_543,Financial Statements and Supplementary Data,ITEM_8,10,10-K,543,"No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2024. The activity in the Level 3 investments during the year ended December 31, 2024 was not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_544,Financial Statements and Supplementary Data,ITEM_8,10,10-K,544,"The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2023 by asset category were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_545,Financial Statements and Supplementary Data,ITEM_8,10,10-K,545,(1) Certain investments that are measured at fair value using the NAV per share (or its equivalent) as a practical expedient have not been classified in the fair value hierarchy.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_546,Financial Statements and Supplementary Data,ITEM_8,10,10-K,546,"No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2023. The activity in the Level 3 investments during the year ended December 31, 2023 was not material.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_547,Financial Statements and Supplementary Data,ITEM_8,10,10-K,547,"In 2025, we expect to contribute approximately $30 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. We do not currently expect to make material discretionary contributions in 2025.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_548,Financial Statements and Supplementary Data,ITEM_8,10,10-K,548,"Note 16: Contingencies We are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_549,Financial Statements and Supplementary Data,ITEM_8,10,10-K,549,"These claims or proceedings can involve various types of parties, including governments, regulatory agencies, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_550,Financial Statements and Supplementary Data,ITEM_8,10,10-K,550,"These matters may involve patent infringement, antitrust, securities, pricing, access, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability, insurance coverage, and regulatory compliance, among others.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_551,Financial Statements and Supplementary Data,ITEM_8,10,10-K,551,"The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_552,Financial Statements and Supplementary Data,ITEM_8,10,10-K,552,Legal proceedings that are significant or that we believe could become significant or material are described below.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_553,Financial Statements and Supplementary Data,ITEM_8,10,10-K,553,We are defending against the legal proceedings in which we are named as defendants vigorously.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_554,Financial Statements and Supplementary Data,ITEM_8,10,10-K,554,"It is not possible to determine the final outcome of these matters, and, unless otherwise noted, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_555,Financial Statements and Supplementary Data,ITEM_8,10,10-K,555,"Litigation accruals and environmental liabilities and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_556,Financial Statements and Supplementary Data,ITEM_8,10,10-K,556,"With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_557,Financial Statements and Supplementary Data,ITEM_8,10,10-K,557,We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_558,Financial Statements and Supplementary Data,ITEM_8,10,10-K,558,We estimate these expenses based primarily on historical claims experience and data regarding product usage.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_559,Financial Statements and Supplementary Data,ITEM_8,10,10-K,559,Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_560,Financial Statements and Supplementary Data,ITEM_8,10,10-K,560,"Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of additional product liability and related claims in the future.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_561,Financial Statements and Supplementary Data,ITEM_8,10,10-K,561,"Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_562,Financial Statements and Supplementary Data,ITEM_8,10,10-K,562,"Patent Matters Emgality Patent Litigation In September 2018, Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (collectively, Teva) filed a complaint in the U.S. District Court for the District of Massachusetts alleging that Lilly's launch and continued sales of Emgality infringed various claims in three Teva patents.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_563,Financial Statements and Supplementary Data,ITEM_8,10,10-K,563,"In November 2022, following a trial, a jury returned a verdict in favor of Teva.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_564,Financial Statements and Supplementary Data,ITEM_8,10,10-K,564,"In September 2023, the trial court overruled the jury verdict, found all asserted claims invalid, and entered judgment in Lilly's favor.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_565,Financial Statements and Supplementary Data,ITEM_8,10,10-K,565,"In October 2023, Teva appealed to the U.S. Court of Appeals for the Federal Circuit.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_566,Financial Statements and Supplementary Data,ITEM_8,10,10-K,566,The appeal is pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_567,Financial Statements and Supplementary Data,ITEM_8,10,10-K,567,"Environmental Matters Superfund Matters Under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as ""Superfund,"" we have been designated as one of several potentially responsible parties with respect to the cleanup of fewer than 10 sites.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_568,Financial Statements and Supplementary Data,ITEM_8,10,10-K,568,"Under Superfund, each responsible party may be jointly and severally liable for the entire amount of the cleanup.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_569,Financial Statements and Supplementary Data,ITEM_8,10,10-K,569,"Brazil Litigation - Cosmopolis Facility Labor Attorney Litigation In March 2008, the state Labor Public Attorney (LPA) filed a public civil action against Eli Lilly do Brasil Limitada (Lilly Brasil) in the Labor Court of Paulinia, State of Sao Paulo, alleging harm to employees and former employees from alleged exposure to soil and groundwater contaminants at a former manufacturing facility in Cosmopolis, operated by the company between 1977 and 2003.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_570,Financial Statements and Supplementary Data,ITEM_8,10,10-K,570,"In May 2014, the trial court ruled against Lilly Brasil, ordering it to undertake several remedial and compensatory actions, including health coverage for a class of individuals and certain of their children.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_571,Financial Statements and Supplementary Data,ITEM_8,10,10-K,571,"The trial court's ruling included a liquidated award of 300 million Brazilian reais, which, when adjusted for inflation, is approximately 1.4 billion Brazilian reais (approximately $226 million as of December 31, 2024).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_572,Financial Statements and Supplementary Data,ITEM_8,10,10-K,572,"In July 2018, the appeals court generally affirmed the trial court's ruling.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_573,Financial Statements and Supplementary Data,ITEM_8,10,10-K,573,Lilly Brasil has appealed to the superior labor court (TST).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_574,Financial Statements and Supplementary Data,ITEM_8,10,10-K,574,"In July 2019, at the LPA's request, the trial court ordered a freeze of Lilly Brasil's immovable property in the amount of 500 million Brazilian reais, which was reduced on Lilly Brasil's appeal and, when adjusted for inflation, is approximately 145 million Brazilian reais (approximately $23 million as of December 31, 2024).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_575,Financial Statements and Supplementary Data,ITEM_8,10,10-K,575,Both parties have appealed this order to the TST.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_576,Financial Statements and Supplementary Data,ITEM_8,10,10-K,576,"The trial court is currently assessing the status of Lilly Brasil's compliance with the obligations as to the land, and an inspection in the industrial plant occurred in October 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_577,Financial Statements and Supplementary Data,ITEM_8,10,10-K,577,Former Employee Litigation Various former employees have filed related claims against Lilly Brasil in the trial court. These lawsuits are at various stages in the litigation process.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_578,Financial Statements and Supplementary Data,ITEM_8,10,10-K,578,"Pricing Matters 340B Litigation and Investigations In January 2021, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, the Health Resources and Services Administration (HRSA), and the Administrator of HRSA.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_579,Financial Statements and Supplementary Data,ITEM_8,10,10-K,579,"The lawsuit challenges HHS's December 2020 advisory opinion that the 340B program requires drug manufacturers to deliver discounts to all contract pharmacies, as well as HHS's December 2020 administrative dispute resolution (ADR) regulations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_580,Financial Statements and Supplementary Data,ITEM_8,10,10-K,580,"It seeks a declaratory judgment that the defendants violated the Administrative Procedure Act (APA) and the U.S. Constitution, a preliminary injunction enjoining implementation of the ADR process and application of the advisory opinion, and other related relief.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_581,Financial Statements and Supplementary Data,ITEM_8,10,10-K,581,"In March 2021, the court preliminarily enjoined the government's use of the ADR process as to us.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_582,Financial Statements and Supplementary Data,ITEM_8,10,10-K,582,"In May 2021, we amended the complaint to add claims related to a May 2021 letter from HRSA asserting that Lilly's contract pharmacy policy violated the 340B statute.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_583,Financial Statements and Supplementary Data,ITEM_8,10,10-K,583,"In October 2021, the court granted in part and denied in part the parties' cross-motions for summary judgment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_584,Financial Statements and Supplementary Data,ITEM_8,10,10-K,584,Both parties appealed to the U.S. Court of Appeals for the Seventh Circuit.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_585,Financial Statements and Supplementary Data,ITEM_8,10,10-K,585,The appeal remains pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_586,Financial Statements and Supplementary Data,ITEM_8,10,10-K,586,We received a civil investigative subpoena in February 2021 from the Office of the Attorney General for the State of Vermont relating to the sale of pharmaceutical products to Vermont covered entities under the 340B program.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_587,Financial Statements and Supplementary Data,ITEM_8,10,10-K,587,We are cooperating with the subpoena.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_588,Financial Statements and Supplementary Data,ITEM_8,10,10-K,588,"We have been named in various ADR petitions, filed in 2021, 2023, and 2024, seeking declaratory, injunctive, and/or monetary relief related to the 340B program.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_589,Financial Statements and Supplementary Data,ITEM_8,10,10-K,589,"In light of the preliminary injunction order described above, these petitions are being held in abeyance as to us.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_590,Financial Statements and Supplementary Data,ITEM_8,10,10-K,590,"In July 2021, Mosaic Health, Inc. filed a putative class action lawsuit in the U.S. District Court for the Western District of New York against us, Sanofi-Aventis U.S., LLC (Sanofi), Novo Nordisk Inc. (Novo Nordisk), and AstraZeneca Pharmaceuticals LP (AstraZeneca), alleging antitrust and unjust enrichment claims related to the defendants' 340B programs.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_591,Financial Statements and Supplementary Data,ITEM_8,10,10-K,591,"In October 2021, an amended complaint added Central Virginia Health Services, Inc. as a plaintiff.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_592,Financial Statements and Supplementary Data,ITEM_8,10,10-K,592,"In September 2022, the court dismissed the amended complaint for failure to state a claim but allowed the plaintiffs to move for leave to file a second amended complaint.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_593,Financial Statements and Supplementary Data,ITEM_8,10,10-K,593,"In January 2024, the court denied the plaintiffs' motion for leave to amend and dismissed the case.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_594,Financial Statements and Supplementary Data,ITEM_8,10,10-K,594,"In February 2024, the plaintiffs appealed to the U.S. Court of Appeals for the Second Circuit.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_595,Financial Statements and Supplementary Data,ITEM_8,10,10-K,595,The appeal remains pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_596,Financial Statements and Supplementary Data,ITEM_8,10,10-K,596,We have multiple other challenges against HHS and related parties related to interpretations and actions under the 340B program.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_597,Financial Statements and Supplementary Data,ITEM_8,10,10-K,597,"Insulin Pricing Litigation Since 2017, various plaintiffs, including consumers, states and state attorneys general, counties, municipalities, Native American tribes, school districts, wholesalers, third-party payers, and others, have filed lawsuits, including putative class actions, against us, other manufacturers, pharmacy benefit managers, and others, relating to the pricing of insulin medications, and in some cases other diabetes medications, and rebates paid by manufacturers to pharmacy benefit managers.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_598,Financial Statements and Supplementary Data,ITEM_8,10,10-K,598,"The complaints in the various lawsuits assert a variety of claims, including among others consumer protection, unfair or deceptive trade practices, fraud, false advertising, unjust enrichment, civil conspiracy, racketeering, antitrust, and unfair competition claims.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_599,Financial Statements and Supplementary Data,ITEM_8,10,10-K,599,Most cases have been coordinated or consolidated for pretrial proceedings in a multidistrict litigation (MDL) pending in the U.S. District Court for the District of New Jersey.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_600,Financial Statements and Supplementary Data,ITEM_8,10,10-K,600,The lawsuits are at various stages in the litigation process.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_601,Financial Statements and Supplementary Data,ITEM_8,10,10-K,601,"In the first-filed case, a putative consumer class action, we and the plaintiffs reached a proposed settlement in May 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_602,Financial Statements and Supplementary Data,ITEM_8,10,10-K,602,"In January 2024, the court denied the plaintiffs' motion for class certification.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_603,Financial Statements and Supplementary Data,ITEM_8,10,10-K,603,We and the plaintiffs subsequently terminated our proposed settlement and stipulated that the court's ruling denying class certification applied to Lilly.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_604,Financial Statements and Supplementary Data,ITEM_8,10,10-K,604,"The MDL court has issued various case management orders, including but not limited to orders establishing separate tracks for state attorney general claims (State AG Track), putative class actions (Class Action Track), and non-class suits by self-funded payers (Self-Funded Payer Track).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_605,Financial Statements and Supplementary Data,ITEM_8,10,10-K,605,"In January 2022, the Michigan attorney general filed a petition in Michigan state court seeking authorization to investigate Lilly for potential violations of the Michigan Consumer Protection Act (MCPA), along with a complaint seeking a declaratory judgment that the state has authority to investigate Lilly's sale of insulin under the MCPA.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_606,Financial Statements and Supplementary Data,ITEM_8,10,10-K,606,The court authorized the proposed investigation and the issuance of civil investigative subpoenas.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_607,Financial Statements and Supplementary Data,ITEM_8,10,10-K,607,"In April 2022, however, the parties entered into a stipulation providing that the state will not issue any civil investigative subpoena to us under the MCPA until the declaratory judgment action is resolved, and in July 2022, the court dismissed the case in its entirety.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_608,Financial Statements and Supplementary Data,ITEM_8,10,10-K,608,"In June 2023, the Michigan Court of Appeals affirmed the judgment in our favor.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_609,Financial Statements and Supplementary Data,ITEM_8,10,10-K,609,"In August 2023, the state filed an application for leave to appeal to the Michigan Supreme Court, and oral argument was held in October 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_610,Financial Statements and Supplementary Data,ITEM_8,10,10-K,610,The state's request for leave to appeal remains pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_611,Financial Statements and Supplementary Data,ITEM_8,10,10-K,611,Lilly has entered into settlement agreements with two states to resolve allegations relating to insulin pricing.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_612,Financial Statements and Supplementary Data,ITEM_8,10,10-K,612,"In particular, in February 2024, after discovery, Lilly entered into a non-monetary settlement with the Minnesota attorney general's office that resolved a lawsuit filed by Minnesota in 2018; and Lilly entered into a similar non-monetary settlement with the New York attorney general's office in May 2023.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_613,Financial Statements and Supplementary Data,ITEM_8,10,10-K,613,These agreements involved no monetary payments and no admission of wrongdoing or liability.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_614,Financial Statements and Supplementary Data,ITEM_8,10,10-K,614,"Insulin and Other Pricing Investigations We have been subject to various investigations and received subpoenas, civil investigative demands, information requests, interrogatories, and other inquiries from various governmental entities related to pricing issues, including the pricing and sale of insulin medications, and in some instances certain other diabetes medications, and/or calculations of average manufacturer price and best price.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_615,Financial Statements and Supplementary Data,ITEM_8,10,10-K,615,"These include subpoenas from the Vermont attorney general office, civil investigative demands from the U.S. Department of Justice, the U.S. Federal Trade Commission, and the Colorado, Indiana, Louisiana, Oregon, Texas, and Washington attorney general offices, as well as information requests from the California, Florida, Hawaii, Mississippi, New Mexico, Nevada, and Washington D.C. attorney general offices.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_616,Financial Statements and Supplementary Data,ITEM_8,10,10-K,616,"To the extent the foregoing governmental entities have not filed lawsuits, we are cooperating with the various investigations, subpoenas, and inquiries.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_617,Financial Statements and Supplementary Data,ITEM_8,10,10-K,617,"Average Manufacturer Price Litigation In November 2014, a relator filed a qui tam action in the U.S. District Court for the Northern District of Illinois against us and Takeda Pharmaceuticals America, Inc.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_618,Financial Statements and Supplementary Data,ITEM_8,10,10-K,618,The relator's complaint alleges that the defendants should have treated certain credits from distributors as retroactive price increases and included such increases in calculating average manufacturer prices.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_619,Financial Statements and Supplementary Data,ITEM_8,10,10-K,619,"In August 2022, following a trial, the jury returned a verdict in favor of the relator.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_620,Financial Statements and Supplementary Data,ITEM_8,10,10-K,620,"Lilly has appealed to the U.S. Court of Appeals for the Seventh Circuit, and the appeal remains pending.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_621,Financial Statements and Supplementary Data,ITEM_8,10,10-K,621,"Other Matters Actos Litigation We, along with Takeda Chemical Industries, Ltd. and Takeda affiliates (collectively, Takeda), are named in a third party payer class action in the U.S. District Court for the Central District of California.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_622,Financial Statements and Supplementary Data,ITEM_8,10,10-K,622,The plaintiffs allege that bladder cancer risk was concealed from them and claim that as a result they and a proposed class of third-party payers are entitled to recover money paid for Actos prescriptions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_623,Financial Statements and Supplementary Data,ITEM_8,10,10-K,623,"Our agreement with Takeda calls for Takeda to defend and indemnify us against losses and expenses with respect to U.S. litigation arising out of the manufacture, use, or sale of Actos and other related expenses in accordance with the terms of the agreement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_624,Financial Statements and Supplementary Data,ITEM_8,10,10-K,624,"In May 2023, the district court granted class certification.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_625,Financial Statements and Supplementary Data,ITEM_8,10,10-K,625,"In August 2023, the U.S. Court of Appeals for the Ninth Circuit granted our and Takeda's petition for permission to appeal the class certification order.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_626,Financial Statements and Supplementary Data,ITEM_8,10,10-K,626,That appeal remains pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_627,Financial Statements and Supplementary Data,ITEM_8,10,10-K,627,"Mounjaro and Trulicity Product Liability Litigation Since August 2023, various plaintiffs have filed lawsuits against us, Novo Nordisk A/S (Novo), and other related Novo entities, alleging injuries following purported use of incretin medicines, including Mounjaro and Trulicity.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_628,Financial Statements and Supplementary Data,ITEM_8,10,10-K,628,"The complaints assert a variety of claims and generally seek damages, medical monitoring, or other relief.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_629,Financial Statements and Supplementary Data,ITEM_8,10,10-K,629,"Most of these lawsuits have been coordinated or consolidated for pretrial proceedings in a federal MDL pending in the U.S. District Court for the Eastern District of Pennsylvania; cases outside the MDL include one case pending in Georgia state court, as well as a class action petition in Israel.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_630,Financial Statements and Supplementary Data,ITEM_8,10,10-K,630,"In November 2024, the MDL plaintiffs filed a master complaint.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_631,Financial Statements and Supplementary Data,ITEM_8,10,10-K,631,"Branchburg Manufacturing Facility In May 2021, we received a subpoena from the U.S. Department of Justice requesting the production of certain documents relating to our manufacturing site in Branchburg, New Jersey. We are cooperating with the subpoena.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_632,Financial Statements and Supplementary Data,ITEM_8,10,10-K,632,"Puerto Rico Tax Matter In May 2013, the Municipality of Carolina in Puerto Rico (Municipality) filed a lawsuit against us alleging noncompliance with respect to a contract with the Municipality and seeking a declaratory judgment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_633,Financial Statements and Supplementary Data,ITEM_8,10,10-K,633,"In June 2019, the Court of First Instance (CFI) granted summary judgment in our favor, dismissing the Municipality's complaint in its entirety.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_634,Financial Statements and Supplementary Data,ITEM_8,10,10-K,634,"In December 2020, the Puerto Rico Appellate Court (AP) reversed and remanded the case to the CFI for trial on the merits.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_635,Financial Statements and Supplementary Data,ITEM_8,10,10-K,635,"After trial began in May 2022, the Municipality filed a motion requesting the CFI to execute an alleged judgment.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_636,Financial Statements and Supplementary Data,ITEM_8,10,10-K,636,"The CFI denied the request, and the Municipality filed for revision at the AP, which we opposed, staying the case.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_637,Financial Statements and Supplementary Data,ITEM_8,10,10-K,637,The AP denied the Municipality's motion for revision.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_638,Financial Statements and Supplementary Data,ITEM_8,10,10-K,638,Trial resumed in October 2024.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_639,Financial Statements and Supplementary Data,ITEM_8,10,10-K,639,"Health Choice Alliance In October 2019, a relator filed a qui tam lawsuit against us in Texas state court asserting claims under the Texas Medicaid Fraud Prevention Act based on allegations about certain patient support programs related to our products Humalog, Humulin, and Forteo.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_640,Financial Statements and Supplementary Data,ITEM_8,10,10-K,640,"The lawsuit seeks to recover the value of payments by the Texas Medicaid Program for these products, as well as civil penalties and other relief.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_641,Financial Statements and Supplementary Data,ITEM_8,10,10-K,641,The action has been stayed since 2020.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_642,Financial Statements and Supplementary Data,ITEM_8,10,10-K,642,"Research Corporation Technologies, Inc.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_643,Financial Statements and Supplementary Data,ITEM_8,10,10-K,643,"In April 2016, Research Corporation Technologies, Inc. (RCT) filed a lawsuit against us in the U.S. District Court for the District of Arizona asserting damages claims for breach of contract, unjust enrichment, and conversion related to processes used to manufacture certain products, including Humalog and Humulin.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_644,Financial Statements and Supplementary Data,ITEM_8,10,10-K,644,"In October 2021, the court issued a summary judgment decision in favor of RCT on certain issues, including with respect to a disputed royalty.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_645,Financial Statements and Supplementary Data,ITEM_8,10,10-K,645,"In July 2024, we reached a confidential agreement with RCT that requires different payments based on various litigation outcomes as determined on appeal.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_646,Financial Statements and Supplementary Data,ITEM_8,10,10-K,646,"The settlement agreement is not an admission of liability or fault, and is subject to conditions.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_647,Financial Statements and Supplementary Data,ITEM_8,10,10-K,647,"Pursuant to the agreement, the court entered final judgment, Lilly filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit, and Lilly made an initial payment under the agreement.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_648,Financial Statements and Supplementary Data,ITEM_8,10,10-K,648,Lilly's appeal remains pending.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_649,Financial Statements and Supplementary Data,ITEM_8,10,10-K,649,"The remaining amount payable under the agreement, if any, should not have a material impact on our financial position, liquidity or results of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_650,Financial Statements and Supplementary Data,ITEM_8,10,10-K,650,Note 17: Other Comprehensive Income (Loss) The following table summarizes the activity related to each component of other comprehensive income (loss):,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_651,Financial Statements and Supplementary Data,ITEM_8,10,10-K,651,"The tax effects on the net activity related to each component of other comprehensive income (loss) for the years ended December 31, were as follows:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_652,Financial Statements and Supplementary Data,ITEM_8,10,10-K,652,"Except for the tax effects of foreign currency translation gains and losses related to our foreign currency-denominated notes, cross-currency interest rate swaps, and other foreign currency exchange contracts designated as net investment hedges (see Note 7), income taxes were not provided for foreign currency translation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_653,Financial Statements and Supplementary Data,ITEM_8,10,10-K,653,"Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_654,Financial Statements and Supplementary Data,ITEM_8,10,10-K,654,"For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in the consolidated statements of operations.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_655,Financial Statements and Supplementary Data,ITEM_8,10,10-K,655,Reclassifications out of accumulated other comprehensive loss were as follows:,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_656,Financial Statements and Supplementary Data,ITEM_8,10,10-K,656,"Note 18: Other-Net, (Income) Expense Other-net, (income) expense consisted of the following: Note 19: Segment Information We operate as a single reportable segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_657,Financial Statements and Supplementary Data,ITEM_8,10,10-K,657,"A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_658,Financial Statements and Supplementary Data,ITEM_8,10,10-K,658,"Our commercial organizations market, distribute, and sell the products.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_659,Financial Statements and Supplementary Data,ITEM_8,10,10-K,659,The business is also supported by global corporate staff functions.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_660,Financial Statements and Supplementary Data,ITEM_8,10,10-K,660,"Our determination that we operate as a single segment is consistent with the nature of our operations and the financial information regularly reviewed by the chief executive officer, in his capacity as the chief operating decision maker (CODM), for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_661,Financial Statements and Supplementary Data,ITEM_8,10,10-K,661,Our purpose is to unite caring with discovery to create medicines that make life better for people around the world.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_662,Financial Statements and Supplementary Data,ITEM_8,10,10-K,662,Our long-term success is significantly dependent on our ability to research and develop innovative medicines.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_663,Financial Statements and Supplementary Data,ITEM_8,10,10-K,663,"The CODM uses consolidated net income to assess performance of our company, ensuring that we are investing in future research and development while efficiently delivering products to patients.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_664,Financial Statements and Supplementary Data,ITEM_8,10,10-K,664,"The CODM allocates research and development resources based upon several factors, including the likelihood of technical success, unmet medical needs, and the viability of commercial success.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_665,Financial Statements and Supplementary Data,ITEM_8,10,10-K,665,A significant component of the CODM's decision-making process is to ensure a balanced investment in our research and development portfolio to drive near-term success and sustain for the long-term.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_666,Financial Statements and Supplementary Data,ITEM_8,10,10-K,666,"The following table summarizes our segment revenue, significant segment expenses, and segment profit:",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_667,Financial Statements and Supplementary Data,ITEM_8,10,10-K,667,(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_668,Financial Statements and Supplementary Data,ITEM_8,10,10-K,668,"(2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_669,Financial Statements and Supplementary Data,ITEM_8,10,10-K,669,The following tables summarize additional segment information: (1) Includes expenditures for property and equipment and computer software costs.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_670,Financial Statements and Supplementary Data,ITEM_8,10,10-K,670,Management's Reports Management's Report for Financial Statements-Eli Lilly and Company and Subsidiaries,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_671,Financial Statements and Supplementary Data,ITEM_8,10,10-K,671,"Management of Eli Lilly and Company and subsidiaries is responsible for the accuracy, integrity, and fair presentation of the financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_672,Financial Statements and Supplementary Data,ITEM_8,10,10-K,672,The statements have been prepared in accordance with generally accepted accounting principles in the United States and include amounts based on judgments and estimates by management.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_673,Financial Statements and Supplementary Data,ITEM_8,10,10-K,673,"In management's opinion, the consolidated financial statements present fairly our financial position, results of operations, and cash flows.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_674,Financial Statements and Supplementary Data,ITEM_8,10,10-K,674,"In addition to the system of internal accounting controls, we maintain a code of conduct (known as ""The Red Book"") that applies to all employees worldwide, requiring proper overall business conduct, avoidance of conflicts of interest, compliance with laws, and confidentiality of proprietary information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_675,Financial Statements and Supplementary Data,ITEM_8,10,10-K,675,All employees must take training annually on The Red Book and are required to report suspected violations.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_676,Financial Statements and Supplementary Data,ITEM_8,10,10-K,676,A hotline number is available on our lilly.com website and on the internal LillyNow website to enable reporting of suspected violations anonymously.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_677,Financial Statements and Supplementary Data,ITEM_8,10,10-K,677,Employees who report suspected violations are protected from discrimination or retaliation by the company.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_678,Financial Statements and Supplementary Data,ITEM_8,10,10-K,678,"In addition to The Red Book, the chief executive officer and all financial management must sign a financial code of ethics, which further reinforces their ethical and fiduciary responsibilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_679,Financial Statements and Supplementary Data,ITEM_8,10,10-K,679,"The consolidated financial statements have been audited by Ernst & Young LLP, an independent registered public accounting firm (PCAOB ID: 42).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_680,Financial Statements and Supplementary Data,ITEM_8,10,10-K,680,Their responsibility is to examine our consolidated financial statements in accordance with generally accepted auditing standards of the Public Company Accounting Oversight Board (United States).,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_681,Financial Statements and Supplementary Data,ITEM_8,10,10-K,681,Ernst & Young's opinion with respect to the fairness of the presentation of the statements is included in Item 8 of our Annual Report on Form 10-K. Ernst & Young reports directly to the audit committee of the board of directors.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_682,Financial Statements and Supplementary Data,ITEM_8,10,10-K,682,"Our audit committee includes four nonemployee members of the board of directors, all of whom are independent from our company.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_683,Financial Statements and Supplementary Data,ITEM_8,10,10-K,683,"The committee charter, which is available on our website, outlines the members' roles and responsibilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_684,Financial Statements and Supplementary Data,ITEM_8,10,10-K,684,"It is the audit committee's responsibility to appoint an independent registered public accounting firm subject to shareholder ratification, pre-approve both audit and non-audit services performed by the independent registered public accounting firm, and review the reports submitted by the firm.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_685,Financial Statements and Supplementary Data,ITEM_8,10,10-K,685,"The audit committee meets several times during the year with management, the internal auditors, and the independent public accounting firm to discuss audit activities, internal controls, and financial reporting matters, including reviews of our externally published financial results.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_686,Financial Statements and Supplementary Data,ITEM_8,10,10-K,686,The internal auditors and the independent registered public accounting firm have full and free access to the committee.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_687,Financial Statements and Supplementary Data,ITEM_8,10,10-K,687,We are dedicated to ensuring that we maintain the high standards of financial accounting and reporting that we have established.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_688,Financial Statements and Supplementary Data,ITEM_8,10,10-K,688,"We are committed to providing financial information that is transparent, timely, complete, relevant, and accurate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_689,Financial Statements and Supplementary Data,ITEM_8,10,10-K,689,Our culture demands integrity and an unyielding commitment to strong internal practices and policies.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_690,Financial Statements and Supplementary Data,ITEM_8,10,10-K,690,"Finally, we have the highest confidence in our financial reporting, our underlying system of internal controls, and our people, who are objective in their responsibilities, operate under a code of conduct and are subject to the highest level of ethical standards.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_691,Financial Statements and Supplementary Data,ITEM_8,10,10-K,691,Management's Report on Internal Control Over Financial Reporting-Eli Lilly and Company and Subsidiaries,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_692,Financial Statements and Supplementary Data,ITEM_8,10,10-K,692,Management of Eli Lilly and Company and subsidiaries is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_693,Financial Statements and Supplementary Data,ITEM_8,10,10-K,693,"We have global financial policies that govern critical areas, including internal controls, financial accounting and reporting, fiduciary accountability, and safeguarding of corporate assets.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_694,Financial Statements and Supplementary Data,ITEM_8,10,10-K,694,"Our internal accounting control systems are designed to provide reasonable assurance that assets are safeguarded, that transactions are executed in accordance with management's authorization and are properly recorded, and that accounting records are adequate for preparation of financial statements and other financial information.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_695,Financial Statements and Supplementary Data,ITEM_8,10,10-K,695,"A staff of internal auditors regularly monitors, on a worldwide basis, the adequacy and effectiveness of internal accounting controls.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_696,Financial Statements and Supplementary Data,ITEM_8,10,10-K,696,The general auditor reports directly to the audit committee of the board of directors.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_697,Financial Statements and Supplementary Data,ITEM_8,10,10-K,697,"We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in ""Internal Control-Integrated Framework"" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_698,Financial Statements and Supplementary Data,ITEM_8,10,10-K,698,"Based on our evaluation under this framework, we concluded that our internal control over financial reporting was effective as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_699,Financial Statements and Supplementary Data,ITEM_8,10,10-K,699,"However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_700,Financial Statements and Supplementary Data,ITEM_8,10,10-K,700,"Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_701,Financial Statements and Supplementary Data,ITEM_8,10,10-K,701,"The effectiveness of internal control over financial reporting as of December 31, 2024 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report, which appears herein.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_702,Financial Statements and Supplementary Data,ITEM_8,10,10-K,702,Their responsibility is to evaluate whether internal control over financial reporting was designed and operating effectively.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_703,Financial Statements and Supplementary Data,ITEM_8,10,10-K,703,"David Ricks Lucas Montarce Chair, President, and Chief Executive Officer Executive Vice President and Chief Financial Officer",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_704,Financial Statements and Supplementary Data,ITEM_8,10,10-K,704,"February 19, 2025 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Eli Lilly and Company",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_705,Financial Statements and Supplementary Data,ITEM_8,10,10-K,705,"Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Eli Lilly and Company and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the ""consolidated financial statements"").",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_706,Financial Statements and Supplementary Data,ITEM_8,10,10-K,706,"In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_707,Financial Statements and Supplementary Data,ITEM_8,10,10-K,707,"We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 19, 2025, expressed an unqualified opinion thereon.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_708,Financial Statements and Supplementary Data,ITEM_8,10,10-K,708,Basis for Opinion These financial statements are the responsibility of the Company's management.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_709,Financial Statements and Supplementary Data,ITEM_8,10,10-K,709,Our responsibility is to express an opinion on the Company's financial statements based on our audits.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_710,Financial Statements and Supplementary Data,ITEM_8,10,10-K,710,We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_711,Financial Statements and Supplementary Data,ITEM_8,10,10-K,711,We conducted our audits in accordance with the standards of the PCAOB.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_712,Financial Statements and Supplementary Data,ITEM_8,10,10-K,712,"Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_713,Financial Statements and Supplementary Data,ITEM_8,10,10-K,713,"Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_714,Financial Statements and Supplementary Data,ITEM_8,10,10-K,714,"Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_715,Financial Statements and Supplementary Data,ITEM_8,10,10-K,715,"Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_716,Financial Statements and Supplementary Data,ITEM_8,10,10-K,716,We believe that our audits provide a reasonable basis for our opinion.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_717,Financial Statements and Supplementary Data,ITEM_8,10,10-K,717,"Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_718,Financial Statements and Supplementary Data,ITEM_8,10,10-K,718,"The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_719,Financial Statements and Supplementary Data,ITEM_8,10,10-K,719,"Medicaid, Managed Care, and Medicare sales rebate accruals Description of the Matter As described in Note 2 to the consolidated financial statements under the caption ""Net",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_720,Financial Statements and Supplementary Data,ITEM_8,10,10-K,720,"Product Revenue,"" the Company establishes provisions for sales rebate and discounts in the same period as the related sales occur. At December 31, 2024, the Company had",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_721,Financial Statements and Supplementary Data,ITEM_8,10,10-K,721,"$11,539.3 million in sales rebate and discount accruals. A large portion of these accruals",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_722,Financial Statements and Supplementary Data,ITEM_8,10,10-K,722,"are rebates associated with sales in the United States for which payment for purchase of the product is covered by Medicaid, Managed Care, and Medicare.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_723,Financial Statements and Supplementary Data,ITEM_8,10,10-K,723,"Auditing the Medicaid, Managed Care, and Medicare sales rebate and discount liabilities is challenging because of the subjectivity of certain assumptions required to estimate the rebate liabilities.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_724,Financial Statements and Supplementary Data,ITEM_8,10,10-K,724,"In calculating the appropriate accrual amount, the Company considers historical Medicaid, Managed Care, and Medicare rebate payments by product as a percentage of their historical sales as well as any significant changes in sales trends, the lag in payment timing, changes in rebate contracts, an evaluation of the current Medicaid and Medicare laws and interpretations, the percentage of products that are sold via Medicaid, Managed Care, and Medicare, and product pricing.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_725,Financial Statements and Supplementary Data,ITEM_8,10,10-K,725,"Given variability in prescription drug costs and variability in prescription data, historical rebate information may not be predictive for management to estimate the rebate accrual and thus, management supplements its historical data analysis with qualitative adjustments based upon current expectations, particularly for select products which contribute the largest portion of the Company's revenue.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_726,Financial Statements and Supplementary Data,ITEM_8,10,10-K,726,How We Addressed the Matter in Our Audit We tested the Company's controls addressing the identified risks of material misstatement related to the valuation of the sales rebate and discount liabilities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_727,Financial Statements and Supplementary Data,ITEM_8,10,10-K,727,"This included testing controls over management's review of the significant assumptions used to calculate the Medicaid, Managed Care, and Medicare rebate liabilities, including the significant assumptions discussed above.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_728,Financial Statements and Supplementary Data,ITEM_8,10,10-K,728,This testing also included management's control to compare actual activity to estimated activity and controls to ensure the data used to evaluate the significant assumptions was complete and accurate.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_729,Financial Statements and Supplementary Data,ITEM_8,10,10-K,729,"Our audit procedures included, among others, evaluating for reasonableness the significant assumptions in light of economic trends, product profiles, and other regulatory factors.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_730,Financial Statements and Supplementary Data,ITEM_8,10,10-K,730,"Our testing involved assessing the historical accuracy of management's estimates by comparing actual activity to previous estimates and performing analytical procedures, based on internal and external data sources, to evaluate the completeness of the reserves.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_731,Financial Statements and Supplementary Data,ITEM_8,10,10-K,731,"Additionally, our procedures included reviewing a sample of contracts, testing a sample of rebate payments and testing the underlying data used in management's evaluation.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_732,Financial Statements and Supplementary Data,ITEM_8,10,10-K,732,"For Medicaid, we involved our professionals with an understanding of the statutory reimbursement requirements to assess the consistency of the Company's calculation methodologies with the applicable government regulations and policy.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_733,Financial Statements and Supplementary Data,ITEM_8,10,10-K,733,/s/ Ernst & Young LLP We have served as the Company's auditor since 1940.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_734,Financial Statements and Supplementary Data,ITEM_8,10,10-K,734,"Indianapolis, Indiana February 19, 2025 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Eli Lilly and Company",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_735,Financial Statements and Supplementary Data,ITEM_8,10,10-K,735,"Opinion on Internal Control Over Financial Reporting We have audited Eli Lilly and Company and subsidiaries' internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_736,Financial Statements and Supplementary Data,ITEM_8,10,10-K,736,"In our opinion, Eli Lilly and Company and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_737,Financial Statements and Supplementary Data,ITEM_8,10,10-K,737,"We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income (loss), shareholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 19, 2025, expressed an unqualified opinion thereon.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_738,Financial Statements and Supplementary Data,ITEM_8,10,10-K,738,Basis for Opinion The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_739,Financial Statements and Supplementary Data,ITEM_8,10,10-K,739,Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_740,Financial Statements and Supplementary Data,ITEM_8,10,10-K,740,We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_741,Financial Statements and Supplementary Data,ITEM_8,10,10-K,741,We conducted our audit in accordance with the standards of the PCAOB.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_742,Financial Statements and Supplementary Data,ITEM_8,10,10-K,742,Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_743,Financial Statements and Supplementary Data,ITEM_8,10,10-K,743,"Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_744,Financial Statements and Supplementary Data,ITEM_8,10,10-K,744,We believe that our audit provides a reasonable basis for our opinion.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_745,Financial Statements and Supplementary Data,ITEM_8,10,10-K,745,Definition and Limitations of Internal Control Over Financial Reporting,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_746,Financial Statements and Supplementary Data,ITEM_8,10,10-K,746,A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_747,Financial Statements and Supplementary Data,ITEM_8,10,10-K,747,"A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_748,Financial Statements and Supplementary Data,ITEM_8,10,10-K,748,"Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_749,Financial Statements and Supplementary Data,ITEM_8,10,10-K,749,"Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_8_750,Financial Statements and Supplementary Data,ITEM_8,10,10-K,750,"/s/ Ernst & Young LLP Indianapolis, Indiana February 19, 2025",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9_0,Changes in and Disagreements With Accountants on Accounting and Financial Disclosure,ITEM_9,11,10-K,0,Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9_1,Changes in and Disagreements With Accountants on Accounting and Financial Disclosure,ITEM_9,11,10-K,1,None.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_0,Controls and Procedures,ITEM_9A,12,10-K,0,"Item 9AControls and Procedures Evaluation of Disclosure Controls and Procedures Under applicable Securities and Exchange Commission (SEC) regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company's ""disclosure controls and procedures,"" which are defined generally as controls and other procedures designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-K) is recorded, processed, summarized, and reported on a timely basis.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_1,Controls and Procedures,ITEM_9A,12,10-K,1,"Our management, with the participation of David Ricks, president and chief executive officer, and Lucas Montarce, executive vice president and chief financial officer, evaluated our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December 31, 2024, and concluded that they were effective.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_2,Controls and Procedures,ITEM_9A,12,10-K,2,"Management's Report on Internal Control over Financial Reporting Mr. Ricks and Mr. Montarce provided a report on behalf of management on our internal control over financial reporting, in which management concluded that the company's internal control over financial reporting is effective at December 31, 2024 based on the framework in ""Internal Control-Integrated Framework"" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_3,Controls and Procedures,ITEM_9A,12,10-K,3,Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_4,Controls and Procedures,ITEM_9A,12,10-K,4,"Due to the inherent limitations, no evaluation over internal control can provide absolute assurance that no material misstatements or fraud exist.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_5,Controls and Procedures,ITEM_9A,12,10-K,5,"In addition, Ernst & Young LLP, the company's independent registered public accounting firm, issued an attestation report on the company's internal control over financial reporting as of December 31, 2024.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_6,Controls and Procedures,ITEM_9A,12,10-K,6,See Item 8 for the full text of management's report and Ernst & Young's attestation report.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9A_7,Controls and Procedures,ITEM_9A,12,10-K,7,"Changes in Internal Control over Financial Reporting During the fourth quarter of 2024, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9B_0,Other Information,ITEM_9B,13,10-K,0,"Item 9BOther Information On November 20, 2024, Donald Zakrowski, senior vice president, finance, and chief accounting officer, adopted a sales plan (Plan).",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9B_1,Other Information,ITEM_9B,13,10-K,1,The Plan was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act of 1934 and our policies regarding trading in our securities.,2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
0000059478,ELI LILLY & Co,2024,0000059478_10-K_2024,0000059478_10-K_2024_section_9B_2,Other Information,ITEM_9B,13,10-K,2,"The Plan calls for the sale of up to 4,000 shares of company common stock between March 13, 2025 and November 19, 2025 subject to the terms and conditions of the Plan.",2834,2025-02-19,2024-12-31,bin_2021_2025,2025-10-27 15:25:00.595973,2025-10-27 15:25:00.595973,v2.1_combined_extraction,datasets\EXTRACTED_FILINGS\10-K\59478_10K_2024_0000059478-25-000067.json,extract_and_convert
